id1,artigotitle1,id2,artigotitle2
2864,Heterologous prime-boost strategies for COVID-19 vaccines,94,Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4671,"COVID-19: vaccine brands can be mixed in ""extremely rare occasions,"" says Public Health England"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,669,Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4049,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1074,Could mixing COVID vaccines bolster immune response?
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3639,WHO. Interim statement on heterologous priming for COVID-19 vaccines
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3889,"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2470,Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3886,"Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2819,A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5689,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3270,Heterologous prime-boost vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5682,"COVID-19: fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1003,What we know about the COVID-19 immune response: the latest on COVID-19 immunity & the current global situation (Coronavirus Update 34
2864,Heterologous prime-boost strategies for COVID-19 vaccines,850,Innate immune sensing of coronavirus and viral evasion strategies
2864,Heterologous prime-boost strategies for COVID-19 vaccines,572,Antibodies and vaccines target RBD of SARS-CoV-2
2864,Heterologous prime-boost strategies for COVID-19 vaccines,174,Antibody responses in COVID-19: a review
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2927,SARS-CoV-2 antibody response in persons with past natural infection
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1010,Antibody-dependent enhancement and COVID-19: moving toward acquittal
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3000,Molecular basis of COVID-19 relationships in different species: a one health perspective
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3992,Interpreting diagnostic tests for SARS-CoV-2
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4964,Profile of specific antibodies to SARS-CoV-2: the first report
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4218,CDC. Interim guidelines for COVID-19 antibody testing
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4968,Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3326,Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2149,SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5579,Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1743,"A single-blind, randomised, phase II UK multi-Centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules -stage 2"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,176,Mix-and-match COVID vaccines trigger potent immune response
2864,Heterologous prime-boost strategies for COVID-19 vaccines,23,Next-generation vaccine platforms for COVID-19
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2161,Immunization guidelines. Dubai Health Authority Department of Public Health & safety
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4382,Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4160,"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5864,DNA vaccines against COVID-19: perspectives and challenges
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3060,The different types of COVID-19 vaccines
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5502,Commonly used adjuvant human vaccines: advantages and side effects
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1877,Comparative safety of vaccine adjuvants: a summary of current evidence and future needs
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5782,"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,165,&#x007E;:text=COVID%2D19%20vaccines%20are%20sa fe
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1831,Optimism and caution for an inactivated COVID-19 vaccine
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5932,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3057,Comparing the COVID-19 vaccines: how are they different
2864,Heterologous prime-boost strategies for COVID-19 vaccines,16,Heterologous ChA-dOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers
2864,Heterologous prime-boost strategies for COVID-19 vaccines,438,"reactogenicity, and immunogenicity of homologous and heterologous primeboost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2594,Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients
2864,Heterologous prime-boost strategies for COVID-19 vaccines,763,Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4360,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Eng
2864,Heterologous prime-boost strategies for COVID-19 vaccines,355,Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5570,An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines
2864,Heterologous prime-boost strategies for COVID-19 vaccines,739,mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1119,Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5571,SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,524,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3245,Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4326,Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4173,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5587,Neutralization of VOCs including Delta one year post COVID-19 or vaccine
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5950,The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
2864,Heterologous prime-boost strategies for COVID-19 vaccines,1473,"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada"
2864,Heterologous prime-boost strategies for COVID-19 vaccines,151,Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4745,Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
2864,Heterologous prime-boost strategies for COVID-19 vaccines,235,Heterologous SARS-CoV-2 booster vaccinations -preliminary report
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
2864,Heterologous prime-boost strategies for COVID-19 vaccines,2960,Heterologous prime-boost immunization with CoronaVac and Convidecia
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
2864,Heterologous prime-boost strategies for COVID-19 vaccines,4776,Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorVvaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon
2864,Heterologous prime-boost strategies for COVID-19 vaccines,379,Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac
2864,Heterologous prime-boost strategies for COVID-19 vaccines,3189,Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
2864,Heterologous prime-boost strategies for COVID-19 vaccines,5915,Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,5464,COVID-19: breaking down a global health crisis
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,2542,Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,814,COVID-19 vaccines: the status and perspectives in delivery points of view
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,3271,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,341,"Sinovac's COVID-19 shot is 83% effective, not 91%, Turkey says"
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,5459,Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,5531,Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,1405,"Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine"
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,2748,Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,695,Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,66,Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,4102,Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine,4830,"Histological appearance of second renal biopsy. (A) Normal histological appearance of glomeruli (haematoxylen & eosin, Â200). (B) Interstitial inflammation composed predominantly of lymphocytes"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5665,Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)/COVID-19 Detection
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3293,Effectiveness of Mrna COVID-19 Vaccines Against SARS-Cov-2 Infection in a Cohort of Healthcare Personnel
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3072,"Mitigating Covid-19 in the Face of Emerging Virus Variants, Breakthrough Infections and Vaccine Hesitancy"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,2772,Mrna-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-Cov-2 Omicron Variant
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,1067,Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series -465 Health Care Facilities
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,535,Covid-19 Vaccine Effectiveness in New York State
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5978,"Immunogenicity and Safety of a Third Dose of Coronavac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results From Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,2567,"Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, BBIBP-Corv, in People Younger Than 18 Years: A Randomised, Double-Blind, Controlled, Phase 1/2 Trial"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,2220,Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine Through 6 Months
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3893,Dynamic Igg Seropositivity After Rollout of Coronavac and BNT162b2 COVID-19 Vaccines in Chile: A Sentinel Surveillance Study
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5712,Effectiveness of the Coronavac Vaccine in Older Adults During a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test Negative Case-Control Study
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3718,"Efficacy and Safety of an Inactivated Whole-Virion SARS-Cov-2 Vaccine (Coronavac): Interim Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in Turkey"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,926,COVID-19 in Cancer and Non-Cancer Patients
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3425,Routine COVID-19 Testing may Not be Necessary for Most Cancer Patients
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5362,Multicenter Study of Antibody Seroprevalence Against COVID-19 in Patients Presenting to Iranian Cancer Centers After One Year of the COVID-19 Pandemic
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,4188,The COVID-19 Outbreak and Oncology Centers in Iran
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,634,"COVID-19 Vaccination and Cancer, the Need for More Data"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3250,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-Cov-2 in Patients Undergoing Treatment for Cancer
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,4580,Efficacy and Safety of BNT162b2 Vaccination in Patients With Solid Cancer Receiving Anticancer Therapy -A Single Centre Prospective Study
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5243,The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5420,Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,3424,"Safety and Immunogenicity of the Vi-DT Typhoid Conjugate Vaccine in Healthy Volunteers in Nepal: An Observer-Blind, Active-Controlled, Randomised, non-Inferiority, Phase 3 Trial"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,1610,"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,272,"Safety and Immunogenicity of an Inactivated SARS-Cov-2 Vaccine, BBIBP-Corv: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,4019,Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Malignancy
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5929,A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,5520,Sex Differences and COVID-19
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer,1341,Sex Differences in Vaccine-Induced Humoral Immunity
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4496,WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5813,Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4163,"Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3916,"Features, Evaluation, and Treatment of Coronavirus (COVID-19)"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5462,"Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,830,"Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. Quest answers"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4329,"Covid-19: Herd immunity is ""unethical and unachievable, "" say experts after report of 5% seroprevalence in Spain"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3785,Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic EClinicalMedicine
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3200,COVID-19 vaccine tracker and landscape
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3255,Global prevalence and drivers of dental students' COVID-19 vaccine hesitancy
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4939,Predictors of willingness to receive COVID-19 vaccine: cross-sectional study of Palestinian dental students
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5533,COVID-19 vaccine in pregnant and lactating women: a review of existing evidence and practice guidelines
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,772,COVID-19 Vaccine acceptance of pregnant and lactating women (PLW) in Czechia: an analytical cross-sectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4034,Hesitant or not? A global survey of potential acceptance of a COVID-19 vaccine
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1809,Prevalence and drivers of COVID-19 vaccine hesitancy among Czech University Students: national cross-sectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1685,Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,440,Iads-Score. Universal predictors of dental students' attitudes towards COVID-19 vaccination: machine learning-based approach
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,859,Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4057,"Effects and perceptions following COVID-19 vaccination in Jordan: a randomised, cross-sectional study implementing machine learning for predicting severity of side effects"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1894,Effects reported by Jordanian healthcare workers who received COVID-19 vaccines
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4110,Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2390,"Adrees AO, Side. effects and perceptions following Sinopharm COVID-19 vaccination"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4533,Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1087,Effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4648,Effects of mRNA-based COVID-19 vaccine: nationwide phase iv study among healthcare workers in Slovakia
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5597,Effects of mRNA-based COVID-19 vaccines among young adults
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5446,Years Old): an independent post-marketing study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1139,Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in central Europe
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2201,Prevalence and risk factors of CoronaVac side effects: an independent crosssectional study among healthcare workers in Turkey
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2082,"COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5690,Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1225,Algeria's response to COVID-19: an ongoing journey
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4413,"Covid-19: Algeria receives US donation of 604,800 doses of J&J vaccine"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4635,Coronavirus Pandemic (COVID-19)
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3838,The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3128,Questionnaire sur les effets secondaires des vaccins anti-COVID-19 chez le staff médical en Algérie −19 . Google Forms
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5452,Epi Info TM for Windows
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1815,COVID-19 Vaccines Safety Tracking (CoVaST): protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines' side effects
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2429,World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1522,Available online at
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2479,Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4298,Unfolding the mild to moderate shortterm side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5479,Which type of the promising COVID-19 vaccines produces minimal adverse effects? A retrospective crosssectional study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1215,Qualitative assessment of early adverse effects of Pfizer-BioNTech and Sinopharm COVID-19 vaccines by telephone interviews
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3403,SARS-CoV-2 Post vaccinated adverse effects and efficacy in the Egyptian population
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1315,Side effects after COVID-19 vaccinations among residents of Poland
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,8,Abdel-Moneim AS. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1170,Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,947,Adverse effects of the COVID-19 vaccine reported by lecturers and staff of Kabul University of medical sciences
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,5364,COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,2326,Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3970,Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4681,"Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4889,Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4107,Sex and Gender Differences in the Outcomes of Vaccination over the Life Course
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,1431,The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,4637,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3791,Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU States
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,3468,"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city"
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers,59,Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
5274,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac 1 (CoronaVac) followed by AstraZeneca (Vaxzevria) 2 3 Running Title: Heterologous prime-boost with CoronaVac-AZD1222,4815,Vaccines for 9
5274,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac 1 (CoronaVac) followed by AstraZeneca (Vaxzevria) 2 3 Running Title: Heterologous prime-boost with CoronaVac-AZD1222,6052,COVID-19: Where do we stand in 2021?
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",3147,Clinical Characteristics of Coronavirus Disease 2019 in China
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",2744,Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",823,Immune Correlates of Protection by mRNA-1273
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",2044,A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",664,Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",5405,Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",3570,Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",4115,Alter G. (2021) Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",419,Correlates of protection against SARS-CoV-2 in rhesus macaques
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",835,CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",2265,Differential contributions of central and effector memory T cells to recall responses
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",1017,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",2948,"2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government",4755,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. Epub ahead of print
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4509,An interactive web-based dashboard to track COVID-19 in real time
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,2944,WHO coronavirus (COVID-19) dashboard. 2021
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,2290,Clinical Characteristics of Coronavirus Disease
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4,response bottleneck of COVID-19 vaccine candidates
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,656,Novel prime-boost vaccine strategies against HIV-1. Expert review of vaccines
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,378,Over 1.8 bln doses of COVID-19 vaccines administered in China
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,2550,VACCINES CANDIDATES BY TRIAL PHASE. 2021
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1612,WHO International Standard for anti-SARS-CoV-2 immunoglobulin
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1269,Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4777,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. The Lancet Microbe
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,5972,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. The Lancet Microbe
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,3682,Effectiveness of CoronaVac among healthcare All rights reserved. No reuse allowed without permission. perpetuity
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4445,"doi: medRxiv preprint workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1560,"Immunogenicity and safety ofa third dose, and immune persistence of CoronaVac vaccine in healthy adultsaged 18-59 years: interim results from a double-blind, randomized,placebo-controlled phase 2 clinical trial. medRxiv"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,3270,Heterologous prime-boost vaccination
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1551,Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4583,The prime-boost strategy: exciting prospects for improved vaccination
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,5689,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4734,"Safety, reactogenicity, and immunogenicity of All rights reserved. No reuse allowed without permission. perpetuity"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,5826,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,4353,Heterologous ChAdOx1 nCoV-19 and mRNA-1273
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1904,The New England journal of medicine
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,876,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. 2021. received. *A seropositivity of neutralizing antibody against SARS-CoV-2 before receiving a boost vaccination"
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia,3811,or GMFI (95% CI). n= the number of participants included the intervention modified intention-to-treat cohort. The P values are the results of comparison between the two treatment groups
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3234,"Guillain-Barre syndrome, influenza, and influenza vaccination: 405 the epidemiologic evidence"
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3241,A collaborative approach to investigating the risk of 407 thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3752,"Vaccine hesitancy, vaccine refusal and the anti-vaccine 410 movement: influence, impact and implications"
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",5716,Efficacy and Safety of the mRNA
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",769,CoV-2 Vaccine
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",1773,Safety and efficacy of the ChAdOx1 nCoV-19 415 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",4587,"First-dose ChAdOx1 and BNT162b2 COVID-19 418 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3519,Bell's palsy following vaccination with mRNA 421 (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-422 control study
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",827,Case of Guillain-Barré syndrome following COVID-19 424 vaccine
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",1905,Barré Syndrome following ChAdOx1
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",4877,S/nCoV-19 Vaccine
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3439,"Guillain-Barré syndrome following the first dose of 428 SARS-CoV-2 vaccine: A temporal occurrence, not a causal association"
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",5387,Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",2884,Cutaneous reactions reported after Moderna 432 and Pfizer COVID-19 vaccination: A registry-based study of 414 cases
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",4157,Immune-Mediated Disease Flares or New-Onset 437 Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3263,Prevention of Dabigatran-Related Gastrointestinal 440
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3938,Bleeding With Gastroprotective Agents: A Population-Based Study
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3450,Kawasaki disease and 13-valent pneumococcal conjugate 557 vaccination among young children: A self-controlled risk interval and cohort study with null results
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3673,The clinical and laboratory manifestations profile 560 of antiphospholipid syndrome among Saudi Arabia population: Examining the applicability of 561 Sapporo criteria
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",1213,Population-based incidence and prevalence of systemic 563 lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",5208,Risk of Systemic Lupus Erythematosus in Patients With Anti-566 phospholipid Syndrome: A Population-Based Study
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3046,The epidemiology of infectious 568 gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",1629,Reactive Arthritis A006. 29 October
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",2649,Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region",3219,Non-alcoholic fatty liver disease among patients with sleep 575 disorders: a Nationwide study of Taiwan
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3709,Waning Immune Humoral Response to BNT162b2
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,6109,Covid-19 Vaccine over 6 Months
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,1369,Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5350,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 31 10
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3626,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,4393,/BNT162b2 vaccination
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,786,A nationwide cohort study
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,1429,Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5241,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,4797,World Health Organization. WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3031,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,1927,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,50,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,2875,seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,2417,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,1859,WHO. Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,4145,Indonesia: Coronavirus Pandemic Country Profile
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3654,"Pandemic inequity in a megacity: a multilevel analysis of individual, community and health care vulnerability risks for COVID-19 mortality in Jakarta"
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,4192,27 WHO. EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,140,Moderna announces preliminary booster data and updates strategy to address Omikron variant. News release on DSecember 12th
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3509,Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant-2021
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3930,Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3575,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine,5885,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
1594,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5,6024,Effectiveness of 551 an Inactivated SARS-CoV-2 Vaccine in Chile
1594,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5,4112,"Dynamics of 553 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. and Salvador, Natalia and Franco"
1594,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5,3892,Randomized 597 Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster 598 Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine
1594,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5,5381,3@A:* =4*58>?>8A:* >4*538?@@A:* 9@*534?;6A:* 3-412-! @@*5@8?=9A:* ;3*54@?@=A:* 9@*5=4?>9A:* 46*5=8?>6A:*
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",4439,an Inactivated SARS-CoV-2 Vaccine
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",1317,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",382,Heterologous Prime-Boost Vaccination
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",3356,"Safety and immunogenicity of an rAd26 and rAd5 vector-based 587 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-588 randomised phase 1/2 studies from Russia"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",5946,Arvind Subramanian write: Why we need to count 590 the Covid dead
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",2650,Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant 593 spreads
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",4782,"Epidemiological and clinical characteristics of 99 cases of 2019 novel 595 coronavirus pneumonia in Wuhan, China: a descriptive study"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",2051,SARS-CoV-2 variants of concern exhibit reduced sensitivity to 598 live-virus neutralization in sera from CoronaVac vaccinees and naturally infected 599 COVID-19 patients
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",159,Immune response elicited from heterologous SARS-CoV-2 602 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 603
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",261,"Production, titration, neutralisation and storage of SARS-CoV-2 605 lentiviral pseudotypes (preprint)"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",3350,All rights reserved. No reuse allowed without permission. perpetuity
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",5826,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",3173,Boosting with heterologous vaccines effectively improves protective 612 immune responses of the inactivated SARS-CoV-2 vaccine
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",3562,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",54,Reduced serum neutralization capacity against SARS-CoV-2 variants 621 in a multiplex ACE2 RBD competition assay
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",2683,Neutralizing antibody levels are highly predictive of immune 624 protection from symptomatic SARS-CoV-2 infection
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",5601,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. 627 medRxiv
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",4794,Immunogenicity of heterologous prime/booster-inactivated and 629 adenoviral-vectored COVID-19 vaccine: real-world data
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",1892,Evidence for antibody as a protective correlate for COVID-19 632 vaccines
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",3538,Overview of SARS-CoV-2 infection in adults living with HIV
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",869,Vaccine effectiveness when combining the ChAdOx1 vaccine as 636 the first dose with an mRNA COVID-19 vaccine as the second dose
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",687,"Safety and immunogenicity of a candidate Middle East 639 respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-640 label, non-randomised, uncontrolled, phase 1 trial. The Lancet Infectious Diseases"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",5859,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 643 administered in a prime-boost regimen in young and old adults (COV002): a single-644 blind, randomised, controlled, phase 2/3 trial"
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32",892,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine 646 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised 647 controlled trial"
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,4959,"SARS-CoV-2 variants, spike mutations and immune escape"
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,5137,Will SARS-CoV-2 variants of concern affect the promise of vaccines?
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,984,SARS-CoV-2 Variants and Vaccines
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,3656,COVID-19 Weekly Epidemiological Update Global overview
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,3562,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,5469,Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,2362,Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,5330,The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,3907,Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,833,"Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant"
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda,2733,Antigenic minimalism of SARS-CoV-2 is
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1007,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4033,Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1803,World Health Organization. Considerations for evaluation of Covid-19 vaccines
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4084,Considerations in boosting COVID-19 vaccine immune responses
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1454,Waning immunity after the BNT162b2 vaccine in Israel
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1888,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv 2021"
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4313,Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3995,Ministry of Health Malaysia. Open data on Malaysia's National COVID-19 Immunisation Programme
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3400,Open Data on COVID-19 in Malaysia
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1709,SARS-CoV-2 Mutations and Variants of Interest
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3399,Association between mRNA vaccination and COVID-19 hospitalization and disease severity
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3204,Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,751,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind"
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,1023,Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,1400,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,4799,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2073,Infection in Adults: A Randomized Clinical Trial
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,5146,All rights reserved. No reuse allowed without permission
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3467,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted"
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2101,COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3939,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,1216,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized"
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,4049,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2232,"doi: medRxiv preprint 10. Pietsch, B. Hundreds of Thais inoculated with Sinovac are infected as cases spike in Southeast Asia. The Washington Post"
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3532,SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,4611,Summary of Product Characteristic CoronaVac
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2557,COVID-19 Vaccine AstraZeneca package leaflet
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3722,Effectiveness of an Inactivated SARS-CoV-2
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,3116,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv"
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2980,Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,5013,Highlyspecific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2526,Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,2262,Enhanced SARS-CoV-2 neutralization by dimeric IgA
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,2439,Twelve-month specific IgG response to SARS-CoV-2 receptor-binding 467 domain among COVID-19 convalescent plasma donors in Wuhan
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,2030,Cellular immunity in COVID-19 convalescents with PCR-470 confirmed infection but with undetectable SARS-CoV-2-specific IgG
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,3163,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months 473 following primary infection
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,3458,Longitudinal analysis shows durable and broad immune memory after 475
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,5045,SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,604,Immunological memory to SARS-CoV-2 assessed for up to 8 months 478 after infection
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,1117,"Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection 480 in a Population in Lombardy, Italy"
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,670,SARS-CoV-2 vaccines in development
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,1958,Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,3370,Antibody responses to the BNT162b2 mRNA vaccine in individuals 485 previously infected with SARS-CoV-2
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2,5537,Effect of previous SARS-CoV-2 infection on humoral and T-cell 487 responses to single-dose BNT162b2 vaccine
4631,To appear in: Vaccine,4509,An interactive web-based dashboard to track COVID-19 in real time
4631,To appear in: Vaccine,4058,COVID-19 vaccines: acting on the evidence
4631,To appear in: Vaccine,1007,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
4631,To appear in: Vaccine,5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
4631,To appear in: Vaccine,2179,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
4631,To appear in: Vaccine,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
4631,To appear in: Vaccine,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
4631,To appear in: Vaccine,1804,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
4631,To appear in: Vaccine,2157,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia"
4631,To appear in: Vaccine,757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial"
4631,To appear in: Vaccine,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4631,To appear in: Vaccine,2532,Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
4631,To appear in: Vaccine,4063,Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
4631,To appear in: Vaccine,1679,"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine"
4631,To appear in: Vaccine,5951,The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
4631,To appear in: Vaccine,3016,Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study
4631,To appear in: Vaccine,5636,Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
4631,To appear in: Vaccine,4062,Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis
4631,To appear in: Vaccine,3494,Immune system and COVID-19 by sex differences and age
4631,To appear in: Vaccine,5156,"Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort"
4631,To appear in: Vaccine,5997,Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints
4631,To appear in: Vaccine,4644,International Society of Hypertension global hypertension practice guidelines
4631,To appear in: Vaccine,300,Sample size determination in health studies: A practical manual. Geneva: World Health Organization
4631,To appear in: Vaccine,4255,Inflammation and hypertension: new understandings and potential therapeutic targets
4631,To appear in: Vaccine,3294,Inflammation in hypertension
4631,To appear in: Vaccine,3842,GISAID's Role in Pandemic Response
4631,To appear in: Vaccine,5251,Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
4631,To appear in: Vaccine,3635,Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
4631,To appear in: Vaccine,147,Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
4631,To appear in: Vaccine,3071,"SARS-CoV-2, COVID-19 and the Ageing Immune System"
4631,To appear in: Vaccine,2978,Immunosenescence and human vaccine immune responses
4631,To appear in: Vaccine,2022,"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine"
4631,To appear in: Vaccine,660,Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
4631,To appear in: Vaccine,4549,Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine
4631,To appear in: Vaccine,4126,Cell Immunometabolism and Redox Signaling in Hypertension
4631,To appear in: Vaccine,3768,The Redox-Metabolic Couple of T Lymphocytes: Potential Consequences for Hypertension
4631,To appear in: Vaccine,5280,Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications
4631,To appear in: Vaccine,4101,Inflammation and Arterial Hypertension-Pathophysiological Links and Clinical Aspects
4631,To appear in: Vaccine,4643,"Inflammation, Immunity, and Oxidative Stress in Hypertension-Partners in Crime?"
4631,To appear in: Vaccine,3903,Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
4631,To appear in: Vaccine,6062,Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till,1023,Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till,676,ChAdOx1 Overall infection N/A 64%
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till,5922,BNT162b2 Overall infection N/A N/A 7 86% (78%-91%) 180766/ 51092 SCC BNT162b2 Overall infection N/A N/A 7 71%
1,,3703,SARS-CoV-2 variants: levels of neutralisation required for protective immunity. medRxiv
1,,3621,Antibody titres decline 3-month post-vaccination with BNT162b2
1,,162,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
1,,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1,,1240,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv
1,,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
1,,1681,Correlates of Vaccine-Induced Protection against SARS-CoV-2
1,,1855,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
1,,2789,Durable Humoral and Cellular Immune Responses 8
1,,3313,Months after Ad26.COV2.S Vaccination
1,,6005,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
1,,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
1,,3486,Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
1,,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
1,,1752,DNA vaccine protection against SARS-CoV-2 in rhesus macaques
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1758,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. 2021. Stockholm: European Centre for Disease Prevention and Control"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3452,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,4173,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1352,"Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2960,Heterologous prime-boost immunization with CoronaVac and Convidecia
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2118,Thailand sticks with Sinovac vaccine after cases of 'stroke-like' side effects. Reuters
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,679,"Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,5503,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3115,"Thailand to mix Sinovac, AstraZeneca vaccine doses"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1631,"Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,525,European Medicines Agency. 2021. COVID-19 Vaccine AstraZeneca. AMSTERDAM: European Medicine Agency
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1943,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3310,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,355,Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,4371,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2158,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,4596,Longterm Specific IgG Response to SARS-CoV-2 Nucleocapsid Protein in Recovered COVID-19 Patients
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3788,Human IgG and IgA responses to COVID-19 mRNA vaccines
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3990,COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,5837,Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,5885,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3054,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial"
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,1511,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,589,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2732,Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection. Vaccine
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,815,Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerg Infect Dis
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,2952,Thailand cites positive results from Sinovac-AstraZeneca vaccine formula. Reuters
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,3350,All rights reserved. No reuse allowed without permission. perpetuity
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults,68,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in"
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,2392,COVID-19) Dashboard with vaccination data
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,1692,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,6086,Infection and death in healthcare workers due to COVID-19: a systematic review
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,2498,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variantassociated epidemic of COVID-19 in Brazil: a test-negative casecontrol study
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,2007,Covid-19 breakthrough infections in vaccinated health care workers
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,1524,Efcacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers,5742,Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",1851,COVID-19 vaccine development pipeline gears up
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",4304,Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",4215,WHO SAGE values framework for the allocation and prioritization of COVID-19
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",3525,Safety and immunogenicity of ChAdOx1
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",3862,"nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",6061,Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers",2191,Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",91,Correlation of SARS-CoV-2-breakthrough 155 infections to time-from-vaccine
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",1304,Covid-19 breakthrough infections in vaccinated 157 health care workers
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",4634,Omicron variant showed lower neutralizing sensitivity than 159 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",3500,Safety and 162 immunogenicity of heterologous and homologous inactivated and adenoviral
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",3030,COVID-19 vaccines in healthy adults
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",3327,Immunogenicity of a third 165 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in 166 healthy adults
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",5152,Reduced neutralization of SARS-CoV-2 B.1.1.7 168 variant by convalescent and vaccine sera
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",2919,Correlates of protection against symptomatic and 170 asymptomatic SARS-CoV-2 infection
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",1367,Antibody response and variant cross-172 neutralization after SARS-CoV-2 breakthrough infection
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",6142,mRNA vaccination boosts cross-variant 175 neutralizing antibodies elicited by SARS-CoV-2 infection
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",5157,Increased risk of SARS-CoV-2 178
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",5313,reinfection associated with emergence of the Omicron variant in South Africa. medRxiv
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron",674,SARS-CoV-2 B. 1.1. 529 variant (Omicron
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5384,World Health Organization. WHO coronavirus disease (COVID-19) dashboard
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3649,Efficacy and Safety of the mRNA-1273
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2901,SARS-CoV-2 Vaccine
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,686,COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais,3631,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais,2581,Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais,1164,Pathologic Antibodies to Platelet Factor 4 after
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais,3837,Vaccination
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais,1077,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
5916,"Safety, Immunogenicity, and Efficacy of COVID-19 Vaccine in Children and Adolescents: A Systematic Review",179,CDC. Vaccines: The Basics
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,3642,Inference of COVID-19 epidemiological distributions from Brazilian hospital data
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,441,World Health Organization W. WHO SAGE Roadmap For Prioritizing Uses Of
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,1181,Vaccines In The Context Of Limited Supply
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,6126,101205. the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,429,World Health Organization W. Evaluation of COVID-19 vaccine effectiveness
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,4747,Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,2790,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,64,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,4927,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,1603,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,1326,"Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases,1839,Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",4263,World Health Organization. Tracking SARS-CoV-2 variants
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",495,Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",4847,"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance"
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1568,Tianjin Municipal Health Commission. Vaccination of COVID-19 in Tianjin
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",2747,World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1971,World Health Organization. Living guidance for clinical management of COVID-19: living guidance
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",160,SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",5406,The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1288,Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1641,Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",326,AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1457,Decoupling of omicron variant infections and severe COVID-19
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",3122,Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet Respiratory medicine 2021
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",3548,Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",4619,Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1843,"Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada"
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",4128,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1471,COVID infection severity in children under 5 years old before and after Omicron emergence in the US
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",1407,"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections"
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background",5245,Alkaline
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,4363,A Novel Coronavirus from Patients with Pneumonia in China
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,4122,COVID-19 vaccines and decreased transmission of SARS-CoV-2
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,3385,Prevention of host-to-host transmission by SARS-CoV-2 vaccines
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,4370,COVID-vaccine booster shot shows promise in Israeli study
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5564,Reconstruction of the full transmission dynamics of COVID-19 in Wuhan
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5999,Special report: The simulations driving the worlds response to COVID-19
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,1578,Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,962,In vivo kinetics of SARS-CoV-2 infection and its relationship with a persons infectiousness
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5148,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases"
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,3882,mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,588,Homeostatic proliferation of B cells
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5131,Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5660,Remdesivir for the Treatment of Covid-19 -Final Report
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5920,COVID-19 and the Path to Immunity
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,4031,Cross-reactive memory T cells and herd immunity to SARS-CoV-2
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,4771,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines (Basel) 9"
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5347,Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,1079,Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,5643,Estimating infectiousness throughout SARS-CoV-2 infection course
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,2330,Social contacts and mixing patterns relevant to the spread of infectious diseases
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness,3344,Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2837,Risking further COVID-19 waves despite vaccination. The Lancet Infectious Diseases
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4259,Relaxing restrictions at the pace of vaccination increases freedom and guards against further covid-19 waves
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,922,Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5414,Immunological characteristics govern the transition of COVID-19 to endemicity
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1869,Concerns about sars-cov-2 evolution should not hold back efforts to expand vaccination
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2208,Low case numbers enable long-term stable pandemic control without lockdowns. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3222,The challenges of containing SARS-CoV-2 via test-trace-and-isolate
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1191,Sars-cov-2 incidence and vaccine escape
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2995,The variant gambit: COVID's next move
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4677,Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1373,Gisaid: Global initiative on sharing all influenza data -from vision to reality
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1795,Alarming COVID variants show vital role of genomic surveillance
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2307,The genomic landscape of sars-cov-2: Surveillance of variants of concern
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,956,How cooperative engagement programs strengthen sequencing capabilities for biosurveillance and outbreak response
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3306,Limited resources of genome sequencing in developing countries: challenges and solutions
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,630,Socioeconomic status determines covid-19 incidence and related mortality in santiago
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2931,Estimating the effect of social inequalities on the mitigation of covid-19 across communities in santiago de chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4606,All things equal? heterogeneity in policy effectiveness against covid-19 spread in chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4690,On the heterogeneous spread of covid-19 in chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4989,A multi-group SEIRA model for the spread of COVID-19 among heterogeneous populations
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4148,Geographical distribution of genetic variants and lineages of sars-cov-2 in chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,826,Covid-19: Chile joins top five countries in world vaccination league
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5720,The story behind chile's rapid rollout of covid-19 vaccination
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,6144,Coronavirus pandemic (covid-19)
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,548,The effect of covid-19 on the economy: Evidence from an early adopter of localized lockdowns
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4070,"Nyna Llanovarced-Kawles, and Álvaro Olivera-Nappa. Statistically-based methodology for revealing real contagion trends and correcting delay-induced errors in the assessment of COVID-19 pandemic"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3376,National strategy for test-trace-and-isolate (COVID-19
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2889,"Vacunas contra sars-cov-2 utilizadas en chile mantienen altos niveles de efectividad para evitar hospitalización, ingreso a uci y muerte"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2652,Effectiveness of an inactivated sars-cov-2 vaccine in chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5370,Mutation in a sars-cov-2 haplotype from sub-antarctic chile reveals new insights into the spike's dynamics
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2342,Infectivity and immune escape of the new sars-cov-2 variant of interest lambda. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1321,The emergence of sars-cov-2 variant lambda (c. 37) in south america. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1238,Emergencia de variante delta-b. 1.617. 2. su impacto potencial en la evolución de la pandemia por sars-cov-2
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3023,Comunicado de sochinf sobre variante delta en chile
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4240,"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3731,MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1525,Subject_term: Classification and taxonomy;Phylogenetics;Phylogeny;SARS-CoV-2;Viral evolution Subject_term_id: classification-and-taxonomy
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4225,Estimating Individual and Household Reproduction Numbers in an Emerging Epidemic
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1962,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,6116,"Yarin Gal, and Jan Kulveit"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,3858,Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1717,Bayesian phylodynamic inference with complex models
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5569,BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,546,Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2667,Characterizing SARS-CoV-2 mutations in the United States
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4707,"Soodeh Hooshmandi, Behrooz Ataei, and Shaghayegh Haghjooy Javanmard. Novel and emerging mutations of SARS-CoV-2: Biomedical implications"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1239,Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,783,"Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,342,Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1303,First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,1176,"COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence"
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2951,Virology Subject_term_id: sars-cov-2;virology
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,2246,Different mutations in SARS-CoV-2 associate with severe and mild outcome
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5421,Increased transmissibility and global spread of sars-cov-2 variants of concern as at
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,215,Ongoing global and regional adaptive evolution of SARS-CoV-2
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,256,Subject_term: Protein analysis;SARS-CoV-2;Vaccines;Viral evolution
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,4961,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants,5873,An interactive web-based dashboard to track covid-19 in real time
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",1851,COVID-19 vaccine development pipeline gears up
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",4304,Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",2133,Vaccine Breakthrough Infections with SARS-CoV-2 Variants
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",2892,WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",6061,Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",2514,"39) Body mass index: kg/m 2 (median, IQR)"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers",5277,*Statistical significance (p-value < 0.05) comparing between ChAdOx1 and CoronaVac group
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5893,COVID-19 Vaccine: Where Are We Now and Where Should We Go?
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,6020,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5889,Development of an Inactivated Vaccine Candidate for SARS-CoV-2
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,2603,Looking Beyond COVID-19 Vaccine Phase 3 Trials
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,364,Progress and Prospects on Vaccine Development Against SARS-CoV-2. Vaccines (2020)
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5496,Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,2937,Human Neutralizing Antibodies Against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1302,Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,2466,A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation Between Neutralizing Antibodies and COVID-19 Severity
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1607,Licence: CC BY-NC-SA 3.0 IGO.). Available at
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,2697,Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers With and Without Prior SARS-CoV-2 Infection
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,881,"Antibodies Against Receptor Binding Domain of SARS-CoV-2 Spike Protein Induced by BNT162b2 Vaccine: Results From a Pragmatic, Real-Life Study"
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,4878,Dynamics of SARS-CoV-2 Neutralising Antibody Responses and Duration of Immunity: A Longitudinal Study
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1455,Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,3978,Incidence of SARS-CoV-2 Infection in Health Care Workers From Northern Italy Based on Antibody Status: Immune Protection From Secondary Infection-A Retrospective Observational Case-Controlled Study
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,4183,Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,3154,Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1796,Regeneron Reports Positive Interim Data With REGEN-COVTM Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,733,Long-Term Protection at 20-31 Years After Primary Vaccination With Plasma-Derived Hepatitis B Vaccine in a Chinese Rural Community
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5781,Duration of Immunity Against Pertussis After Natural Infection or Vaccination
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1391,Effectiveness of Influenza Vaccination on Influenza-Associated Hospitalisations Over Time Among Children in Hong Kong: A Test-Negative Case-Control Study
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5679,Evolution of Antibody Immunity to SARS-CoV-2
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1687,Evolution of Immune Res1ponses to SARS-CoV-2 in Mild-Moderate COVID-19
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,4454,Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,3292,mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,229,WHO Approval of Chinese CoronaVac COVID Vaccine Will be Crucial to Curbing Pandemic
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,2371,IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,4137,IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days,1417,Enhanced SARS-CoV-2 Neutralization by Dimeric IgA
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults,2745,et als for the COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults,3729,-Chile´s Ministry of Health daily official report
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults,3756,Chile´s Ministry of Health. Effectiveness of the SARS-CoV-2 vaccine program
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults,2275,2%) COVID-19 admissions in adults with incomplete vaccination and/or <14 days of last dose at COVID-19 diagnosis; these patients were not eligible for the study CCU: Critical Care Unit
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,409,"Excess deaths associated with COVID-19, by age and race and ethnicity: United States"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3364,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5303,International consensus (ICON): allergic reactions to vaccines
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4756,"COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to -COVID-19 vaccine anaphylaxis -PEG or not?"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5799,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3368,Centers for Disease Control and Prevent. Interim clinical considerations for use of COVID-19 vaccines currently approved and authorized in the United States
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5942,CDC_ AA_refVal=https%3A%2F%2F Accessed
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3719,Allergic reactions to CO-VID-19 vaccinations-unveiling the secret(s)
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1800,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to CO-VID-19 vaccines"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1021,"The international EAACI/GA2LEN/EuroGuiDerm/ APAAACI guideline for the definition, classification, diagnosis, and management of urticaria"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,760,Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3960,Chronic urticaria and autoimmunity: associations found in a large population study
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,611,Multiple drug hypersensivity: insight into the underlying mechanism and correlation with autoimmune diseases
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,225,Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,740,Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2825,Coagulation cascade and fibrinolysis in patients with multipledrug allergy syndrome
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4026,Vasovagal episode or anaphylaxis
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2131,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,885,Vaccine allergy: evidence to consider for COVID-19 vaccines
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5858,World allergy organization anaphylaxis guidance 2020
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2714,"Anaphylaxis: clinical patterns, mediator release, and severity"
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5456,Scadding GK. Allergic rhinitis
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,6098,Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1153,Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1598,Global strategy for asthma management and prevention (update 2021)
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2874,Adverse reactions to COVID-19 vaccines: a practical approach
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3808,Allergy to COVID-19 vaccines: a current update
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1742,Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,6054,Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis)
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3814,Polyethylene glycol may be the major allergen in depot medroxyprogesterone acetate
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4931,Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2621,Aluminum and vaccines: current state of knowledge
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5822,Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,6078,Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3906,Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,742,CoronaVac COVID-19 vaccineinduced anaphylaxis: clinical characteristics and revaccination outcomes
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5005,Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University hospital
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4896,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5294,Safety of CO-VID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,2548,mRNA CO-VID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4277,Clinical characteristics and risk profile of patients with elevated baseline serum tryptase
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,3991,Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5513,Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,5748,The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,6027,Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,1241,Administration of a second dose of the Moderna CO-VID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines,4706,Immediate-type systemic hypersensitivity reactions after the inactivated Sars-Cov-2 vaccine in healthcare workers
3989,The Journal of Headache and Pain,5672,The International Classification of Headache Disorders
3989,The Journal of Headache and Pain,3394,Biphasic neurovascular changes in prolonged migraine aura in familial hemiplegic migraine type 2
3989,The Journal of Headache and Pain,3498,Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase
3989,The Journal of Headache and Pain,105,Pathophysiology of Migraine: A Disorder of Sensory Processing
3989,The Journal of Headache and Pain,472,Diagnostic and therapeutic aspects of hemiplegic migraine
3989,The Journal of Headache and Pain,4092,Migraine headache is present in the aura phase: a prospective study
3989,The Journal of Headache and Pain,4131,A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria
3989,The Journal of Headache and Pain,1827,Sporadic hemiplegic migraine with permanent neurological deficits
3989,The Journal of Headache and Pain,1611,Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice
3989,The Journal of Headache and Pain,866,Spreading depression and the clinical correlates of migraine
3989,The Journal of Headache and Pain,3299,Reduced threshold for cortical spreading depression in female mice
3989,The Journal of Headache and Pain,1343,Menstrual migraine: a distinct disorder needing greater recognition
3989,The Journal of Headache and Pain,872,"A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
3989,The Journal of Headache and Pain,5423,Induction of production of nitric oxide in microglial cells by insoluble form of aluminium
3989,The Journal of Headache and Pain,4604,Aluminum treatment induces nitric oxide synthase in the rat brain
3989,The Journal of Headache and Pain,3322,Glyceryl trinitrate triggers premonitory symptoms in migraineurs
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5224,WHO. WHO coronavirus disease (COVID-19) dashboard. 2020
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",3150,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5197,Association between age and clinical characteristics and outcomes of COVID-19
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5874,COVID-19 and older adults: what we know
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5608,"SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",4448,Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2159,"Nutrition, diet and immunosenescence"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",4268,Draft landscape of COVID-19 candidate vaccines
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2272,Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2310,Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5852,Our progress in developing a potential COVID-19 vaccine
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5086,AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5654,Sputnik V: general information
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2687,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",1281,Guidelines for grading standards of adverse events in clinical trials of preventive vaccines
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",4347,Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method-experience across the 2010/11 season
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",1762,Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",1371,Severe necrotizing pancreatitis following combined hepatitis A and B vaccination
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",1752,DNA vaccine protection against SARS-CoV-2 in rhesus macaques
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5721,An effective COVID-19 vaccine needs to engage T cells
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",5095,An mRNA vaccine against SARS-CoV-2-preliminary report
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",55,A new accelerated vaccination schedule for rapid protection against hepatitis A and B
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,3017,World Health Organization. WHO coronavirus (COVID-19) dashboard 2021
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,790,Repurposed antiviral drugs for COVID-19 -interim WHO Solidarity Trial results
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,3691,COVID-19 vaccine efficacy and effectivenessthe elephant (not) in the room
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2084,Adaptive immunity to SARS-CoV-2 and COVID-19
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,3772,Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,6010,How the world is (not) handling surplus doses and expiring vaccines
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,927,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5875,"Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines (Basel) 2020"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,705,Intradermal COVID-19 vaccination could solve supply problems
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,358,Delivery systems for intradermal vaccination
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,951,WHO international standard for anti-SARS-CoV-2 immunoglobulin
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5192,Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,699,CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,4211,"Th1 cytokines, true functional signatures for protective immunity against TB?"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,4049,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,6115,"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,4289,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5394,Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test?
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,1615,Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2782,Adenovirus vector-based vaccine for infectious diseases
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,14,A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5377,"Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cellstimulating skin-emigrated dendritic cells"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2446,Antigen presentation and adaptive immune responses in skin
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2876,Antigen-presenting cells in the skin
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,955,A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,3823,Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,1068,Adenovirus receptors
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,556,Adenovirus receptors and their implications in gene delivery
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,4203,Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5070,World Health Organization. Rabies vaccines: WHO position paper
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2011,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy"
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,5705,Intradermal ChAdOx1 vaccine following two CoronaVac shots: a case report. Vaccines (Basel)
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial,2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2151,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic [Internet]. Nature. Nature
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5468,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5146,All rights reserved. No reuse allowed without permission
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3467,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,1652,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Front Immunol
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3758,5% de la población objetivo ha recibido la primera o única dosis de la vacuna contra SARS-CoV-2 -Ministerio de Salud -Gobierno de Chile
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5160,Protection duration after vaccination or infection -Swiss National COVID-19
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,4196,Science Task Force
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,6036,Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5385,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Front Immunol
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2339,World medical association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3453,2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,1455,Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3009,despite high seroprevalence
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3325,BNT162b2 vaccine booster dose protection: A nationwide study from Israel. medRxiv
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,3116,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,5467,Available from: All rights reserved. No reuse allowed without permission
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,4063,Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,499,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled"
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2669,Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2,2094,BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,2012,Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,888,"Confronting the Delta variant of SARS-CoV-2, Summer"
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,6156,Coronavirus Pandemic (COVID-19). Our World in Data
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5110,COVID-19 (SARS-CoV-2) variants. GOV.UK; 2021
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,4173,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5722,Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5231,Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,1847,Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3433,COVID-19 vaccines for moderately to severely immunocompromised people. Cdc.gov; 2021
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,1794,Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. U.S. Food and Drug Administration
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,2014,A country-by-country guide to coronavirus vaccine booster plans. POLITICO; 2021
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3968,Turkey's national immunization program
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,2075,Indonesia begins to give third COVID-19 shots to 1.5 million health workers. Jakarta Post
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,145,A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5281,"Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups"
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3253,Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,4376,Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5600,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,6075,Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,2492,Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,1103,Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3282,Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,1136,Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,873,Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-a nationwide survey
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,2152,Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3103,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,685,Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5851,Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,3844,Protection of BNT162b2 vaccine booster against Covid-19 in Israel
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,63,Safety monitoring of an additional dose of COVID-19 vaccine-United States
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine,5282,Supporting Information section at the end of this article. How to cite this article
4631,To appear in: Vaccine,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
4631,To appear in: Vaccine,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
4631,To appear in: Vaccine,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
4631,To appear in: Vaccine,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
4631,To appear in: Vaccine,5345,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and"
4631,To appear in: Vaccine,957,Thailand sticks with Sinovac vaccine after cases of''stroke-lik'' side effects
4631,To appear in: Vaccine,5235,"World Health Organization. Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
4631,To appear in: Vaccine,3617,Amsterdam: European Medicine Agency
4631,To appear in: Vaccine,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
4631,To appear in: Vaccine,3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
4631,To appear in: Vaccine,3438,COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
4631,To appear in: Vaccine,775,Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
4631,To appear in: Vaccine,2960,Heterologous prime-boost immunization with CoronaVac and Convidecia
4631,To appear in: Vaccine,5188,Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
4631,To appear in: Vaccine,5410,Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
4631,To appear in: Vaccine,2893,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
4631,To appear in: Vaccine,4087,Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
4631,To appear in: Vaccine,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",4995,"*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of COVID-19 in adults (aged 18 years), by age group"
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",2045,COVID-19 vaccination coverage in adults 18 years (any type of vaccines) during
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",2545,Indonesia (Data source: Ministry of Health of Indonesia)
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",1252,Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry 622 of Health of Indonesia)
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",3024,Distribution of SARS-CoV-2 variants of concern (VOCs) in samples examined during 632
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",5483,Variant proportions are estimated against total sequences of 633 collected samples of each month. Total samples are varied for each month. Data are subject to change 634 over time and will be updated as more data become available. Variant proportions may not represent 635 national estimates
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia",2189,Data source: Ministry of Health of Indonesia)
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,4873,"Immunization stress-related response: a manual for program managers and 308 health professionals to prevent, identify and respond to stress-related responses following 309 immunization"
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,2836,Current Concepts in 311 Diagnosis and Treatment of Functional Neurological Disorders
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,1973,Complex regional pain syndrome and 313 functional neurological disorders -time for reconciliation
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,1475,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the 317 first case report
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,1399,Abnormal parietal function in 319 conversion paresis
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,2843,Motor cortical 321 activity during motor tasks is normal in patients with complex regional pain syndrome
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,3481,324 Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV 325 vaccination in Rio Branco
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,2591,"HPV vaccine confidence and cases of mass 327 psychogenic illness following immunization in Carmen de Bolivar, Colombia. Human vaccines & 328 immunotherapeutics"
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,3517,Mass psychogenic illness in nationwide in-school vaccination 330 for pandemic influenza A (H1N1)
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,1870,Mass psychogenic response to human papillomavirus vaccination. The 333
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,2029,Psychogenic illness following vaccination: exploratory study of 335 mass vaccination against pandemic influenza A (H1N1) in 2009 in South Korea. Clinical and experimental 336 vaccine research
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,1726,Disorder After SARS-CoV-2 Vaccines: Two Case Reports and Discussion of Potential Public Health 339 Implications
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations,5233,Functional neurological disorder after COVID-341 19 vaccination
2516,63rd ASH Annual Meeting Abstracts POSTER ABSTRACTS 642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey),680,Cidara: Membership on an entity's Board of Directors or advisory committees
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1359,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,4881,Associations of baseline use of biologic or targeted synthetic DMARDs 16
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5187,Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,3471,An mRNA Vaccine against SARS-CoV-2 -Preliminary Report
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1545,"SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,4966,Antigen-specific antibody responses in lupus patients following immunization
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,2162,The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,4678,Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1948,Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5407,PROSPERO's progress and activities 2012/13
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,2431,JBI Manual for Evidence Synthesis
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1908,GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5612,Measuring inconsistency in meta-analyses
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1423,High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5308,"Correspondence on ""SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,895,"but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,3423,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1992,Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,3345,"Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,3732,Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5717,Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5735,Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,514,Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study)
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,2752,Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1580,The importance of cell-mediated immunity in COVID-19 -An opinion
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,1722,Preprint manuscripts and servers in the era of coronavirus disease 2019
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,3391,"Heterogeneity: I 2 = 0%, Q = 1.65, P ="
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,5529,"Heterogeneity: I 2 = 0%, Q = 1.33"
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis,4790,Heterogeneity: I 2 = 0%
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,360,Vaccine-associated hypersensitivity
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1469,World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,433,Data from the Ministry of Public Health
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,221,"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data"
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,5984,Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1220,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, Phase 1/2 trial"
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,4888,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase 3 trial in Turkey"
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,6099,EAACI guideline: anaphylaxis (2021 update)
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,5782,"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations"
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1742,Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,3972,Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,152,Immunemediated adverse reactions to vaccines
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,2321,Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive?
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,5098,Total and IgE antibody levels following booster immunization with aluminum absorbed and nonabsorbed tetanus toxoid in humans
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,317,Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,2095,Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,4597,Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1212,First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1512,Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,3976,Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,1818,International Consensus (ICON): allergic reactions to vaccines
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes,6160,Clinical Immunization Safety Assessment Network Hypersensitivity Working G. Irritant skin test reactions to common vaccines
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,2005,"Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape"
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,4918,Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,5648,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treating Healthcare Professionals With the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A Structured Summary of a"
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,3955,Interim Report : Safety and Immunogenicity of an Inactivated Vaccine
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,5927,Ministerio de Salud Gobierno de Chile. Ficha Vacuna Contra Sars-Cov-2
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,3260,Available at
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,4154,"A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association With Severity"
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,5861,Insights Into Neutralizing Antibody Responses in Individuals Exposed to SARS-CoV-2 in Chile
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,6084,Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,3576,Cell-Mediated Immune Response to Respiratory Coronaviruses
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,4028,SARS Coronavirus Spike Protein-Induced Innate Immune Response Occurs via Activation of the NF-kb Pathway in Human Monocyte Macrophages In Vitro
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,1262,SARS-CoV-2 Nsp14 Activates NF-kb Signaling and Induces IL-8 Upregulation
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,1634,"Dynamic Changes in Serum IL-6, IL-8, and IL-10 Are Associated With the Outcome of Patients With Severe COVID-19 in ICU"
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,4358,Duration of Humoral Immunity to Common Viral and Vaccine Antigens
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,6020,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,5075,Immunology of COVID-19: Current State of the Science
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,6029,COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,5061,Changes of Lymphocyte Subsets in Patients With COVID-19 and Clinical Significance: A Case-Control Observational Study
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group,59,Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,4213,World Health Organization. The Sinovac COVID-19 vaccine: What you need to know
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,368,What do we know about China's covid-19 vaccines?
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,3867,A review of the progress and challenges of developing a vaccine for COVID-19
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,3906,Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,4813,Sinovac COVID-19 vaccine: What are the side effects?
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,5551,18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report,566,Seasonal influenza vaccine-induced pneumonitis presenting with multiple pulmonary nodules
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4207,An Interactive Web-Based Dashboard to Track COVID-19 in Real Time
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3044,SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4017,SARS-CoV-2 D614G Spike Mutation Increases Entry Efficiency With Enhanced ACE2-Binding Affinity
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3330,COVID-19 mRNA Vaccine Induced Antibody Responses and Neutralizing Antibodies Against Three SARS
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3416,The Spike D614g Mutation Increases Sars-Cov-2 Infection of Multiple Human Cell Types
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,918,"SARS-CoV-2 Variants, Spike Mutations and Immune Escape"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,985,The N501Y Spike Substitution Enhances SARS-CoV-2 Transmission
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4679,Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4934,"Neutralization of SARS-CoV-2 Spike 69/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2241,Molecular Determinants and Mechanism for Antibody Cocktail Preventing SARS-CoV-2 Escape
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,1587,Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2574,SARS-CoV-2 Spike P681R Mutation Enhances and Accelerates Viral Fusion
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4149,"Transmission, Infectivity, and Neutralization of a Spike L452R SARS-CoV-2 Variant"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,4629,Plan Nacional De Vacunacioń
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3874,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-spike Protein-Protein Interaction
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2222,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,1470,Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3727,Immune Responses Against SARS-CoV-2 Variants After Heterologous and Homologous ChAdOx1 Ncov-19/BNT162b2 Vaccination
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,847,Effectiveness of the CoronaVac Vaccine in the Elderly Population During a P.1 Variant-Associated Epidemic of COVID-19 in Brazil: A Test-Negative Case-Control Study
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3073,"A Third Dose of Inactivated Vaccine Augments the Potency, Breadth, and Duration of Anamnestic Responses Against"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2301,Neutralisation of SARS-CoV-2 Lineage P.1 by Antibodies Elicited Through Natural SARS-CoV-2 Infection or Vaccination With an Inactivated SARS-CoV-2 Vaccine: An Immunological Study
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3421,Infectivity and Immune Escape of the New SARS-CoV-2 Variant of Interest Lambda
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3026,"Neutralization of Alpha, Gamma, and D614G SARS-CoV-2 Variants by CoronaVac Vaccine-Induced Antibodies"
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,601,Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,6122,CoronaVac Induces Lower Neutralising Activity Against Variants of Concern Than Natural Infection
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,901,Neutralizing Activity of BNT162b2-Elicited Serum
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,3533,BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2706,Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,2572,Development of Neutralizing Antibody Responses Against SARS-CoV-2 in COVID-19 Patients
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,5256,Impact of SARS-CoV-2 Variants on the Total CD4+ and CD8+ T Cell Reactivity in Infected or Vaccinated Individuals
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine,6020,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,5386,WHO coronavirus disease (COVID-19) dashboard
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,2678,"Pregnancy, viral infection, and COVID-19"
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,1875,Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,4056,COVID-19 vaccines: interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,2902,"The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations"
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,5080,In-terim guidance for COVID-19 vaccination in children and adolescents
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,1746,CoV-2 IgG II. FDA emergency use authorization instructions manuscript
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,3246,Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination -a case report. C Pediatr
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,3692,Cord blood antibodies following maternal COVID-19 vaccination during pregnancy
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,2508,Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. MA Pediatr
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,4754,Antibodies in the breast milk of a maternal woman with COVID-19. Emerg Microbes Infect
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,5557,SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,3544,Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy,2166,"Infectious diseases society of America. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the infectious diseases society of America"
1,,2796,"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment"
1,,2282,COVID-19 Vaccination Programme
1,,4309,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
1,,937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
1,,5371,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry
1,,4746,view points on SARS-CoV-2 vaccination in patients with RMDs
1,,3552,Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients
1,,3543,COVID-19) vaccination information for public health professionals
1,,1537,European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
1,,1789,The Hong Kong society of rheumatology consensus recommendations for COVID-19 vaccination in adult patients with autoimmune rheumatic diseases
1,,1325,COVID-19 vaccination and antirheumatic therapy
1,,553,Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases
1,,3274,Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries
1,,1011,2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
1,,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
1,,4299,BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting
1,,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
1,,3411,Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
1,,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
1,,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
1,,3074,Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis
1,,4341,Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey
1,,3602,Challenges to vaccination against SARS-CoV-2 in patients with immune-mediated diseases
1,,1132,Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
1,,1009,Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",5928,COVID-19 vaccine tracker
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",758,SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",1682,Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",4403,"Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",2133,Vaccine Breakthrough Infections with SARS-CoV-2 Variants
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",4609,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",3921,Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",4576,Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",2196,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",569,"Severe acute respiratory syndrome coronavirus 2 P.2 lineage associated with reinfection case, Brazil"
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",4999,A human monoclonal antibody blocking SARS-CoV-2 infection
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",284,Human neutralizing antibodies elicited by SARS-CoV-2 infection
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies",2512,Comparison of four SARS-CoV-2 Neutralization Assays
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",233,Draft landscape and tracker of COVID-19 candidate vaccines 415
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3660,Assessing transmissibility 418 of SARS-CoV-2 lineage B.1.1.7 in England
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2476,Model-420 based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",519,Increased mortality in 423 community-tested cases of SARS-CoV-2 lineage B.1.1.7
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4325,Risk of 425 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort 426 study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",380,Genomics and 428 epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5663,Sensitivity of 431 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4078,Neutralizing Antibodies Against SARS-CoV-434 2 Variants After Infection and Vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1761,Resistance of SARS-CoV
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3902,1.351 and B.1.1.7 to Antibody Neutralization
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1846,Escape of SARS-CoV-2 501Y.V2 438 from neutralization by convalescent plasma
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4698,V2 escapes neutralization by South African COVID-19 donor plasma
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5180,Direct gene transfer into 443 mouse muscle in vivo
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2831,History of vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",451,Safety and Efficacy of 446 the BNT162b2 mRNA Covid-19 Vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5637,Safety and Efficacy 448 of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",74,Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2032,Efficacy and Safety of the 454 mRNA-1273 SARS-CoV-2 Vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5222,Efficacy of 457 the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",21,Press release. CureVac Final Data from Phase 2b/3 Trial of First-Generation
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1381,"Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4514,Efficacy of ChAdOx1 nCoV-465 19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an 466 exploratory analysis of a randomised controlled trial. The Lancet [Internet]. 30 mars 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",490,"Safety and efficacy 470 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 471 randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",185,Efficacy of the ChAdOx1 474 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2821,AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 476 at interim analysis
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3497,Effectiveness of 602 the Single-Dose Ad26.COV2.S COVID Vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1657,FDA-606 authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across 607 a multi-state health system
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4090,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3050,MMWR 611 Morb Mortal Wkly Rep
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5238,Effect of Vaccination on 614 Transmission of SARS-CoV-2
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5881,An 616 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",565,Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by 618
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4027,Clin Infect Dis
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1430,Impact of Delta 621 on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK 622
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5315,BNT162b2 625 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 626
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1198,Comparison 629 of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant 630 prevalence
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",6060,Interim Estimates of 637 Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-638
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3037,"CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and 639"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3194,MMWR Morb Mortal 640 Wkly Rep
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2861,BNT162b2 643 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary 644 report
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",754,Effectiveness of BNT162b2 647 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2684,Multicentre Prospective Cohort Study (the SIREN Study)
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2422,Social Science Research Network; 2021 févr
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3442,BNT162b2 Vaccine 652 Effectiveness in Preventing Asymptomatic Infection with SARS-CoV-2 Virus: A Nationwide 653
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2055,Historical Cohort Study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3815,Social Science Research Network; 2021 mars 654
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2153,Vaccine 657 effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term 658 care facility residents and healthcare workers -a Danish cohort study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5478,Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened 662 Workforce
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2766,Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",510,Molecular Screening
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5101,SARS-CoV-2 Vaccine Effectiveness in a High-Risk 669 National Population in a Real-World Setting
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1882,Prevention of COVID-19 by 671 mRNA-based vaccines within the general population of California
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2701,"REACT-1 round 13 final report: 674 exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with 675 Delta variant in England during"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",365,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among 678
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",898,Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1024,Effectiveness of 682 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the 683 USA: a retrospective cohort study. The Lancet
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",715,Early Release -Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-686
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5402,-687 Emerging Infectious Diseases journal -CDC
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",417,Prevention and 690 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3102,Initial report of 693 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4074,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by 696 Vaccination Status"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4317,"Brown CM. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough 700 Infections"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",367,Virological and serological 704 kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort 705 study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",523,Virological 708 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers 709
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",655,Effect of Vaccination on 712 Household Transmission of SARS-CoV-2 in England
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3034,Vaccination with 714 BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5760,High coverage COVID-19 mRNA vaccination 717 rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1808,Transmission dynamics and 720 epidemiological characteristics of Delta variant infections in China
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1372,"Risk factors and disease 724 profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study 725 app: a prospective, community-based, nested, case-control study"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4579,Antibody 733 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1727,Dynamics of antibody 736 response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg 737 Health -Eur
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4884,Durability of mRNA-1273 740 vaccine-induced antibodies against SARS-CoV-2 variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2083,Comparative Effectiveness of Moderna
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5003,Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without 743 Immunocompromising Conditions -United States
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2253,No evidence for increased 747 transmissibility from recurrent mutations in SARS-CoV-2
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4660,CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 751 medRxiv
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4712,Emergence 753 and rapid spread of a new severe acute respiratory syndrome
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3463,CoV-2) lineage with multiple spike mutations in South Africa
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4361,Estimated 757 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1945,Public Health England. SARS-CoV-2 variants of concern and variants under investigation
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1052,Increased 763 transmissibility and global spread of SARS-CoV-2 variants of concern as at
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",635,"Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) for 766 the Scientific Advisory Group for Emergencies (SAGE). SPI-M-O: Consensus statement on 767 COVID-19"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5514,SARS-CoV-2 B.1.1.7 and B.1.351 spike 771 variants bind human ACE2 with increased affinity
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",899,The continuous 775 evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations 776 of concern and global detection
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3174,Hospital 784 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared 785 with alpha (B.1.1.7) variants of concern: a cohort study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",571,Neutralizing Activity of 789 BNT162b2-Elicited Serum
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1986,"Neutralization of SARS-CoV-2 spike 791 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1307,.351 and P.1 escape from neutralizing antibodies
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",35,CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5898,Two doses of 800 SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 801 variants of concern than does natural infection
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4925,CoV-2 variants escape neutralization by vaccine-induced humoral immunity
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",673,CoV-2 variants by convalescent and vaccinated serum. medRxiv. 9 avr 809 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2962,Reduced neutralization of 811 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5,Qualitatively 814 distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1856,mRNA vaccine-elicited 817 antibodies to SARS-CoV-2 and circulating variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5085,1 strain of SARS-CoV-2. Cell [Internet]. 30 mars 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2372,Neutralizing Response 822 against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1158,Ineffective 825 neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2580,mRNA-1273 vaccine 829 induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",366,Susceptibility of Circulating 832 SARS-CoV-2 Variants to Neutralization
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4411,Neutralization of UK-834 variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",76,Serum neutralising activity against SARS-CoV-2 837 variants elicited by CoronaVac
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3053,SARS-CoV-2 variant B.1.1.7 is 845 susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3765,Neutralization of SARS-CoV-2 VOC 501Y.V2 848 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD 849 ZF2001 vaccines
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1635,"851 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant 852 spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5457,Infection-and 855 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4738,1.429 and B.1.351
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2998,Reduced neutralisation of 860 the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5361,Infectious Diseases (except HIV/AIDS); 2021 juin
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3730,S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of 865 concern
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5752,Temporal 867 Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape 868 after Sputnik V Vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3108,Infection and Vaccine-871 Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",610,Comparison of 875 Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-876
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3965,CoV-2 Variants. bioRxiv. 19 juill 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",347,Serum Neutralizing Activity of 878 mRNA-1273 against SARS-CoV-2 Variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3646,BNT162b2-elicited neutralization of 880 B.1.617 and other SARS-CoV-2 variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2804,Reduced 882 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4053,Neutralising capacity 886 against Delta (B.1.617.2) and other variants of concern following Comirnaty
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4350,BioNTech/Pfizer) vaccination in health care workers
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5697,SARS-CoV-2 B.1.617.2 890 Delta variant replication and immune evasion
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3776,Reduced neutralization of SARS-CoV-2 B.1.617 893 variant by inactivated and RBD-subunit vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1436,"Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern 896 (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. 897 Vaccines"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2323,Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3235,CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection 903 and vaccination. bioRxiv. 5 mai 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1691,"Vaccine 905 effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3700,"Transmission, 908 infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California 909 carrying a L452R spike protein mutation"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1233,"A Novel and 911 Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",675,"Reduced 914 neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",6133,B.1.1.7+E484K and a sub-variant of C.37 [Internet]. 2021 juill
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1305,SARS-CoV-2 immune evasion 919 by variant B.1.427/B.1.429
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5357,BNT162b2-Elicited Neutralization 921 against New SARS-CoV-2 Spike Variants
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2941,CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3130,Disponible sur: 925
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",92,SARS-CoV-2 Lambda 927 Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",522,Neutralizing antibody 931 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5066,BNT162b2 vaccine 934 induces neutralizing antibodies and poly-specific T cells in humans
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5126,Low dose mRNA-937 1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-938 existing crossreactive T cell memory
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3464,Evidence of SARS-Cov-2-942 specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3389,COVID-19 vaccination: initial reactogenicity data. The Lancet
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1118,Un ensayo clínico evaluará una segunda dosis de la vacuna de 950
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4683,Pfizer en personas ya vacunadas con una dosis de AstraZeneca
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1259,"Safety and 954 immunogenicity of heterologous versus homologous prime-boost schedules with an 955 adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, 956 non-inferiority trial. The Lancet"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3897,Induction of robust neutralizing antibodies 958 against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster 959 following a primary vaccination series with CoronaVac
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3977,Single-dose 963 administration and the influence of the timing of the booster dose on immunogenicity and 964 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. 965 The Lancet. 6 mars 2021
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4658,Strong humoral 967 immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 968 sixteen-week interval between doses
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2938,Extended interval 972 BNT162b2 vaccination enhances peak antibody generation in older people
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",294,Safety 976 and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients 977 with cancer: interim analysis of a prospective observational study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1876,Immunogenicity of 981 a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. 982 JAMA
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5525,High seroconversion rate 984 but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients 985 treated with chemotherapy for solid cancers
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1918,Randomized Trial of a 989 Third Dose of mRNA-1273 Vaccine in Transplant Recipients
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5521,Antibody 991 Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 992 Recipients With Minimal Serologic Response to 2 Doses
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4390,Short Term Reduction in 994 the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three 995 doses of the BNT162b2 Vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3487,Protection 999 of BNT162b2 Vaccine Booster against Covid-19 in Israel
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3574,SARS-CoV-2 1001 Neutralization with BNT162b2 Vaccine Dose 3
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1949,Safety and immunogenicity of SARS-CoV-2 1003 variant mRNA vaccine boosters in healthy adults: an interim analysis
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4844,mRNA vaccination 1006 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5518,Antibody 1010 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2990,Antibody Response in Persons with Past Natural Infection
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1309,Distinct 1015 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals 1016 following mRNA vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4515,Poor 1019 antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-1020 experienced individuals
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5818,Single Dose 1022 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2136,COVID-19 vaccine safety update
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1531,Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine 1029 Recipients: Update from the Advisory Committee on Immunization Practices -United States
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3320,MMWR Morb Mortal Wkly Rep
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4827,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1066,Receipt of mRNA Covid-1036 19 Vaccines and Risk of Spontaneous Abortion
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1528,"Clinical manifestations, risk 1038 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living 1039 systematic review and meta-analysis"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4375,Surveillance for Adverse 1041
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",363,Events After COVID-19 mRNA Vaccination
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",2356,1042 Disponible sur
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1978,Coronavirus vaccine -weekly summary 1044 of Yellow Card reporting
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",851,Safety of the BNT162b2 1048 mRNA Covid-19 Vaccine in a Nationwide Setting
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3006,Safety Monitoring of COVID-19 Vaccines in Hong Kong
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1385,Moderna COVID-19 Vaccine -United States
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",4593,A Retrospective observational survey of 1058 adverse events following immunization comparing tolerability of covishield and covaxin 1059 vaccines in the real world
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5776,ROCCA observational 1063 study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San 1064 Marino using active surveillance
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",6037,Active monitoring of early safety of Sputnik V vaccine in
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5088,Quinto Informe Estadistico: 1069 ESAVI asociados a la administracion de las vacunas SARS-CoV-2 en Chile
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1349,Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1613,Potential adverse effects of COVID19 1076 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a 1077 retrospective cross-sectional study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",782,"Effectiveness of BNT162b2 and 1079 ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 1080 80 years: a test-negative, case-control study"
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3070,Interim findings from first-1083 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a 1084 national prospective cohort study
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3924,Early rate reductions of SARS-CoV-2 1086 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet. 6 mars
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",3062,Experience of 1089 COVID-19 Vaccination of Healthcare Workers in a Hospital Setting
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5207,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two 1093 Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1053,Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for 1098 COVID-19. medRxiv
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",5285,Association 1100 Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3",1149,"Effectiveness 1103 of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant 1104 transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health -Am 1105"
1,,5625,The proximal origin of SARS-CoV-2
1,,4108,Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2
1,,2006,"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status"
1,,5189,Vírus emergentes e reemergentes
1,,1120,Animal and Human Coronavirus Disease
1,,5866,Invasion Science and the Global Spread of SARS-CoV-2
1,,1572,History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic
1,,1529,The presence of SARS-CoV-2 RNA in human sewage
1,,3148,Immunology of COVID-19: Current state of the science
1,,4015,Polyclonal F(ab )2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
1,,3188,Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
1,,2147,Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a Hif-1a/Glycolysis Dependent Axis
1,,2517,Antiviral activities of type I Interferons to SARS-CoV-2 infection
1,,4282,Structural basis for the recognition of the SARS-CoV-2 by full length human ACE-2
1,,2571,How to discover antiviral drugs quickly
1,,2614,Mutations of SARS-CoV-2-What Do They Mean?
1,,1123,Potential host range of multiple SARSlike coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
1,,1889,Characterizing genomic variants and mutations in SARS-CoV-2 proteins from Indian isolates
1,,467,Microchip-based structure determination of low-molecular weight proteins using cryo-electron microscopy
1,,4234,The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?
1,,1342,The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation
1,,5744,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
1,,4775,Genomic characterization of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings
1,,5254,Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy
1,,4570,"Convergent evolution of SARS-CoV-2 spike mutations L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra"
1,,1495,Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian 5 origin harbouring both substitutions N501Y and E484K in the spike protein
1,,4550,SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
1,,2507,Severe acute respiratory coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
1,,3496,Coronavirus vaccine trials have delivered their first results-But their promise is still unclear
1,,3028,The COVID-19 vaccine development landscape
1,,23,Next-generation vaccine platforms for COVID-19
1,,3297,A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
1,,4600,ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
1,,3051,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind"
1,,4748,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial"
1,,3119,Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein
1,,5661,Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
1,,2595,An mRNA Vaccine against SARS-CoV-2-Preliminary Report
1,,1538,Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
1,,504,Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
1,,3187,Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
1,,5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
1,,3075,"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial"
1,,2402,A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
1,,532,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia"
1,,2354,First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
1,,5853,Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
1,,3988,Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. FDA News Release
1,,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
1,,1206,Immunogenicity of Heterologous Prime/Booster-Inactivated and Adenoviral-Vectored COVID-19 Vaccine: Real-World Data
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",4409,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",550,Association between 3 doses of mRNA COVID-19 Vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",1078,Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",1045,Malaysia: Ministry of Health Malaysia
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",2531,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",3228,Computation and analysis of multiple structural change models
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",443,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study"
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection",2107,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,1222,Fatal anaphylaxis in children in France: analysis of national data
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,1092,Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,5015,Maintaining safety with SARS-CoV-2 vaccines
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,317,Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,4170,"Department of Health, the Government of Hong Kong Safety monitoring of COVID-19 vaccines in Hong Kong"
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,672,Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,2249,BÜHLMANN Laboratories AG. Flow CAST® Basophil Activation Test (BAT) Flow Cytometry
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,716,Basophil activation test application in drug hypersensitivity diagnosis: an empirical approach
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,3232,Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a,5678,Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5213,The epidemiology and clinical information about COVID-19
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4123,COVID-19: insight into the asymptomatic SARS-CoV-2 infection and transmission
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3784,Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,410,Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4309,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2043,COVID-19 pathophysiology: a review
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5868,Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5850,A Review of coronavirus disease-2019 (COVID-19)
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4414,Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3754,Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5141,"SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,814,COVID-19 vaccines: the status and perspectives in delivery points of view
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,1039,A Review of the progress and challenges of developing a vaccine for COVID-19
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,545,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3144,"Eficácia global da Coronavac é de 50,38%, anuncia governo paulista"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5788,Present yourself! By MHC Class I and MHC Class II molecules
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2779,"Serological testing for COVID-19, immunological surveillance, and exploration of protective antibodies"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2536,Development of low-cost serological immunoassay to detect antiviral antibodies to SARSars-Cov-2 Spike protein
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3751,Relation between COVID-19 and Guillain-Barré syndrome in adults. Systematic review
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,1331,Guillain-Barré syndrome associated with SARS-CoV-2
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,1036,The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,5364,COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,4637,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,953,SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2589,SARS-CoV-2 seroprevalence and risk factors among health care workers: estimating the risk of COVID-19 dedicated units
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2250,Vaccination and induction of autoimmune diseases
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,152,Immunemediated adverse reactions to vaccines
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,3079,"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence"
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers,2543,Sequential IgG antibody monitoring for virusinactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5353,High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,858,World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,1236,The impact of the COVID-19 pandemic on medical education
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3505,"Emotional, behavioral, and psychological impact of the COVID-19 pandemic"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,1425,Observed impacts of the COVID-19 pandemic on global trade
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3347,World Health Organization. Draft landscape of COVID-19 candidate vaccines
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,1031,World Health Organization. COVID-19 advice for the public: Getting vaccinated
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,82,Viral targets for vaccines against COVID-19
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3338,Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5341,Approaches and challenges in SARS-CoV-2 vaccine development
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5352,Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4461,World Health Organization. Covid-19 vero cell inactivated
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,183,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,404,"Food and Drug Administration, Ministry of Public Health, Thailand. Details of Medicinal Product"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5275,Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4659,ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3975,Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,195,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial"
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5815,Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5600,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,419,Correlates of protection against SARS-CoV-2 in rhesus macaques
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,501,Antibody status and incidence of SARS-CoV-2 infection in health care workers
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,3725,Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,941,Antibody response to SARS-CoV-2 infection in humans: a systematic review
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4874,A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,4406,Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,1669,Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",3485,A novel coronavirus from patients with pneumonia in China
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4051,Immune responses to SARS-CoV-2 among patients with cancer: what can seropositivity tell us?
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4607,• Comment about seropositivity in cancer patients
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4906,WHO. WHO coronavirus (COVID-19) dashboard
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5258,Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5758,Determinants of COVID-19 disease severity in patients with cancer
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",2333,SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5450,Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",2637,COVID-19 and cancer: current challenges and perspectives
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5205,Impact of the COVID-19 pandemic on surgical oncology in Europe: results of a European survey
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4650,Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",513,"Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study"
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",486,Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs study
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",1276,Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4088,SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5493,National Comprehensive Cancer Network. Recommendations of the NCCN COVID-19 vaccination advisory committee
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5784,Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",1787,•• Study which evaluated antibody development in cancer patients after COVID-19 infection
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4045,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, Phase 1/2 trial"
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",3880,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, Phase 3 trial in Turkey"
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",2672,•• Study which evaluated the efficacy and safety profile of CoronaVac
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",6014,Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4616,• Study which evaluated the efficacy and safety profile of CoronaVac in cancer patients
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",3358,Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",2334,• Study which evaluated the mRNA vaccine BNT162b2 in cancer patients
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5244,SARS-CoV-2-Immnuoassays
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",1911,AdviseDx SARS-CoV-2 IgG II package insert
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4228,Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",1124,Influenza vaccination in patients with breast cancer: a case-series analysis
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",670,SARS-CoV-2 vaccines in development
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",4627,Association of SARS-CoV-2 seropositive antibody test with risk of future infection
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",969,Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",5885,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study",3247,Epub ahead of print) future science group
1,,1573,BNT162b2 mRNA COVID-19 Vaccine Effectiveness among Health Care Workers
1,,4692,Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
1,,1211,Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
1,,2133,Vaccine Breakthrough Infections with SARS-CoV-2 Variants
1,,3611,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
1,,1145,SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
1,,2047,COVID-19 dynamics after a national immunization program in Israel
1,,3944,Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,3846,Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,5111,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,5901,Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The Lancet. Infectious diseases 21
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,3134,Homologous and Heterologous Covid-19 Booster Vaccinations
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,2619,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,1044,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,4865,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,4409,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,2528,"Balazs, mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,949,"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,3344,Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,5714,The T cell immune response against SARS-CoV-2
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,4923,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,166,Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,688,Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,3746,Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming,1855,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,6143,"MRA and PPB were supported by Coordination for the Improvement of Higher Education Personnel (88887.356527/2019-00) fellowships, and DAT-T and LSM were supported by CNPq fellowships"
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1409,MSD was supported by a grant from the National Institutes of Health (U01 grant AI151810). We thank Wendy Barclay for helpful discussions
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2242,"all blood donors, vaccinated individuals, and SARS-CoV-2 patients who provided clinical specimens for this study"
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2481,Thermo Fisher Scientific for provision of an EVOS inverted microscope for the biosafety level 3 facility at the Emerging Viruses Laboratory; the National Institute of Science and Technology of Photonics Applied to Cell Biology for confocal microscopy analysis; UNICAMP-Task-Force against COVID-19
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,626,for technical support; all individuals involved in the diagnosis and generation of SARS-CoV-2 sequences as part of the CADDE-Genomic-Network; and the MCTI and all members of the Corona-ômica network for support
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,4654,A new coronavirus associated with human respiratory disease in China
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,4906,WHO. WHO coronavirus (COVID-19) dashboard
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1142,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,5899,SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,755,A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1147,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,761,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,3820,Detection of a SARS-CoV-2 variant of concern in South Africa
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2079,Antibody evasion by the P.1 strain of SARS-CoV-2
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2366,Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2999,"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil"
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,3218,Virological assessment of hospitalized patients with COVID-2019
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,3793,SARS-CoV-2 uses CD4 to infect T helper lymphocytes
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,2396,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,387,SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1822,SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1214,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1159,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021: published online
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,5378,Mapping the antigenic and genetic evolution of influenza virus
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,567,A human coronavirus evolves antigenically to escape antibody immunity
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,1285,Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study,3329,Delayed production of neutralizing antibodies correlates with fatal COVID-19
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,5217,mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,2569,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,5469,Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection,889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,5495,Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1325,COVID-19 vaccination and antirheumatic therapy
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,2578,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases"
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1502,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1966,"The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress"
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,3436,Systemic sclerosis and the COVID-19 pandemic: world Scleroderma Foundation preliminary advice for patient management
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1204,2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,4013,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,4887,Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,749,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy,1826,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",3083,Sjögren's syndrome: a systemic autoimmune disease
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2524,Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2171,The epidemiology of Sjögren's syndrome
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",5472,Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a crosssectional study from the Big Data Sjögren Project Consortium
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2996,Clinical and prognostic characteristics of 573 cases of primary Sjögren's syndrome
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",136,"Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1070,Mortality in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. Rheumatology (Oxford) keab364
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1574,Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",633,"COVID-19 in association with development, course, and treatment of systemic autoimmune rheumatic diseases"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4484,Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",3777,SARS-CoV-2 infection in patients with systemic autoimmune diseases
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4523,SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2017,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis annrheumdis-2021-220503
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4374,"Sinovac is the most used vaccine in the world, with 943M doses delivered"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2198,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1548,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",3365,Short and longterm effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",5240,Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",5628,Research electronic data capture (REDCap)-a metadatadriven methodology and workflow process for providing translational research informatics support
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4684,WHO. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",3068,Development of the ClinESSDAI: a clinical score without biological domain A tool for biological studies
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",5264,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2052,Sex differences in vaccine-induced humoral immunity
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1275,Comparison of ESS-DAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1880,Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4708,"Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis"
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",4886,A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",446,Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2381,Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2975,Arthritis Foundation. ACR COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",1009,Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",3074,Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",2311,Salivary glands are a target for SARS-CoV-2: a source for saliva contamination
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine",5499,Will the COVID-19 pandemic trigger future occurrence of autoimmunity like Sjögren's syndrome?
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4928,Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5497,Validation of real-time RT-PCR for detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5699,Characteristics of SARS-CoV-2 and COVID-19
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1479,Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,2297,Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4261,Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,335,Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,931,COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19-Molecular Mechanisms and Research Perspectives
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3864,Association between IL-10 systemic low level and pain during symptomatic SARS-CoV-2 infection
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3440,"Mask up to keep it up"": Preliminary evidence of the association between erectile dysfunction and COVID-19"
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3190,Emergence of SARS-CoV-2 Variants in the World: How Could This Happen? Life
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5069,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination-Kentucky
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4125,Efficacy and safety of COVID-19 vaccines: A systematic review
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,426,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data"
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3427,Do vaccines protect against long COVID? What the data say
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1649,Data. Coronavirus Pandemic (COVID-19). 2022. Available online
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1763,"Vacunas SARS CoV-2, estudios en fase III"
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3928,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded"
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4331,Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. Front. Public Health
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,218,Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4397,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Reagent Pack
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,3560,CoV-2 nAb FIA
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,731,IFN-Gamma) Technical Document
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4190,Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1022,Covid-19: Canada relaxes age limits on AstraZeneca vaccine as Ontario cases surge
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,773,Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4010,Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5117,Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,2725,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,2532,Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,4560,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers"
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,711,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,1667,Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination,5369,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1614,A novel Coronavirus from patients with pneumonia in china
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5699,Characteristics of SARS-CoV-2 and COVID-19
484,Dynamics of antibody response to CoronaVac vaccine Funding information,704,WHO declares COVID-19 a pandemic
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1134,SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
484,Dynamics of antibody response to CoronaVac vaccine Funding information,3319,Rapid COVID-19 vaccine development
484,Dynamics of antibody response to CoronaVac vaccine Funding information,933,The race for coronavirus vaccines: a graphical guide
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1852,An mRNA vaccine against SARS-CoV-2-preliminary Report
484,Dynamics of antibody response to CoronaVac vaccine Funding information,670,SARS-CoV-2 vaccines in development
484,Dynamics of antibody response to CoronaVac vaccine Funding information,287,A strategic approach to COVID-19 vaccine R&D
484,Dynamics of antibody response to CoronaVac vaccine Funding information,33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,3298,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4885,"COVID-19 in health-care workers: a living systematic review and metaanalysis of prevalence, risk factors, clinical characteristics, and outcomes"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2413,COVID-19: protecting health-care workers
484,Dynamics of antibody response to CoronaVac vaccine Funding information,3112,"World Health OrganizationInterim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac: Interim Guidance"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5704,2 -Vaccine immunology. Plotkin's vaccines. 7th end. Elsevier
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4942,Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
484,Dynamics of antibody response to CoronaVac vaccine Funding information,6027,Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4757,"Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge"
484,Dynamics of antibody response to CoronaVac vaccine Funding information,372,Cellular and humoral immune responses in Covid-19 and immunotherapeutic approaches
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2084,Adaptive immunity to SARS-CoV-2 and COVID-19
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5129,SARS-CoV-2 Immunoassays: advancing diagnostics of COVID-19
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2488,Remembrance of things past: long-term b cell memory after infection and vaccination
484,Dynamics of antibody response to CoronaVac vaccine Funding information,3594,Sex differences in immune responses
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4615,Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5468,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
484,Dynamics of antibody response to CoronaVac vaccine Funding information,891,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VI-VALDI): a prospective cohort study
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2223,COVID-19 mRNA vaccination generates greater immunoglobulin g levels in women compared to men
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1664,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
484,Dynamics of antibody response to CoronaVac vaccine Funding information,3975,Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4321,Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5102,Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5017,SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1747,Single dose vaccination in healthcare workers previously infected with SARS-CoV-2
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1026,SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4362,First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
484,Dynamics of antibody response to CoronaVac vaccine Funding information,230,Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
484,Dynamics of antibody response to CoronaVac vaccine Funding information,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5507,The impact of pre-existing comorbidities and therapeutic interventions on COVID-19
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
484,Dynamics of antibody response to CoronaVac vaccine Funding information,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
484,Dynamics of antibody response to CoronaVac vaccine Funding information,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
484,Dynamics of antibody response to CoronaVac vaccine Funding information,5312,How to cite this article: Fonseca MHG
484,Dynamics of antibody response to CoronaVac vaccine Funding information,4980,Dynamics of antibody response to CoronaVac vaccine
1,,4179,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac"
1,,984,SARS-CoV-2 Variants and Vaccines
1,,2768,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
1,,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
1,,4739,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial"
1,,1133,Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
1,,1759,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
1,,2078,Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
1,,5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
1,,3607,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
1,,3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey
1,,2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
1,,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
1,,817,Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1
1,,3196,Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
1,,3324,Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems
1,,3568,Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
1,,88,Peculiarities of the T Cell Immune Response in COVID-19
1,,2555,Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
1,,6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
1,,975,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience
1,,2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
1,,909,WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
1,,5263,"Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine"
1,,4834,SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
1,,258,T cell responses to SARS-CoV-2 spike cross-recognize Omicron
1,,1689,Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
1,,589,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
1,,113,Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
1,,5567,Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates
1,,1617,Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
1,,5369,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
1,,5536,SARS-CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv 2021
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,1462,The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2909,Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4165,Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2325,New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination. Case Rep Rheumatol
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2041,ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4913,New-onset autoimmune phenomena post-COVID-19 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,1100,"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination"
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4464,Oral pemphigus after COVID-19 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4831,"Autoimmune bullous skin diseases, pemphigus and pemphigoid"
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,462,Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review. Vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2764,Diagnosis and management of pemphigus: Recommendations of an international panel of experts
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,3770,Food and Drug Administration Rituxan label
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,3161,Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,1983,Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4962,Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2636,An unusual presentation of pemphigus foliaceus following COVID-19 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4636,Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,209,Epub ahead of print
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,255,Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2538,A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,3407,Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,644,Bullous pemphigoid and COVID-19 vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,6066,Case of bullous pemphigoid following coronavirus disease 2019 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,130,New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2174,Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2905,Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4542,Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,5561,Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,708,Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,910,Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4072,Pemphigus vulgaris after SARS-CoV-2 vaccination: a case with new-onset and two cases with severe aggravation
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2418,COVID-19) Dashboard
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2379,The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,1810,Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,298,Covid-19 and autoimmunity
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,4324,"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to ""potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review,2894,Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,3307,Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,4665,Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2276,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,5560,Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years-United States
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,1297,The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2643,Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,1729,Practical Statistics for Medical Research
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,459,Statistics in Clinical Vaccine Trials
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,3931,Survival Analysis: Techniques for Censored and Truncated Data
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,5796,R: A Language and Environment for Statistical Computing
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,3933,Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,4013,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,210,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma-variant transmission in Manaus, Brazil: a test-negative case-control study"
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,4992,Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2903,Plano Nacional de Operacionalização da Vacinação contra a COVID-19. 2021. Ministério da Saúde website
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,1863,Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2676,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,1166,Vaccine breakthrough infections with SARS-CoV-2 variants
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,1925,COVID-19 vaccine breakthrough infections reported to CDC-United States
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,2104,A systematic review of quasiexperimental study designs in the fields of infection control and antibiotic resistance
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,3341,Interim Public Health recommendations for fully vaccinated people
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers,3268,Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination. US Food and Drug Administration website
1,,182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
1,,146,Thailand Allows Emergency Use of Sinovac's COVID-19 Vaccine
1,,4611,Summary of Product Characteristic CoronaVac
1,,2003,Vaxzevria (Previously COVID-19 Vaccne AstraZeneca)
1,,1847,Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
1,,2007,Covid-19 breakthrough infections in vaccinated health care workers
1,,3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
1,,1506,Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
1,,3910,Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
1,,4546,Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
1,,2027,Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
1,,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
1,,5363,Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection
1,,5217,mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
1,,4457,Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
1,,2692,SARS-CoV-2 B. 1.1. 529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",62,Vacunación contra COVID-19 Bogotá D.C.2022
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5389,"Comparing COVID-19 vaccines for their characteristics, efficacy, and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",795,Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4535,Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5656,COVID -2019) en Colombia: Instituto Nacional de Salud
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",2079,Antibody evasion by the P.1 strain of SARS-CoV-2
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5972,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. The Lancet Microbe
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4098,Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",3716,Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4883,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",6120,Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5778,A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",5060,Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4749,"Association of SARS-CoV-2 Vaccinations with SARS-CoV-2 Infections, ICU Admissions and Deaths in Greece. Vaccines (Basel)"
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",2112,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines. Vaccines (Basel)
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4105,"Correlation Between SARS-Cov-2 Vaccination, COVID-19 Incidence and Mortality: Tracking the Effect of Vaccination on Population Protection in Real Time"
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4332,High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",2406,Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies. Vaccines (Basel)
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",1683,Neutralizing antibody titres in SARS-CoV-2 infections
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021",4555,Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,392,International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis?
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,1895,Vaccination against COVID-19 and inequalities -avoiding making a bad situation worse. Public Health Pract (Oxf) 2:100101
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,4491,Strengthened health systems are needed to tackle COVID-19 in Africa
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2416,"COVID-19 and postinfection immunity: limited evidence, many remaining questions"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,812,Covid-19 vaccines: delivering protective immunity
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2674,Rapid generation of neutralizing antibody responses in COVID-19 patients
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,4366,COVID-19 Vaccines: a review of the safety and efficacy of current clinical trials
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,974,Organization WH (2021) Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5176,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,460,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coro-naVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5872,Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines (Basel)
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,3397,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,3409,Current advances in the development of SARS-CoV-2 vaccines
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2711,Inactivated COVID-19 vaccines to make a global impact
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5231,Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2624,First case of 2019 novel coronavirus in the United States
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2604,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,458,Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,18,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2186,Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,728,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel)
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,5696,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19,4967,Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4379,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4506,"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2368,Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3611,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3947,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3289,Serum antibody profile of a patient with coronavirus disease 2019 reinfection
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1507,"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1361,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,536,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4193,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2616,Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5998,National study group for C-E. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3069,Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1418,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4398,Transmission of Omicron (B.1.1.529) -SARS-CoV-2 variant of concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2585,Enhanced readiness for Omicron (B.1.1.529): technical brief and priority actions for member states
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2347,SARS-CoV-2 variants of concern and variants under investigation in England
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1323,Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2187,The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2768,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5952,Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5836,Plasma neutralization of the SARS-CoV-2 Omicron variant
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4761,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 33
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2068,Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4242,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5535,Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4997,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,468,Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2283,Antibody response of BNT162b2 and CoronaVac platforms in recovered individuals previously infected by COVID-19 against SARS-CoV-2 wild type and delta variant
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4820,Performance of a surrogate SARS-CoV-2-neutralizing antibody assay in natural infection and vaccination samples
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3728,On determining the most appropriate test cut-off value: the case of tests with continuous results
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4142,SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,6162,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5847,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2007,Covid-19 breakthrough infections in vaccinated health care workers
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2827,Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2879,"M on behalf of the VIPER (Vaccines IdP, and Epidemiology Research) group COVID-19 vaccine development and approvals tracker team, COVID-19 vaccine development and approvals tracker"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,416,China's COVID vaccines have been crucial -now immunity is waning
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5365,Recognition of Variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,50,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3020,Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,4806,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,2035,"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay"
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,658,Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5198,Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,5614,Tracking coronavirus vaccinations around the world
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines,3390,Multilateral leaders task force on COVID-19. Data. Available at
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4099,Will SARS-CoV-2 become endemic?
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,3861,SARS-CoV-2 vaccines: status report
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4936,Rapid field determination of SARS-CoV-2 by a colorimetric and fluorescent dual-functional lateral flow immunoassay biosensor
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4892,"Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays"
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4652,Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-reactive antibodies
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,1147,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4513,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,1484,Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5046,Verification of precision and estimation of bias; approved guideline
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,2525,"Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. West Valley Road, Suite 2500"
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5804,Interference Testing in Clinical Chemistry; Approved Guideline
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5706,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4803,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled phase 1/2 clinical trials. medRxiv"
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,3353,A thermostable mRNA vaccine against COVID-19
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,2244,Antibody titres decline 3-month post-vaccinationwith BNT162b2
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,6031,Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,2337,Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine. Vaccines (Basel)
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5172,Effect of COVID-19 on anti-S antibody response in health care workers six months post-vaccination. Vaccines (Basel)
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5216,Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5261,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,1819,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,2493,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples"
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,2121,A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5793,Potently neutralizing and protective human antibodies against SARS-CoV-2
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,4682,Publisher's Note
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,296,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the first case report
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,5522,Immunization related focal neurological syndrome after coronavac vaccination
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,4424,Evaluating and managing severe headache in the emergency department
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,5583,"Timing and topography of cerebral blood flow, aura, and headache during migraine attacks"
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,2899,Time course of cerebral perfusion changes in children with migraine with Aura mimicking stroke
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,172,Migraine associated cerebral hyperperfusion with arterial spin-labeled MR imaging
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,3603,"Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura"
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,1095,Prolonged hemiplegic migraine associated with unilateral hyperperfusion on perfusion weighted magnetic resonance imaging
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,1899,Cerebral perfusion changes in hemiplegic migraine: illustrated by Tc-99m ECD brain perfusion scan
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,3394,Biphasic neurovascular changes in prolonged migraine aura in familial hemiplegic migraine type 2
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,4716,Pathophysiology of migraine: a disorder of sensory processing
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,5116,The typical duration of migraine aura: a systematic review
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,5672,The International Classification of Headache Disorders
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,1611,Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,866,Spreading depression and the clinical correlates of migraine
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,4131,A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,2070,"Migraine, obesity and body fat distribution -a population-based study"
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,126,"Triggers, protectors, and predictors in episodic migraine"
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,3586,COVID-19: is it just a lung disease? A casebased review
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,5423,Induction of production of nitric oxide in microglial cells by insoluble form of aluminium
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,4604,Aluminum treatment induces nitric oxide synthase in the rat brain
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series,2224,"Time to re-evaluate. SN Compr Clin Med:1, 1-2. Advance online publication"
2618,Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines,2176,Respirology Epub ahead of print
2618,Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines,2135,Clin Infect Dis (2021) Epub ahead of print
2618,Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines,385,"Table Table: Age, sex and geometric mean 50% plaque reduction neutralization test (PRNT 50 ) titres vs"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,2418,COVID-19) Dashboard
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,3200,COVID-19 vaccine tracker and landscape
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,581,COVID-19 Aşısı Ulusal Uygulama Stratejisi
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,1301,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,3406,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,498,Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,3149,"Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 2021"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,416,China's COVID vaccines have been crucial -now immunity is waning
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,745,Naming SARS-CoV-2 variants
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,4632,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in Sao Paulo, Brazil"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,1520,BNT162b2-Elicited Neutralization against New SARS-CoV-2 spike variants
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,2447,Vaccines highly effective against hospitalisation from Delta variant
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,2845,Michos A SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,2150,Turkey: 85% of new COVID-19 cases due to UK variant
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,5825,"Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,384,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R)"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,1833,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines medRxiv
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,5621,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival,6152,"Indonesia's Doctors Got Vaccinated With Sinovac, and Got Sick 2021"
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,4589,"A randomized, double-blind, placebocontrolled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,252,Diagnosis of breast cancer with infrared spectroscopy from serum samples
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,3580,Ultrarapid on-site detection of sars-cov-2 infection using simple atr-ftir spectroscopy and an analysis algorithm: high sensitivity and specificity
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5849,The global phosphorylation landscape of SARS-CoV-2 infection
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,174,Antibody responses in COVID-19: a review
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,1460,Screening of protective effect of amifostine on radiation-induced structural and functional variations in rat liver microsomal membranes by FT-IR spectroscopy
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,502,The structural and functional damages of whole body ionizing radiation on rat brain homogenate membranes and protective effect of amifostine
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5556,Understanding the symptoms of the common cold and influenza
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,3126,Multivariate Data Analysis: In Practice: an Introduction to Multivariate Data Analysis and Experimental Design
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,4843,Fouriertransform infrared spectroscopy coupled with a classification machine for the analysis of blood plasma or serum: a novel diagnostic approach for ovarian cancer
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2735,Bladder cancer diagnosis from bladder wash by Fourier transform infrared spectroscopy as a novel test for tumor recurrence
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,90,"Restoring effect of selenium on the molecular content, structure and fluidity of diabetic kidney brush border cell membrane"
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5337,"Methylation, sugar puckering and Z-form status of DNA from a heavy metal-acclimated freshwater Gordonia sp"
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,1720,Principal Component Analysis. Springer Series in Statistics
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5447,Use of FTIR spectroscopy and PCA-LDC analysis to identify cancerous lesions within the human colon
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,3374,Spectroscopy as a tool for detection and monitoring of Coronavirus (COVID-19)
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,1775,Disease recognition by infrared and Ramanspectroscopy
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,1254,Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,3315,FTIR spectroscopy of whole cells for the monitoring of yeast apoptosis mediated by p53 over-expression and its suppression by Nigella sativa extracts
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2042,Phosphorylation regulates the subcellular localization of Cucumber Mosaic Virus 2b protein
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,753,Serum-based diagnostic prediction of oral submucous fibrosis using FTIR spectrometry
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,3140,Study of SH-SY5Y cancer cell response to treatment with polyphenol extracts using FT-IR spectroscopy
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,639,ATR-FTIR spectroscopy for virus identification: a powerful alternative
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,4226,FT-IR spectroscopy in diagnosis of diabetes in rat animal model
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,4529,Introduction to vibrational spectroscopy in diagnosis and screening
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2504,Early alterations in myocardia and vessels of the diabetic rat heart :An FTIR microspectroscopic study
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5109,The importance of hydration and DNA conformation in interpreting infrared spectra of cells and tissues
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2243,Virological assessment of hospitalized patients with COVID
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2336,Plasma metabolomic and lipidomic alterations associated with COVID-19
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,5184,Relapsing-remitting multiple sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics,2449,Immune phenotyping based on the Neutrophil-to-Lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19
1,,2664,World Health Organization. COVID-19 Vaccines WHO EUL Issued
1,,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
1,,500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
1,,1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
1,,3267,BNT162b2 mRNA COVID-19 caccine in a nationwide mass vaccination setting
1,,1169,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study"
1,,1033,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
1,,4817,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study
1,,3216,Updates on COVID-19 Variants of Concern
1,,2114,SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse
1,,5024,Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
1,,82,Viral targets for vaccines against COVID-19
1,,3254,Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
1,,2718,Adaptive value of high mutation rates of RNA viruses: Separating causes from consequences
1,,3627,The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity
1,,4864,Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?
1,,3278,Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
1,,3064,SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 11. SARS-CoV-2 Variants of Concern and Variants under Investigation in England
1,,920,Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant
1,,939,Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
1,,5944,Understanding interobserver agreement: The kappa statistic
1,,2562,The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews. Checklist for Qualitative Research
1,,249,"Null hypothesis significance testing, p-values, effects sizes and confidence intervals"
1,,1195,"Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv 2021"
1,,3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
1,,1396,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
1,,4798,Effectiveness of BNT162b2 vaccine against Delta variant in adolescents
1,,5761,"SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness"
1,,3926,Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: The REACT-SCOT case-control study
1,,2505,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): A double-blind, randomised"
1,,4516,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection during a Delta variant epidemic surge in Multnomah County
1,,4394,Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults-United States
1,,2015,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study
1,,5056,"Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah. medRxiv 2021"
1,,1974,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
1,,4851,A review on current COVID-19 vaccines and evaluation of particulate vaccine delivery systems
1,,1167,COVID-19 Treatment and Vaccination Trackers
1,,4278,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis
1,,4685,Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
1,,6134,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant-National Healthcare Safety Network
1,,3896,"New COVID-19 cases and hospitalizations among adults, by vaccination status"
1,,4814,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2) variant in Qatar
1,,3446,"Rapid increase in circulation of the SARS-CoV-2, B. 1.617. 2 (Delta) variant-Mesa County"
1,,5306,"Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation"
1,,1811,"What Scientists Know about New, Fast-Spreading Coronavirus Variants"
1,,4786,"Vygen-Bonnet, S. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B. 1.617. 2) variant: Second interim results of a living systematic review and meta-analysis"
1,,2815,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis
1,,5814,World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines
1,,2294,Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials
1,,701,Factors that influence the immune response to vaccination
1,,3284,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
1,,4258,Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention
1,,768,The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
1,,53,"Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med. 2021, 41, 100998"
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,5799,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,3184,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,2563,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines. medRxiv
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,299,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,5376,The immunology of SARS-CoV-2 infections and vaccines
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH,1575,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,3518,COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,5799,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,2201,Prevalence and risk factors of CoronaVac side effects: an independent crosssectional study among healthcare workers in Turkey
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,2237,Centers for Disease Control and Prevention What to do if you had an allergic reaction after getting a COVID-19 vaccine
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,6166,Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,4380,Aluminiuminduced granulomas after inaccurate intradermal hyposensitisation injections of aluminium-adsorbed depot preparations
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination,2868,SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",2340,WHO remarks at the media briefing on COVID-19 -11
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4882,COVID-19 Vaccine: Critical Questions with Complicated Answers
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4819,Optic Neuritis After Influenza Vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",3118,"Optic Neuritis Complicating Measles, Mumps, and Rubella Vaccination"
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",5871,Bilateral optic neuritis complicating rabies vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4030,Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr Oslo Nor
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",5908,Bilateral retrobulbar optic neuritis with hepatitis B vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",1075,Optic neuritis after meningococcal vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",793,Optic neuritis and myelitis after booster tetanus toxoid vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",2533,Coronavirus Disease
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",5886,Late emergence of macular sparing in a stroke patient
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",1322,Middle Cerebral Artery Stroke
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",1668,Posterior Cerebral Artery Stroke
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",6045,Reversible cerebral vasoconstriction syndrome
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",3418,Cerebral venous sinus thrombosis
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",1779,"Retinal, ophthalmic, or ocular migraine"
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4750,Optic neuritis
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",2932,Multiple Evanescent White Dot Syndrome
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",2016,Acute Idiopathic Blind Spot Enlargement Syndrome: A Review of 27 New Cases
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",3316,Vascular wall imaging in reversible cerebral vasoconstriction syndrome -a 3-T contrast-enhanced MRI study
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",2781,Infectious optic neuropathies: a clinical update
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4781,Multiple evanescent white dot syndrome following influenza immunization -A multimodal imaging study
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",4271,Acute idiopathic blind spot enlargement syndrome following influenza vaccination
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report",3616,High-definition optical coherence tomography findings in acute idiopathic blind spot enlargement (AIBSE) syndrome
1805,Citation,3272,Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China
1805,Citation,642,Part II-The Positive Sense Single Stranded RNA Viruses
1805,Citation,5247,"Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum. Vaccines Immunother"
1805,Citation,5644,Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
1805,Citation,1141,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
1805,Citation,3201,An overview of COVID-19
1805,Citation,2477,"Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals"
1805,Citation,865,World Health Organization. COVID-9 Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide
1805,Citation,2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
1805,Citation,3520,COVID-19 Map-Johns Hopkins Coronavirus Resource Center
1805,Citation,124,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid"
1805,Citation,4984,Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil
1805,Citation,1440,ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
1805,Citation,4303,Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine
1805,Citation,2387,Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses
1805,Citation,5517,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
1805,Citation,2234,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19
1805,Citation,5231,Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
1805,Citation,2794,Antibody responses to SARS-CoV-2 in patients with COVID-19
1805,Citation,1143,Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
1805,Citation,4802,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
1805,Citation,6026,Predictors of Nonseroconversion after SARS-CoV-2 Infection
1805,Citation,3383,Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
1805,Citation,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
1805,Citation,2881,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid. In Plano de Operacionalização da Vacinação Contra a COVID-19, 11 a ; Brasil. Ministério da Saúde: Brasília, Brazil"
1805,Citation,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
1805,Citation,5100,Differential Kinetics of Immune Responses Elicited by COVID-19 Vaccines
1805,Citation,4922,Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study
1805,Citation,2085,"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden"
1805,Citation,396,SARS-CoV-2 Variants of Concern and Variants Under Investigation in England
1805,Citation,231,WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply: An Approach to Inform Planning and Subsequent Recommendations Based on Epidemiological Setting and Vaccine Supply Scenarios
1805,Citation,5481,SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3644,BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3604,"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1664,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1887,Secondary cases of Delta-variant COVID-19 among vaccinated healthcare workers with breakthrough infections is rare
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1008,An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1263,COVID-19 vaccine-breakthrough infections requiring hospitalization in Mayo Clinic Florida through
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3917,Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4201,"TAG-VE), classification of omicron (B.1.1.529): SARS-CoV-2 variant of Concern"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4630,Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,450,"Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,28,Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1019,"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5373,Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2853,Distribution of total cases of COVID-19 in the United States as of
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5251,Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1036,The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,415,Influence of immune aging on vaccine responses
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3714,Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,6030,Antibody response to influenza vaccination in the elderly: a quantitative review
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4751,The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,618,The immune response to influenza in older humans: beyond immune senescence
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,640,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary serie. medRxiv
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2007,Covid-19 breakthrough infections in vaccinated health care workers
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1756,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,455,Thai Healthcare Workers. medRxiv
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,950,Reduced mortality rate after coronavac vaccine among healthcare workers
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2675,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,285,"Public health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5393,Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. medRxiv
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4477,Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5743,"WHO Health Emergencies Programme, Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5748,The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4959,"SARS-CoV-2 variants, spike mutations and immune escape"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5692,BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. medRxiv
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,129,A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,356,IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,4219,The protective and pathogenic roles of IL-17 in viral infections: friend or foe?
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2500,Interleukin 17 is a chief orchestrator of immunity
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3561,CD8+ T cells clear influenza virus by perforin or Fas-dependent processes
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5839,Role of TNF-alpha in CD8+ cytotoxic T lymphocytemediated lysis
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2001,Between immunomodulation and immunotolerance: the role of IFNgamma in SARS-CoV-2 disease
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2405,The dual nature of type I and type II interferons
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1313,Interferongamma is a master checkpoint regulator of cytokine-induced differentiation
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2588,COVID-19 vaccines: modes of immune activation and future challenges
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5939,Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5848,Many Th cell subsets have Fas ligand-dependent cytotoxic potential
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,3987,Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,474,Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,2812,Cytomegalovirus-specific CD4 T cells are Cytolytic and mediate vaccine protection
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,212,High efficiency of antiviral CD4(+) killer T cells
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5430,Vaccination against persistent viral infection exacerbates CD4+ T-cell-mediated immunopathological disease
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine"
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,1732,Differential CD147 functional epitopes on distinct leukocyte subsets
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3894,"Lastest news, COVID-19 Coronavirus pandamic"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5762,The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3375,Vaccines against the B.1.617.2 (Delta) Variant
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5713,Thailand Medicines Regulation Division
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",4221,SARS-CoV-2 IgG Antibody Response after Immunization of Healthcare Workers with Inactivated COVID-19 Vaccine
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3818,Phyathai 3 Hospital. The. Bangkok
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5214,"All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3661,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3040,Confronting the Delta Variant of SARS-CoV-2
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5883,Delta to dominate world
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3745,Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",628,Correlation of SARS-CoV-2-breakthrough infections to time-fromvaccine
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",2596,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving twodose inactivated vaccines in healthy adults
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1834,"Boosting with heterologous vaccines effectively improves protective All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",930,"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1007,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1511,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3759,Boosting immunity to COVID-19 vaccines
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3715,China's COVID vaccines have been crucial-now immunity is waning
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",77,The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1941,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1377,Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1355,Humoral Responses and Serological Assays in SARS-CoV-2 Infections
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3063,A SARS-CoV-2 antibody curbs viral nucleocapsid proteininduced complement hyperactivation
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",1647,A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5914,Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",3339,T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",5691,Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers,4509,An interactive web-based dashboard to track COVID-19 in real time
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers,2840,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers,2535,"Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion"
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers,1931,Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers,5899,SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",5062,Second wave of COVID-19 in Brazil: Younger at higher risk
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",5384,World Health Organization. WHO coronavirus disease (COVID-19) dashboard
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",2375,Governo do Estado
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",1772,Efficacy and safety of a COVID-19 inactivated vaccine in health care professionals in Brazil: The PROFISCOV study
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",5964,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",849,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) -preliminary report
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",3985,Um ano de pandemia da COVID-19: Diversidade genética do SARS-CoV-2 no Brasil
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",1708,SARS-CoV-2 monitoramento atualizado em 21 de maio
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",1193,SARS-CoV-2: monitoramento -vigilância epigenômica
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",2820,SES/SP; 2021
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",6097,A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",6006,The increase in the risk of severity and fatality rate of COVID-19 in southern Brazil after the emergence of the variant of concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil",167,Genomic surveillance tracks the first communitary outbreak of Delta (B.1.617.2) variant in Brazil. SARS-CoV-2 coronavirus / nCoV-2019
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2409,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. Stockholm: European Centre for Disease Prevention and Control"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5106,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,4173,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5265,"Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime. medRxiv preprint"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5092,Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2118,Thailand sticks with Sinovac vaccine after cases of 'stroke-like' side effects. Reuters
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2369,"World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,238,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data. Res Sq
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3115,"Thailand to mix Sinovac, AstraZeneca vaccine doses"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1631,"Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3617,Amsterdam: European Medicine Agency
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,470,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,355,Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,4371,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2158,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5226,Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Res Sq
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1235,Development of an inactivated vaccine candidate for SARS-CoV-2. Science
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3788,Human IgG and IgA responses to COVID-19 mRNA vaccines
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3990,COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,820,Evolution of antibody immunity to SARS-CoV-2. bioRxiv
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,4937,Safety and Immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,801,COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,3298,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial"
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,5812,Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,589,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,1107,Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2611,Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine. Emerg Infect Dis
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study,2952,Thailand cites positive results from Sinovac-AstraZeneca vaccine formula. Reuters
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5191,COVID-19) Situation Report
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5924,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1953,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3180,Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3474,"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1974,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,4180,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5899,SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1443,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3022,"The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,314,Efficacy of NVX-CoV2373 COVID-19 Vaccine against the B.1.351 Variant
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,4673,Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,530,"Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5904,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5923,Could mixing COVID vaccines boost immune response?
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,2038,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1114,Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,2268,"mRNA vaccines for COVID-19: What, why and how"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3510,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,97,Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,1357,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,2163,Principles for designing an optimal mRNA lipid nanoparticle vaccine
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,162,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5882,Effectiveness of COVID-19 vaccines BNT162b2 and mRNA-1273 by days from vaccination: A reanalysis of clinical trial data
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,4403,"Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,4743,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,3531,Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants,5879,"COVID-19 vaccination: What's the evidence for extending the dosing interval? Bmj 2021, 372, n18"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4788,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5276,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,663,CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5461,Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,978,Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1548,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4890,Exercise and the Regulation of Immune Functions
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4280,"Effects of Regular Physical Activity on the Immune System, Vaccination and Risk of Community-Acquired Infectious Disease in the General Population: Systematic Review and Meta-Analysis"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,2050,World Health Organization 2020 guidelines on physical activity and sedentary behaviour
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5659,"Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3136,Causal diagrams in systems epidemiology
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,925,"Data, design, and background knowledge in etiologic inference"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1253,The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3705,Vaccines in historic evolution and perspective: a narrative of vaccine discoveries
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5538,Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,2648,"World Health Organization, Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE Working Group on COVID-19 Vaccines. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1956,Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1853,"Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3553,Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3636,Moderate exercise improves antibody response to influenza immunization in older adults
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,2826,Effect of physical activity on the production of specific antibody in response to the 1998-99 influenza virus vaccine in older adults
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,457,Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5290,Cardiovascular Exercise Training Extends Influenza Vaccine Seroprotection in Sedentary Older Adults: The Immune Function Intervention Trial
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1621,Effects of a Taiji and Qigong intervention on the antibody response to influenza vaccine in older adults
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4774,"Sitting Time, Physical Activity, and Risk of Mortality in Adults"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,40,Effects of exercise on vaccine-induced immune responses
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3748,Acute exercise enhancement of pneumococcal vaccination response: A randomised controlled trial of weaker and stronger immune response
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4197,The acute stressinduced immunoenhancement hypothesis
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,5480,Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,1312,"Physical activity and influenza-coded outpatient visits, a population-based cohort study"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3749,Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3722,Effectiveness of an Inactivated SARS-CoV-2
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,2080,"Rcommendation for an Emergency Use Listing of COVID-19 Vaccine (Vero Cell), Inactivated Submitted by Sinovac"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4295,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,4694,"Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy)"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,6048,Adjusted risk factors for immunogenicity data in non-autoimmune rheumatic diseases (non-ARD) individuals
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,2883,"CIs) with binary data was used for frequency of seroconversion rates of total anti-SARS-Cov-2 S1/S2 IgG (SC) and neutralizing antibodies (NAb) positivity. Tobit regression was used for natural log transformed GMT, FI-GMT and neutralizing activity. *P<.05, **P<.01, ***P<.001. Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination"
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases,3101,Positivity for NAb was defined as a neutralizing activity ≥ 30% (cPass sVNT Kit
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,3261,"000 (82) 2,751,916/3,443,000 (80) 171,899/3,443,000 (5.0) 30-39 889"
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,4767,hk * Total persons vaccinated divided by total population in the age group
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,2929,booster doses are considered third and fourth doses after the 2-dose primary COVID-19 vaccination series vaccines
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,263,The Government of the Hong Kong Special Administrative Region. CHP investigates six cases tested positive for SARS-CoV-2 virus involving Silka Seaview Hotel Hong Kong
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,5709,The Government of the Hong Kong Special Administrative Region
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,3314,"The Government of the Hong Kong Special Administrative Region. Together we fight the virus. Hong Kong, China: The Government of the Hong Kong Special Administrative Region"
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,5947,Coronavirus pandemic (COVID-19)
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,4419,Policy notes: interpretation of the protocol for prevention and control of COVID-19 in China
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,4614,New Zealand Ministry of Health
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,2460,"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China"
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,6145,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,5399,World Health Organization
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,1413,Understanding the social determinants of vaccine acceptance and hesitancy: evidence from Hong Kong
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative,5725,Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2415,Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and Risk at different exposure periods before and after symptom onset
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,3212,"Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5662,Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,3589,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2036,Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2169,COVID-19 vaccine type and humoral immune response in patients receiving dialysis
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,3900,"COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,4752,Hydroxychloroquine inhibits the trained innate immune response to interferons
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2046,Review: ischemia reperfusion injury-A translational perspective in organ transplantation
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5650,COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2293,COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5182,Vaccination in chronic kidney disease
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2645,COVID-19 vaccination in kidney transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5785,Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,4669,"The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2247,Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: is inactivated vaccine effective? Ther Apher Dial
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,4552,Short-term immunogenicity profiles and predictors for suboptimal immune responses in patients with end-stage kidney disease immunized with inactivated SARS-CoV-2 vaccine
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,2475,Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,1449,Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,6136,"The RECOVAC immune-response Study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2021. Online ahead of print"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,539,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,1310,Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,315,Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,1703,The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,1975,Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,6075,Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,1896,Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,2942,Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,38,Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: an observational study
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,598,Government of the Hong Kong Special Administration Region. Government tightens restrictions and compulsory quarantine requirements for persons arriving at Hong Kong who have stayed in places outside China
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,226,Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,305,"Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens"
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,508,Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,2478,Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,2777,Lessons learned one year after SARS-CoV-2 emergence leading to COVID-19 pandemic
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,4367,Anomalous COVID-19 tests hinder researchers
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine,3828,New recommendation policies for pathogen surveillance testing of researchers and improved stewardship of diagnostic DNA
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4645,Guillain-Barré syndrome and influenza vaccines: A meta-analysis
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1540,Guillain-Barré syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5976,The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2348,The unequal scramble for coronavirus vaccines -by the numbers
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,3366,"Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2468,Incidencia de casos nuevos de enfermedad por grupos de edad Estados Unidos Mexicanos
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4431,Advisory Committee on Immunization Practices -United States
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2971,COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1227,Política nacional rectora de vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5319,Criteria for diagnosis of Guillain-Barré syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4522,Global manual on surveillance of adverse events following immunization
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,3085,Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4891,Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4727,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4996,Controlled trial prednisolone in acute polyneuropathy
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4872,Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1266,Early recognition of poor prognosis in Guillain-Barre syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1004,Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5055,"Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,4733,"Probable Inference, the Law of Succession, and Statistical Inference"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1793,Modern epidemiology
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,6118,Quantitative Contrasts: The Magnitude of Distinctions
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,6105,Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1704,Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2202,"Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS)"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,3940,Vaccines and the risk of Guillain-Barré syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2341,Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,127,Surveillance for Adverse Events After COVID-19 mRNA Vaccination
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2641,Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,781,Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,405,Neurological Events Reported after COVID
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2238,A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,17,"UNESCO Office Montevideo and Regional Bureau for Science in Latin America and the Caribbean. COVID-19 and vaccination in Latin America and the Caribbean: challenges, needs and opportunities"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5164,Prognostic Factors in Elderly Patients With Guillain-Barré Syndrome: Does Age Matter?
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,2961,Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,288,Clinical Characteristics and Predictors of Short-Term Outcome in Mexican Adult Patients with Guillain-Barré Syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5288,Predictors of mechanical ventilation in Guillain-Barré syndrome with axonal subtypes
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1923,"Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience"
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5078,NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,427,Post-adenoviral-based vaccines Guillain-Barre Syndrome: A proposed mechanism
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,3259,Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,3412,Maintaining Safety with SARS-CoV-2 Vaccines
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,5040,Regional variation of Guillain-Barré syndrome
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines,1072,279 non-serious AEFI 81
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,3744,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,1770,Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,1369,Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,2197,Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,4392,Strategic Advisory Group of Experts on Immunization -SAGE (WHO). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,4184,Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,3230,Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,1766,Omicron thwarts some of the world's most-used COVID vaccines
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,2584,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,5390,Epidemiologic Surveillance Guide. National Emergency of Public Health Concern due to the COVID-19 disease
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,5354,Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,3133,Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,2949,R: A language and environment for statistical computing
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,3138,Austria: R Foundation for Statistical Computing
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,5847,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant,2763,"Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases systems**, n (%) 17564 (25.4) 11866 (17.2) and RT-PCR testing, median (p25-p75)"
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,6155,La OMS caracteriza a COVID-19 como una pandemia
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,242,"Organización Panamericana de la Salud,organización Mundial de la Salud"
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,700,COVID-19) -the data -Statistics and Research
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,4029,Actualización Epidemiológica Enfermedad por coronavirus (COVID-19) [Internet] Washington DC: Organización Panamericana de la Salud
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,4856,Reino Unido comienza vacunación masiva contra la covid-19: cómo es el proceso y qué se puede esperar
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3186,Data. Coronavirus (COVID-19) Vaccinations -Statistics and Research
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2122,COVID-19 vaccine tracker and landscape [Internet]Ginebra:Organización Mundial de Salud
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1041,Manual para la elaboración de análisis de impacto presupuestal
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2111,The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1101,Economic evaluation for mass vaccination against COVID-19
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3107,Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,5255,Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on Good Research Practices -Budget Impact Analysis. Value Heal
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2349,Coronavirus y realidad: los imposibles costos de internarse en una clínica privada
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1387,Mortalidad y factores pronósticos en pacientes hospitalizados por COVID-19 en la Unidad de Cuidados Intermedios de un hospital público de Lima
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,5894,Se define valores de referencia a pagar por servicios UCI de covid-19 [Internet]Bogóta: Ministerio de de Salud y Protección Social
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3038,Períodico el Contribuyente México. Éstos son los costos de atención médica en el IMSS en
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,4481,COVAX anuncia un nuevo acuerdo y previsiones sobre las primeras entregas de vacunas
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1623,Bogóta: Ministerio de Saud y Protección Social
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3199,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3490,ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,6022,"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3740,Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,4185,NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO's COVID-19 Vaccine ConvideciaTM
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3414,Evidence assessment: Sinopharm/BBIBP COVID-19 vaccine
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2577,Plan Estratégico Para La Vacunación Contra La Covid-19 En La república de Argentina
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,4952,Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: Una guía práctica
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1137,La salud pública en la primera ola: una agenda para la cooperación ante Covid-19
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1251,Vacunas e inmunización: ¿qué es la vacunación? [Internet] Ginebra: Organización Mundial de la Salud
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,5326,El COVID-19 como renovado detonador del acaparamiento y la depredación comercial: ¿el multilaterismo en coma? Glob Trade Alert Rep
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,3151,Disponible en: www.globaltradealert.org/reports 35. ForoALC2030. Cuarta reunión virtual del Foro de los Países de América Latina y el Caribe sobre el Desarrollo Sostenible
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,482,"Aceptado para su publicación, tras revisión, el 13 de octubre del 2021. coronavirus-vacuna-plan-estrategico-vacunacion-covid-19-diciembre -2020.pdf 26. Ministério da Saúde"
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,862,Operacionalização Da Vacinação Contra a Covid-19
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,1360,Planificación: vacunación contra sars-cov-2
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2384,Plan Nacional de Vacunación contra el SARS-CoV-2. 2021;Bogóta: Ministerio de de Salud y Protección Social
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina,2019,Plan Nacional Actualizado contra la COVID-19
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,3867,A review of the progress and challenges of developing a vaccine for COVID-19
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,1710,Interım report: safety and immunogenicity of an inactivated vaccine agaınst SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,4217,SINOVAC科兴. 2021. 为人类消除疾病提供疫苗. Accessed
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,860,US authorization of first COVID vaccine marks new phase in safety monitoring
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,1484,Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,3945,mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,2631,Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience,2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,4299,BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,5724,The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,2012,Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,1082,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,3676,Grading of corneal and conjunctival staining in the context of other dry eye tests
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,3252,The Short Time Exposure (STE) test for predicting eye irritation potential: intra-laboratory reproducibility and correspondence to globally harmonized system (GHS) and EU eye irritation classification for 109 chemicals
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,852,Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,5905,Hazardous Substances Data Bank: PubChem data source
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,5973,TOXBASE: poisons information database for clinical toxicology advice
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,3363,Exhaled particles and small airways
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,4637,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,277,Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report,3286,Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3209,"Progress of the COVID-19 365 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,416,China's COVID vaccines have been crucial -now immunity is waning
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,1739,Waning Immunity after the BNT162b2
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,2412,Vaccine in Israel
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3877,Emerging SARS-CoV-2 variants of concern and potential 388 intervention approaches
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3687,Structural and 390 functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,4940,"The Global Epidemic of the SARS-CoV-2 delta variant, 393 key spike mutations and immune escape"
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,5388,Delta spike P681R mutation enhances SARS-CoV-2 395 fitness over Alpha variant. bioRxiv
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,1547,CoronaVac induces lower 398 neutralising activity against variants of concern than natural infection
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3540,Reduced neutralization of SARS-CoV-2 B.1.617 401 by vaccine and convalescent serum
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3454,Omicron escapes the majority of existing SARS-CoV-2 403 neutralizing antibodies
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination,3959,Omicron (B. 1.1. 529) variant of concern and its global perspective
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3349,"COVID-19 coagulopathy, thrombosis, and bleeding"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4808,Inflammation and coagulation
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1636,Immunopathology of hyperinflammation in COVID-19
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3488,Thrombosis and COVID-19 pneumonia: the clot thickens!
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4333,Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5310,Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",794,Treatment of antiphospholipid syndrome
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4171,"Lessons from the ""Euro-Phospholipid"" project"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",102,International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5642,COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS AC-TION)
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4686,Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2780,Viral coagulopathy in patients with COVID-19: Treatment and care
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2638,Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",374,Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2956,Pathogenesis of the antiphospholipid syndrome
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5651,The pathogenesis of the antiphospholipid syndrome
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1496,"COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3847,Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Practice
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",874,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1998,A new SARS-CoV-2 dual-purpose serology test: Highly accurate infection tracing and neutralizing antibody response detection
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",759,World Health Organization. World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. World Health Organization
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1871,The REDCap consortium: Building an international community of software platform partners
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5236,Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5082,GAPSS: the Global Anti-Phospholipid Syndrome Score
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3158,The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",4307,Update of the guidelines for lupus anticoagulant detection
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1548,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2823,"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1277,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5490,New and upcoming treatments in antiphospholipid syndrome: A comprehensive review
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1543,Importance of COVID-19 vaccine efficacy in older age groups
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2281,"COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations"
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5772,The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3914,Common risk factors for both arterial and venous thrombosis
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",3631,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",2540,Thrombosis after covid-19 vaccination
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1764,Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1390,Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",1500,Antiphospholipid antibodies in patients with COVID-19: A relevant observation?
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome",5114,The epidemiology of antiphospholipid syndrome: A populationbased study
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4848,"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5242,Covid-19 in Brazil: a sad scenario
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1442,condicionantes e desafios de coordenação do Estado federativo brasileiro no contexto da COVID-19
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4343,COVID-19 Vaccine Tracker: Latest Updates -The New York Times. The New York Times
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3001,Agência Brasil -Vacinação contra COVID-19 começa em todo país
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4251,COVID-19) Vaccinations. Our World in Data
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2981,Monitor da COVID: Vacinação. Lagom Data
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4466,Introducing COVID-19 vaccination: Guidance for determining priority groups and microplanning. Version 1
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5857,Plano Nacional de Operacionalização da Vacinação contra Covid-19 -Português (Brasil)
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2397,DATASUS -TabNet Win32 3.0: CNES -Recursos Humanos -Profissionais -Indivíduos -segundo CBO 2002 -Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4052,"Cerca de 570 mil profissionais de saúde se infectaram e 2,5 mil morreram por COVID-19 nas Américas"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5020,Censo 2010 IBGE
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",612,Levantamento -Plano de Vacinação nos Estados e nas Cidades do Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2401,Covid Performance Index: Deconstructing pandemic responses -Methodology
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",512,The hindrances to perform the COVID-19 vaccination in Brazil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2483,A beacon for the COVID-19 epidemic control in Brasil: seroepidemiological population-based surveys
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",785,What policy makers need to know about COVID-19 protective immunity
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5204,World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5279,National COVID-19 vaccination plan: using artificial spatial intelligence to overcome challenges in Brazil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5723,"Estabelece diretrizes gerais para a instituição de Regiões de Saúde no âmbito do Sistema Único de Saúde (SUS), nos termos do Decreto n. 7.508, de 28 de junho de 2011"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1940,A spatial scan statistic
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3839,Interactive spatial data analysis in medical geography
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1318,46 anos do Programa Nacional de Imunizações: uma história repleta de conquistas e desafios a serem superados
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3335,"Brasileiro perdeu quase 2 anos de expectativa de vida na pandemia, e 2021 deve ser pior, diz demógrafa de Harvard. BBC News Brasil"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2703,COVID-19 and Older Adults: What We Know
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",78,Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1924,COVID-19 in the elderly people and advances in vaccination approaches
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3301,Saúde do idoso em tempos de pandemia COVID-19
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3179,Secretaria de Vigilância em Saúde
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4229,Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years-United States
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3969,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalised Adults Aged ≥65 Years -United States
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3047,Boletim do Observatório Covid-19 -semanas epidemiológicas 16 e 17 de 2021
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4222,Brasil receberá as primeiras vacinas contra COVID-19 por meio do Mecanismo COVAX neste domingo
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4900,Vacina de Oxford ultrapassa CoronaVac e é a mais usada no Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4446,Lira diz que inclusão de pessoas com comorbidades diminuiu ritmo de vacinação no Brasil. Valor Econômico
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3554,COVID-19 and comorbidities in the Americas: Hands-on tool to estimate the population at increased and high risk of severe COVID-19 due to underlying health conditions for the Americas
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3475,dos que não tomaram segunda dose. Agência Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",332,Boletim do Observatório Covid-19 -semanas 31 e 32 de 2021
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5967,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5641,The Brazilian Government's mistakes in responding to the COVID-19 pandemic
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1451,One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: a political and social overview
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",6016,A partisan pandemic: state government public health policies to combat COVID-19 in
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2259,"convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4025,Data. Statistics and Research -Coronavirus (COVID-19) Vaccinations. 2021
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1145,SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",643,"Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network -United States"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1421,Inferring the effectiveness of government interventions against COVID-19
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3973,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2057,Considerations for fair prioritisation of COVID-19 vaccine and its mandate among healthcare personnel
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",3684,Physician COVID-19 Vaccination Study (Final Report)
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2866,Is It Lawful and Ethical to Prioritise Racial Minorities for COVID-19 Vaccines?
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",636,Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4584,COVID-19 mortality among Indigenous people in Brazil: a nationwide register-based study
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",120,Análise da distribuição e tendência de coberturas vacinais para crianças indígenas menores de cinco anos de idade. Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",613,"STF obriga governo a priorizar indígenas urbanos em vacinação, mas medida ainda tem obstáculos"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",2059,Menos de 7% das áreas quilombolas no Brasil foram tituladas. Agência Brasil
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",6013,Brazil vaccine drive faces challenges in remote communities
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5515,Quilombolas têm que recorrer à Justiça e até comprar geladeira para conseguir vacina. Brasil de Fato
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",917,Instituto Brasileiro de Geografia e Estatística (IBGE)
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1533,Fundação Cultural Palmares. Informações Quilombolas. 2021
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4838,Covid-19 vaccination hesitancy
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",107,Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",1209,COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",5018,Desafios das Fake News com Idosos durante Infodemia sobre Covid-19: Experiência de Estudantes de Medicina
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",310,"Por conta de fake news, 70% dos índigenas do Tapajós resistem à vacinação. CNN Brasil"
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access",4508,62% dos indígenas na Amazônia estão vacinados contra COVID; AC e PA têm aldeias com baixa adesão. G1 Globo/ Instituto Socioambiental
1,,4981,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"
1,,4441,"COVID-19) Dashboard, Overview of all Countries"
1,,1255,"The current COVID-19 situation, Iran (Islamic Republic of)"
1,,828,COVID-19: Prevention and control measures in community
1,,473,COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir. Viruses
1,,5351,Vaccine confidence in the time of COVID-19
1,,3197,The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States
1,,5138,Identifying airborne transmission as the dominant route for the spread of COVID-19
1,,5605,Estimation of basic reproduction number for COVID-19 and the reasons for its differences
1,,163,The vaccine journey for COVID-19: A comprehensive systematic review of current clinical trials in humans
1,,2154,The Covid-19 Candidate Vaccine Landscape and Tracker
1,,3417,Covid-19 Vaccines
1,,1060,Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review
1,,5090,Tracking Coronavirus Vaccination Around the World
1,,1988,The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
1,,5022,SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse
1,,2928,Mutation D614G increases SARS-CoV-2 transmission
1,,5786,An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in
1,,2426,Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus
1,,4975,"Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ 2021"
1,,2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
1,,4216,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Frontline Workers Before and During B. 1.617. 2 (Delta) Variant Predominance-Eight US Locations
1,,870,The Equitable Distribution of COVID-19 Therapeutics and Vaccines
1,,339,"Population and Housing Census, Census"
1,,654,WHO. COVID-19 Clinical Management: Living Guidance
1,,2117,"COVID-19 Attributable Deaths on Longevity, Premature Mortality and DALY: Estimates of"
1,,961,Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations
1,,4266,How Much is the Cost of Each Covid-19 Patient? Available online
1,,4488,How Much Will a Covid-19 Vaccine Cost? The Financial Times
1,,2063,The Cost per Jab of Covid-19 Vaccine Candidates
1,,1665,The Price Tags on the COVID-19 Vaccines
1,,368,What do we know about China's covid-19 vaccines?
1,,4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1,,905,Sinovac Shot Shown 78% Effective in Brazil after Data Confusion. Bloomberg News
1,,3769,Turkey Finds Chinese Vaccine Efficacy Rate of 91.25% in Trial
1,,4040,Sinovac's Vaccine Approved by Indonesia for Emergency Use
1,,4735,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study
1,,5639,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial"
1,,897,Assessment: Sinopharm/BBIBP COVID-19 vaccine
1,,6148,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials
1,,3935,Mounting evidence suggests Sputnik COVID vaccine is safe and effective
1,,5095,An mRNA vaccine against SARS-CoV-2-preliminary report
1,,2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
1,,4082,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: Test negative design study"
1,,1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
1,,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
1,,2314,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
1,,2179,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
1,,2315,"Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years-COVID-NET, 13 States"
1,,912,Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
1,,1581,Results of the Coviran Barekat Vaccine Trials
1,,5427,"Gholamzadeh Baeis, M. The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data"
1,,5695,Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain
1,,3095,COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
1,,4581,The Role of Cost-Effectiveness in U.S. Vaccination Policy
1,,1463,"The World Bank, Data. GDP per Capita (Current US$)-Iran, Islamic Rep"
1,,3796,COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
1,,3221,Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. medRxiv 2021
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,173,Respiratory follow-up of patients with COVID-19 pneumonia
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2791,PMCID:PMC7447111)
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2108,The socio-economic implications of the coronavirus pandemic (COVID-19): a review
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2359,"COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5439,C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3005,COVE Study Group (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4505,Thrombotic events and COVID-19 vaccines
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4639,Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3094,Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3629,Antibody response to COVID-19 vaccination in adults with hematologic malignant disease
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2123,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5917,Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,1502,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,496,Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,444,PMCID:PMC8213359)
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5816,Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4711,Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,47,Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4768,A flare of Still's disease following COVID-19 vaccination in a 34-year-old patient
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5026,Autoimmune phenomena following SARS-CoV-2 vaccination
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,540,ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5862,Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2857,Uveitis and other ocular complications following COVID-19 vaccination
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3887,PMCID:PMC8704915)
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,749,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,267,International Study Group for Behçet's Disease (1990) Criteria for diagnosis of Behçet's disease
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,1048,Criteria for the diagnosis of familial Mediterranean fever
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4306,Behçet's-like adverse event or inaugural Behçet's disease after SARS-CoV-2 mRNA-1273 vaccination?
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5454,Emergence of Behçet's disease post-SARS-CoV2-vaccination: two clinical cases in Japan
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2156,"Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,765,Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-a multicenter study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,844,Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2806,Behcet's disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,584,Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2453,"The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4042,Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4106,COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5201,Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5630,Autoinflammatory disease reloaded: a clinical perspective
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2093,Surveillance for adverse events after COVID-19 mRNA vaccination
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,1106,Guillain-Barré syndrome associated with COVID-19 vaccination
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3883,PMCID:PMC8632191)
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,1208,Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5930,Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,5985,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,296,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the first case report
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4181,The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,873,Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-a nationwide survey
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,1591,The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine,2427,Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5426,Endocrine Conditions and COVID-19
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1458,"Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care"
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1384,"Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19"
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5673,SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,762,Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1602,Viruses and thyroiditis: an update
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1697,COVID-19: vaccine's progress. Microb Biotechnol
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,4617,The SARS-CoV-2 as an instrumental trigger of autoimmunity
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,570,ASIA syndrome and endocrine autoimmune disorders
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,4504,Subacute thyroiditis following the H1N1 vaccine
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,649,Subacute thyroiditis following seasonal influenza vaccination
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5555,Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,3191,Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,732,Subacute thyroiditis after hepatitis B vaccination
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1939,Occurrence of Subacute Thyroiditis following Influenza Vaccination
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,2549,Two cases of Graves' disease following SARS-CoV-2 vaccination: An autoimmune/inflammatory syndrome induced by adjuvants
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,4020,"double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,671,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind"
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,156,Endocrine Significance of SARS-CoV-2's Reliance on ACE2
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,3556,COVID-19-associated ophthalmoparesis and hypothalamic involvement
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,3239,Adrenal Vascular Changes in COVID-19 Autopsies
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,2530,Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,2617,Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1414,Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5339,Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5058,Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5791,Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,1965,Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome,5029,Approach to the patient with postpartum thyroiditis
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,2261,Recombinant vaccines for COVID-19
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5516,Histamine-induced coronary artery spasm: the concept of allergic angina
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5986,Allergic myocardial infarction following recombinant human insulin
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,1295,"Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. 2021, 9"
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5283,Kounis Syndrome in a patient after administration of influenza vaccine
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,6056,A Rarely Seen Type-I Kounis Syndrome Caused By Tetanus Vaccine
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,2370,Coronary hypersensitivity disorder: the Kounis syndrome
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5511,"Myocardial infarction after aspirin treatment, and Kounis syndrome"
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,2464,Treatment of Kounis syndrome
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,2907,Allergic acute coronary syndrome (Kounis syndrome)
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,5036,Allergic reaction reveals a non-lethal late stent thrombosis. A new subtype of Kounis syndrome?
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,1798,"Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management"
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,4284,Current understanding of Kounis syndrome
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,1350,Vasospastic angina induced by nonsteroidal antiinflammatory drugs
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,6094,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,481,Vaccine -United States
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2089,IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2803,COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,93,"Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey"
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5650,COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,155,Covid-19 and kidney transplantation
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2615,COVID-19 in kidney transplant recipients: a multicenter experience in Istanbul
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,3043,At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,6131,COVID-19 and solid organ transplantation: a review article
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2593,The impact of COVID-19 on kidney transplantation and the kidney transplant recipient -One year into the pandemic
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5662,Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5566,Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,3529,Safety and immunogenicity of anti-sars-cov-2 messenger RNA vaccines in recipients of solid organ transplants
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5211,Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,938,Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2385,High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,1449,Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5253,Betjes MGH. Protective cytomegalovirus (CMV)-Specific T-Cell immunity is frequent in kidney transplant patients without serum anti-CMV antibodies
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5510,"Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation"
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,3806,Serologic vaccination response after solid organ transplantation: a systematic review
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,5715,Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,3410,Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,2475,Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,1912,Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,480,Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients,554,Impact of prior influenza and pneumoccocal vaccines on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. Vaccines (Basel)
201,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor",1358,Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases
201,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor",2469,Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines
201,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor",5067,The health of the healthcare workers
201,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor",2878,Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,2418,COVID-19) Dashboard
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,82,Viral targets for vaccines against COVID-19
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3357,Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,893,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,743,Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,479,Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,5475,Durable humoral and cellular immune responses 8 months after Ad26. COV2.S vaccination
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3021,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4956,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,5084,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, doubleblind, randomised, placebo-controlled phase 2 clinical trials"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,1769,MICE: multivariate imputation by chained equations in R
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3794,SARS-CoV-2 variants: levels of neutralisation required for protective immunity
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,5602,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4250,Moderna 2Q 2021 Earnings Call
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,1174,Second Quarter 2021 Financial Results and Operational Highlights
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,5669,SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,6005,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3486,Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,1752,DNA vaccine protection against SARS-CoV-2 in rhesus macaques
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4289,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,6077,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,6158,Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4699,Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in elderly people over 85 years of age in Greece
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,4682,Publisher's Note
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,2940,COVID-19 dashboard
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,1799,Clinical manifestations of COVID-19 in the general population: systematic review
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,503,Mild or moderate Covid
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,3385,Prevention of host-to-host transmission by SARS-CoV-2 vaccines
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,1502,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,729,Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,2124,"Vaccine hesitancy: definition, scope and determinants"
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,302,COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,1955,"Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean"
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,5596,SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,175,COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,1487,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a webbased survey"
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,4711,Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,4341,Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study,5246,Reporting survey based studies-a primer for authors
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,421,Centro de Vigilância Epidemiológica
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,3279,"Documento técnico: campanha de vacinação contra a COVID-19: 23 de julho de 2021, 18ª atualização"
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial"
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,5264,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,4544,Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,291,Prevalence and types of vaccination errors from 2009 to 2018: a systematic review of the medical literature
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,515,Incidence of post-vaccination adverse events in children
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,3879,"Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,1267,"Children and adolescents with SARS-CoV-2 infection: epidemiology, clinical course and viral loads"
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,5581,Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children,4153,The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children
4631,To appear in: Vaccine,3485,A novel coronavirus from patients with pneumonia in China
4631,To appear in: Vaccine,988,The Turkish Ministry of Health Covid19 information page n.d
4631,To appear in: Vaccine,950,Reduced mortality rate after coronavac vaccine among healthcare workers
4631,To appear in: Vaccine,3746,Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
4631,To appear in: Vaccine,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
4631,To appear in: Vaccine,219,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
4631,To appear in: Vaccine,3708,Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
4631,To appear in: Vaccine,2467,Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
4631,To appear in: Vaccine,2686,Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
4631,To appear in: Vaccine,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4631,To appear in: Vaccine,4477,Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
4631,To appear in: Vaccine,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
4631,To appear in: Vaccine,1782,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. The Lancet Infectious Diseases
4631,To appear in: Vaccine,4132,BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
4631,To appear in: Vaccine,5170,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled"
4631,To appear in: Vaccine,5102,Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
4631,To appear in: Vaccine,5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
4631,To appear in: Vaccine,5517,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
4631,To appear in: Vaccine,6088,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers
4631,To appear in: Vaccine,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
4631,To appear in: Vaccine,5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
4631,To appear in: Vaccine,257,Long-lived plasma cells are contained within the CD19− CD38hiCD138+ subset in human bone marrow
4631,To appear in: Vaccine,3767,Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
4631,To appear in: Vaccine,1071,A single-cell atlas of the peripheral immune response in patients with severe COVID-19
4631,To appear in: Vaccine,315,Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients
4631,To appear in: Vaccine,1612,WHO International Standard for anti-SARS-CoV-2 immunoglobulin
4631,To appear in: Vaccine,4247,"Correlation of the units (U) of the Elecsys® Anti-SARS-CoV-2 S assay to the ""binding antibody units"" (BAU) of the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin"
4631,To appear in: Vaccine,5192,Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
4631,To appear in: Vaccine,5865,"Immune Assays Team § Moderna, Inc. Team § Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team § United States Government (USG)/CoVPN Biostatistics Team § Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial"
4631,To appear in: Vaccine,2007,Covid-19 breakthrough infections in vaccinated health care workers
4631,To appear in: Vaccine,3743,Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects
4631,To appear in: Vaccine,993,"BNT162b2 Vaccine-Induced Immune Responses and Dynamics Vary Among Age Groups, Sex and Co-Morbidities: A Longitudinal Prospective Cohort Study n"
4631,To appear in: Vaccine,5703,"Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study"
4631,To appear in: Vaccine,5925,Immunogenicity After Two Doses of Inactivated Virus Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: Prospective Observational Study
4631,To appear in: Vaccine,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4631,To appear in: Vaccine,5779,Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
4631,To appear in: Vaccine,4084,Considerations in boosting COVID-19 vaccine immune responses
4631,To appear in: Vaccine,837,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and halfdead lymphocytes"
4631,To appear in: Vaccine,3929,B cell memory and Plasma cell development
4631,To appear in: Vaccine,5749,Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells
4631,To appear in: Vaccine,6124,Germinal center reaction: antigen affinity and presentation explain it all
4631,To appear in: Vaccine,4202,"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus"
4631,To appear in: Vaccine,4328,Extrafollicular responses in humans and SLE
4631,To appear in: Vaccine,5632,Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19
4631,To appear in: Vaccine,1498,Fundamental Immunology. Fundamental Immunology
4631,To appear in: Vaccine,2633,"Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19"
4631,To appear in: Vaccine,4983,Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
1,,56,Report of the SAGE Working Group on Vaccine Hesitancy
1,,5668,World Health Organization. Ten Threats to Global Health in 2019
1,,603,Understanding Vaccine Hesitancy around Vaccines and Vaccination from a Global Perspective: A Systematic Review of Published Literature
1,,5655,Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines
1,,2830,Using the Internet for Surveys and Health Research
1,,2018,Twitter as a Tool for Health Research: A Systematic Review
1,,857,Social Media Vaccine Websites: A Comparative Analysis of Public and Moderated Websites
1,,5120,Analysis of the Anti-Vaccine Movement in Social Networks: A Systematic Review
1,,4260,Content Themes and Influential Voices within Vaccine Opposition on Twitter
1,,1785,The Ministry of Health of Turkey Health Statistics Yearbook 2019; General Directorate of Health Information Systems
1,,1737,Vaccine hesitancy in turkey
1,,4177,Systematic review of studies to determine factors affecting vaccine rejection/instability/contrast
1,,619,An analysis on the anti-vaccination movement in Turkish digital platforms: Ekşisözlük and Facebook. Eskişehir Türk Dünyası Uygul. Araştırma Merk. Halk Saglıgı Derg
1,,2933,Youtube'daki Aşılarlaİlgili Türkçe Videolar Neler Söylüyor? Birİçerik Analizi
1,,6129,Social media and vaccine hesitancy: New updates for the era of COVID-19 and globalized infectious diseases. Hum. Vaccines Immunother
1,,4804,Digital 2021: Turkey. Available online
1,,2957,What is an adequate sample size? Operationalising data saturation for theory-based interview studies
1,,3834,A simple method to assess and report thematic saturation in qualitative research
1,,1595,Lessons learned from frontline skilled nursing facility staff regarding COVID-19 vaccine hesitancy
1,,2693,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries
1,,4497,COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey
1,,1330,"COVID-19 vaccination hesitancy, misinformation and conspiracy theories on social media: A content analysis of Twitter data"
1,,71,European Centre for Disease Prevention and Control. Rapid Literature Review on Motivating Hesitant Population Groups in Europe to Vaccinate; ECDC Technical Report
1,,3025,COVID-19 Vaccine Hesitancy in Canada: Content Analysis of Tweets Using the Theoretical Domains Framework
1,,2037,COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population
1,,2657,Relational ethical approaches to the COVID-19 pandemic
1,,982,Diyanet: Salgında Aşı Yaptırmamak Kul Hakkına Girer
1,,4973,"The relationship of COVID-19 vaccine attitude with life satisfaction, religious attitude and COVID-19 avoidance in Turkey. Hum. Vaccines Immunother"
1,,1700,The anti-vaccination infodemic on social media: A behavioral analysis
1,,2817,Republic of Turkey Ministry of Health. COVID-19 Vaccination Information Platform
1,,2013,Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
1,,117,Resistance to COVID-19 vaccination has increased in Ireland and the United Kingdom during the pandemic
1,,5162,Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated
1,,4232,"Mapping the Dutch vaccination debate on Twitter: Identifying communities, narratives, and interactions"
1,,5745,Optimal control of the COVID-19 pandemic: Controlled sanitary deconfinement in Portugal
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,414,and Author Information Accepted for Publication
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,4857,"França Acquisition of data: Fernandes, Magliano, Macedo, Padila, Braga Analysis and interpretation of data: Fernandes, Santos, Tura, Macedo, Padila, França Drafting of the manuscript: Fernandes, Magliano, Macedo, Padila, França, Braga Critical revision of the paper for important intellectual content: Fernandes"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,430,Novel coronavirus 2019 (COVID-19) pandemic outbreak: a comprehensive review of the current literature
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,1027,The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review of the current global status
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5931,COVID-19 hospitalizations in Brazil's Unified Health System (SUS)
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,1389,"Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo state, Brazil"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5508,Epidemiologic and clinical features of patients with COVID-19 in Brazil. Einstein (São Paulo)
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,3822,Evolution and epidemic spread of SARS-CoV-2 in Brazil
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,4077,"Wię ckiewicz M. Demographic, clinical, laboratory, and genetic risk factors associated with COVID-19 severity in adults: a narrative review"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5266,"Characteristics and factors associated with COVID-19 infection, hospitalization, and mortality across race and ethnicity"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,1645,COVID-19). World Health Organization
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,4133,Ten months of COVID-19 in metropolitan region of Curitiba: the pandemic in the territory and the mitigation damage public policies in 2020
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5103,"Bases técnicas para decisão do uso emergencial, Em caráter experimental de vacinas contra a COVID-19. ANVISA, Relatório"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,3225,FDA Briefing Document-Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. US Food and Drug Administration
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5042,Waiting vaccines. FGV IBRE
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5400,Health Vigilance
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,1873,Flu -Severe respiratory syndrome notifications
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,3771,Mortality National Information System
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,5181,"Drugs prosthesis and procedures -(management system of SUS procedures, drugs, and orthotics, prostheses and materials data). SIGTAP, Management System of Procedures Table"
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,3493,Health system accounts in the international accountability perspective: Brazil
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,3912,Health prices database
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,1849,Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,839,Economic value of treatment and vaccine to address the COVID-19 pandemic
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,2751,Cost-effectiveness and budget impact analysis
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,359,Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation
5575,Cost Utility of Vaccination Against COVID-19 in Brazil,4316,"Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3485,A novel coronavirus from patients with pneumonia in China
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,138,"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1999,Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4897,Offline: COVID-19 is not a pandemic
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4848,"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,453,Role of genetic variants and gene expression in the susceptibility and severity of COVID-19
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,652,Geneva: WHO
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,622,Secretaria de Vigilância em Saúde. Painel Coronavírus
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,5096,Coordenação Geral do Programa Nacional de Imunizações. Plano Nacional de Operacionalização da Vacinação contra a Covid-19. Brasil Imunizado Somos Uma Só Nação 2020
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,5573,Estratégia de Vacinação contra o Vírus SARS-CoV-2 COVID-19: Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação 2020
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1731,World Health Organization; Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Work Group on Vaccine Pharmacovigilance. Geneva: WHO/CIOMS
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,520,"Secretaria de Vigilância em Saúde, Departamento de Imunizações e Doenças Transmissíveis. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3333,BR). e-SUS Notifica
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,6050,Efficacy and safety of COVID-19 vaccines: a systematic review
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,6149,The Brazilian National Immunization Program: 46 years of achievements and challenges
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1221,Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,5550,Rio de Janeiro: IBGE
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,2813,Estimativas da população residente no Brasil e unidades da federação com data de referência em 1º de julho de 2019. Rio de Janeiro: IBGE
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4000,"Situação epidemiológica dos eventos adversos pós-vacinação contra a covid-19, Brasil"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1730,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4618,Perfil da Enfermagem no Brasil: relatório final. Rio de Janeiro: Fiocruz/COFEN
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4127,"World Health Organization. GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2. Geneva: WHO; 2021"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3996,"Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 11/2021-CGPNI/DEIDT/SVS/MS. Esclarecimentos sobre eventos adversos supostamente atribuíveis à vacinação contra a covid-19"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1812,Análise da ocorrência de evento adverso pós-vacinação decorrente de erro de imunização
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,1230,Avaliação do sistema brasileiro de vigilância de eventos adversos pós-vacinação
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,3581,Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 21/2021-CGPNI/DEIDT/SVS/MS. Orientações referentes aos erros de imunização relacionados às vacinas COVID-19
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4471,COVID-19 vaccine response in pregnant and lactating women: a cohort study
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,2966,"Secretaria de Atenção Primária à Saúde, Departamento de Açõe Programáticas Estratégicas. Nota Técnica Nº 1/2021-DAPES/SAPS/MS. Recomendações referentes a administração de vacinas covid 19 em gestantes, puérperas e lactantes, incluindo os esclarecimentos que devem ser fornecidos para tomada de decisão"
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais,4573,The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,2587,REFERENCES 1. WHO Health Emergency Dashboard.WHO (COVID-19). Homepage; 2021. Accessed
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,3655,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,4321,Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,1670,For recommendatıon by the Strategıc Advısory Group of Experts (Sage) on Immunızatıon. Prepared by the SAGE Working Group on COVID-19 vaccines; 2021. Accessed
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,2742,World Health Organization.WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,4917,Commercial serology assays predict neutralization activity against SARS-CoV-2
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,5600,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,4006,Public attention; 2021
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,5544,COVID-19 clinical management: living guidance; 2021. Accessed
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,845,SARS-CoV-2 IgG II Quant Assay User Manual
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,2967,Susceptibility of circulating SARS-CoV-2 variants to neutralization
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,2181,SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,3947,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,4301,Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,1332,"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,5687,Kinetics of viral load and antibody response in relation to COVID-19 severity
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study,1096,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study
1,,5780,SARS-CoV-2 vaccines
1,,877,Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
1,,343,Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
1,,5624,Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination
1,,2049,Adverse effect after COVID-19 vaccination in Thailand
1,,3248,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/ polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
1,,4595,Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
1,,5482,Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients
1,,1012,"Allele frequency net database (AFND) 2020 update. How to cite this article: Noikongdee P, Police P"
1,,3013,Prevalence of anti-platelet factor 4/ polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais
1,,3696,"Anti-PF4/polyanionic antibodies were positive in five participants in the ChAdOx1 nCoV-19, and four participants in the CoronaVac group by ELISA. The highest OD was 0.9. OD of >0.3 indicates positive result. Black dots indicate OD after first-dose vaccination, and red diamonds indicate OD after second-dose vaccination. Gray shading indicates negative range. OD; optical density"
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5441,Weekly epidemiological update on COVID-19 -27
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2281,"COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations"
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4172,COVID-19 vaccines for low-and middle-income countries
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3021,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4114,Plan Nacional de Vacunacion Covid
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2066,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases"
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4985,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3913,Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,531,Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4138,Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel)
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,978,Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,1055,Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,6039,Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2239,Occurrence of severe COVID-19 in vaccinated transplant patients
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3210,Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5486,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5666,Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,1738,Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3478,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV. Clinical Infectious Diseases
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4443,"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment"
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2752,Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5448,vaccine BNT162b1 elicits human antibody and TH1 T cell responses
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,2487,Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5117,Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,4021,Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile,3851,"TNF inhibitors: infliximab, golimumab, adalimumab, etanercept, certolizumab pegol 2. Other cancers: peritoneum, gastric, liver, ovarium, testicular and small bowel 3. HSC: hematopoietic stem cell transplant"
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,1006,Isolation of whole mononuclear cells from peripheral blood and cord blood
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,5268,Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,4675,Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,594,Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,318,Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,3116,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv"
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,1177,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,907,Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,475,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel)"
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,50,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,1933,CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,3655,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study,1096,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,2958,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,3361,China COVID vaccine reports mixed results-what does that mean for the pandemic?
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,5023,Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them?
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,2090,Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report,1784,Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature
1,,670,SARS-CoV-2 vaccines in development
1,,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1,,3361,China COVID vaccine reports mixed results-what does that mean for the pandemic?
1,,678,Vaccine allergy
1,,360,Vaccine-associated hypersensitivity
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2918,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,6081,Nosocomial Outbreak of Coronavirus Disease 2019 by Possible Airborne Transmission Leading to a Superspreading Event
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2777,Lessons learned one year after SARS-CoV-2 emergence leading to COVID-19 pandemic
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2270,The World Health Organzation. COVD-19 vaccine tracker
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3084,RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,1632,The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,509,COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2304,Transmission of
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,5425,529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,4457,Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3619,Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2347,SARS-CoV-2 variants of concern and variants under investigation in England
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3677,Antibody response of BNT162b2 and CoronaVac platforms in COVID-19 recovered individuals against SARS-CoV-2 wild type and delta variant
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,1142,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,4503,Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2459,B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3716,Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3184,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,1660,Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,3308,Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2668,Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2362,Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,2255,SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,423,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,4135,"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2"
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,5432,Omicron likely to weaken COVID vaccine protection
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5176,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5118,Delayed second dose versus standard regimen for COVID-19 vaccination
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",774,What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3103,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",6046,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a twodose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4770,Evaluation of COVID-19 vaccination strategies with a delayed second dose
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4357,Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",592,Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5433,The how's and what's of vaccine reactogenicity
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1150,"Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4060,Myocarditis and pericarditis after vaccination for COVID-19
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",780,"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4541,COVID-19 vaccine adverse reactions bring patients to emergency departments
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5845,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Republic of"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3087,Real-time analysis of a mass vaccination effort confirms the safety of FDAauthorized mRNA COVID-19 vaccines
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2299,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2954,Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3830,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3915,COVID-19 vaccines and risks of hematological abnormalities: nested case-control and selfcontrolled case series study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3264,Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2565,Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1832,Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3949,Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1490,The Government of the Hong Kong Special Administrative Region. Government announces 2019 COVID-19 vaccination programme
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3441,The Government of the Hong Kong Special Administrative Region. Government expands scope of priority groups and opens more CVCs
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",543,The Government of the Hong Kong Special Administrative Region. Vaccination priority groups to be expanded to cover people aged 30 or above
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3683,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme opens to persons aged 16 or above
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1985,The Government of the Hong Kong Special Administrative Region. Secretary for Food and Health approves lowering age limit for receiving Comirnaty vaccine
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4346,nsus_ inter im_ recom menda tions_ on_ the_ use_ of_ covid 19_ vacci nes_ inhk
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2229,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",779,gclid= CjwKC Ajwvu GJBhB 1EiwA CU1Ai dX-t9s2o kQDMm PxKmJ-pL9iA zrq0L ZrTJb GcmQx mWAzg D6yCi Jjbxo CZl4Q AvD_ BwE
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5267,Accessed 28
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4044,Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1552,COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons -United States
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1554,National Health Commission of the People's Republic of China. Novel coronavirus vaccine technical guide
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5133,The Bonferonni and `idák corrections for multiple comparisons
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4988,Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4501,Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals. Hum Vaccines Immunother
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5177,Extended interval BNT162b2 vaccination enhances peak antibody generation
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1485,Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",253,Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5443,The safety of COVID-19 mRNA vaccines: a review
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3508,Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3841,"Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1768,Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3340,"Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2454,Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3518,COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",843,Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1664,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2644,Why promoting a COVID-19 vaccine booster dose?
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2724,Protection against COVID-19 by BNT162b2 booster across age groups
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1346,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",3238,Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2602,Serological responses to COVID-19 Comirnaty booster vaccine
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",443,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study"
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",2913,Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against omicron variant
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",1180,The emergence of new SARS-CoV-2 variant (omicron) and increasing calls for COVID-19 vaccine boosters-the debate continues
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",4682,Publisher's Note
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access",5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,4753,Considerations in boosting COVID-19 vaccine immune 4 responses
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,5574,Accessed 12
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,2083,Comparative Effectiveness of Moderna
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,6163,& Johnson) Vaccines in Preventing
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,3211,Hospitalizations Among Adults Without Immunocompromising Conditions -United States
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,796,Comparing the clinical efficacy of COVID-19 14 vaccines: a systematic review and network meta-analysis
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,1867,A systematic review of COVID-19 vaccine efficacy and 17 effectiveness against SARS-CoV-2 infection and disease
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,5453,"Comparing COVID-19 vaccines for their 21 characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern"
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,2105,Efficacy and Safety of the mRNA-1273 SARS-CoV-2
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,5206,Comparative immunogenicity of mRNA and inactivated 7 vaccines against COVID-19
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,1711,/fulltext#coronavirus-linkback-header
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,2869,Effectiveness of an Inactivated SARS-CoV-2 Vaccine 11 in Chile
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,2490,Comparison of antibody and T cell responses elicited 14 by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in 15 healthy adult humans
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore,846,Pfizer-BioNTech and Sinopharm: A 19 Comparative Study on Post-Vaccination Antibody Titers
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2606,Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3820,Detection of a SARS-CoV-2 variant of concern in South Africa
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5512,"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil"
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,4743,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1293,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3098,A leading coronavirus vaccine trial is on hold: scientists react
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1840,Novavax offers first evidence that COVID vaccines protect people against variants
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5744,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1504,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: Pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials"
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5166,"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS"
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5097,Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,4577,Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1447,Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2044,A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5249,Structure-based development of human antibody cocktails against SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3169,N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,199,Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3275,Article
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,22,Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1486,Structural basis of a shared antibody response to SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3184,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1154,An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5828,Evolution of antibody immunity to SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,6058,Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1157,Circular RNA vaccines against SARS-CoV-2 and emerging variants
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2424,Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2448,Phaser crystallographic software
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,232,"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix"
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3285,Features and development of Coot
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3549,Automated electron microscope tomography using robust prediction of specimen movements
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,4080,MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2273,CTFFIND4: fast and accurate defocus estimation from electron micrographs
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,2786,New tools for automated high-resolution cryo-EM structure determination in RELION-3
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,5436,UCSF Chimera -a visualization system for exploratory research and analysis
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,3290,Comprehensive integration of single-cell data
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,1854,Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,4663,RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,183,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1018,The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,214,Antibody response to Covıd-19 infectıon clinical variables at play. medRxiv
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,3513,SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1028,Factors That Influence the Immune Response to Vaccination
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,274,COVID-19: Characteristics and Therapeutics
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1532,SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,929,Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,2441,Anti-Spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1202,Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1002,Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,3695,The potential danger of suboptimal antibody responses in COVID-19
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1842,Immunological considerations for COVID-19 vaccine strategies
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,119,Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,406,Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,977,Vaccines for the elderly
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,466,"Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. medRxiv"
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,422,The relationship between influenza vaccine-induced specific antibody responses and vaccine-induced nonspecific autoantibody responses in healthy older women
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,6030,Antibody response to influenza vaccination in the elderly: a quantitative review
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,5487,Obesity is associated with impaired immune response to influenza vaccination in humans
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,3171,Obesity and COVID-19: The Two Sides of the Coin
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,177,Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins. medRxiv
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,6042,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coronavac): interim results of a double blind, randomised, placebocontrolled, phase 3 trial in Turkey"
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,2403,Quantitation of antibodies against SARS-CoV-2 spike proteinafter two doses of CoronaVac in healthcare workers
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,115,Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,2935,Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,5053,Measurement of multiple SARS-CoV-2 antibody titer after vaccination represents individual vaccine response and contributes to individually appropriate vaccination schedules. medRxiv
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,320,Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1,2235,Evaluation of antibody response after COVID-19 vaccination of healthcare workers
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2509,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action 2021
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,222,"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: meta-analysis with 55 studies and 10014 cases"
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,445,A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,3909,Prevalence of comorbidities and their association with mortality in patients with COVID-19: a systematic review and metaanalysis
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,1172,Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,325,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2188,Global Rheumatology Alliance physician-reported registry
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,5591,Inflammatory muscle diseases
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,3835,European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,5957,Immune-mediated necrotizing myopathy
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,3193,COVID-19 and myositis -unique challenges for patients
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,248,Infectious complications in polymyositis and dermatomyositis: a series of 279 patients
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,1109,Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2578,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases"
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4785,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a postvaccination cross-sectional survey
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,895,"but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases"
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,1497,Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2177,A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2798,Defining clinical improvement in adult and juvenile myositis
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,361,"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis"
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,5209,Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,5264,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,3426,Considering how biological sex impacts immune responses and COVID-19 outcomes
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4893,Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,840,Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,2277,Guideline on risk management systems for medicinal products for human use
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4709,Guidance for Industry: Clinical data needed to support the licensure of pandemic influenza vaccines. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,5572,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations 2021
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,1277,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4811,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,4688,A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology,1325,COVID-19 vaccination and antirheumatic therapy
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,736,"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5418,"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5318,Prevention is better than the cure: risk management of COVID-19
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4340,"Covid-19: WHO declares pandemic because of ""alarming levels"" of spread, severity, and inaction"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,19,"Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4401,Rapid SARS-CoV-2 antigen detection assay in comparison with realtime RT-PCR assay for laboratory diagnosis of COVID-19 in ailand
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,3359,Understanding the most important facilitators and barriers for online education during COVID-19 through online photovoice methodology
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4291,"Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,1802,"Students' views towards sarscov-2 mass asymptomatic testing, social distancing and selfisolation in a university setting during the COVID-19 pandemic: a qualitative study"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,2712,Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,1194,"Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, ailand"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4463,Seoul metropolitan government COVID-19
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,2221,"Coronavirus disease exposure and spread from nightclubs, South Korea"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,2910,What other countries can learn from Italy during the COVID-19 pandemic
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5273,Characteristics of SARS-CoV-2 positive cases beyond health-care professionals or social and health-care facilities
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5888,Evaluation of a rapid antigen test (Panbio ™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4938,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 Years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,958,Draft Landscape of COVID-19 Candidate Vaccines
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,1134,SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4513,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4852,COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5983,AstraZeneca's COVID-19 vaccine authorised in five other countries
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,2583,Medical studies during the COVID-19 pandemic; the impact of digital learning on medical students' murnout and metal health
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,4151,"High seroprevalence of SARS-CoV-2 (COVID-19)-Specific antibodies among healthcare workers: a cross-sectional study in guilan, Iran"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay,5125,COVID-19 in longterm care facilities: an upcoming threat that cannot be ignored
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,308,Execution of laboratory tests were performed by Rosemeire Yamashiro and Marcia J. Castejon. Samples management was performed by
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,2419,Statistical analysis was performed by
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,2887,The manuscript was written by Valéria O. Silva and Luís F. de Macedo Brígido
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,452,Anonymized datasets generated for the current study are available from the corresponding author upon reasonable request
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,3643,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,4473,SARS-CoV-2 reinfection and implications for vaccine development
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,3782,Severe COVID-19: what have we learned with the immunopathogenesis?
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,5374,The effectiveness of the twodose BNT162b2 vaccine: analysis of real-world data
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,6008,Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,48,"COVID-19): serology, antibodies and immunity. World Health Organization"
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,3395,Throat wash as source of SARS-CoV-2 RNA to monitor community spread of COVID-19
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,5977,CoV-2 Neutralization Antibody Detection Kit. Food and Drug Administration
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,5083,The coronavirus is here to stay-here's what that means
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines,1290,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/ Oxford's AZD1222 SARS-CoV-2 vaccines
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1419,HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3538,Overview of SARS-CoV-2 infection in adults living with HIV
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,4628,"Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2039,Immunogenicity of pneumococcal vaccination in HIV infected individuals: a systematic review and meta-analysis
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3032,Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2192,CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,5143,Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2914,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3061,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1738,Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1246,Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2862,Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1577,"COVID-19 vaccination in people living with HIV (PLWH) in China: a cross sectional study of vaccine hesitancy, safety, and immunogenicity"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,470,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,4846,Vacina adsorvida covid-19 (inativada)
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,5798,A new SARS-CoV-2 dualpurpose serology test: highly accurate infection tracing and neutralizing antibody response detection
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1693,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3591,Pathogenesis of HIV infection: what the virus spares is as important as what it destroys
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,36,Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2877,Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,1935,Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,5584,Change in COVID-19 risk over time following vaccination with CoronaVac: a test-negative case-control study
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,4605,Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,2052,Sex differences in vaccine-induced humoral immunity
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,3638,Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study,5892,Anvisa faz recomendações sobre doses de reforço de vacinas contra Covid-19
1,,4509,An interactive web-based dashboard to track COVID-19 in real time
1,,1872,Coronavirus vaccine tracker
1,,6165,WHO approval of Chinese coronaVac COVID vaccine will be crucial to curbing pandemic
1,,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
1,,2327,Effectiveness of an inactivated SARS-CoV-2 vaccine
1,,2288,"CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
1,,5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
1,,6131,COVID-19 and solid organ transplantation: a review article
1,,4430,The full spectrum of COVID-19 development and recovery among kidney transplant recipients
1,,3120,Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients
1,,5566,Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
1,,4189,Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants
1,,5615,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
1,,1567,"Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in kidney transplant recipients"
1,,4661,"Kidney transplantation in the time of COVID-19: dilemmas, experiences, and perspectives"
1,,717,AdviseDx SARS-CoV-2 IgG II instructions for use
1,,2219,SARS-CoV-2 surrogate virus neutralization test (sVNT) kit (RUO)
1,,1788,Interrupted time series regression for the evaluation of public health interventions: a tutorial
1,,2087,Review of early immune response to SARS-CoV-2 vaccination among patients with CKD
1,,2205,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
1,,1308,Prevalence of frailty among kidney transplant candidates and recipients in the United States: Estimates from a National Registry and Multicenter Cohort Study
1,,2132,Boletim completo SP contra o coronavirus
5470,Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2,836,"active site C, respectively"
5470,Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2,638,"examined 19 hydrolysable tannins against 3CLpro of SARS-CoV-2, and they found that of these (Figure 25), pedunculagin (205), tercatain (206) and castalin (207) showed the best binding affinities of −18.58, −23.11 and −14.04 kcal/mol, respectively, on the selected target"
1,,3766,"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china"
1,,4646,Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of ireland
1,,3707,Challenges to the system of reserve medical supplies for public health emergencies: Reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in china
1,,4256,Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study
1,,4530,Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in new jersey
1,,5593,Seroprevalence of hospital staff in a province with zero COVID-19 cases
1,,1835,COVID-19 seroprevalence among hospital staff and preprocedural patients in thai community hospitals: A cross-sectional study
1,,5808,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (coronavac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1,,2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers
1,,621,Comparison of the immunogenicity of bnt162b2 and coronavac COVID-19 vaccines in hong kong
1,,1217,Dynamic igg seropositivity after rollout of coronavac and bnt162b2 COVID-19 vaccines in chile: A sentinel surveillance study
1,,980,Should a third booster dose be scheduled after two doses of coronavac? A single-center experience
1,,3873,"Immunogenicity and safety of a third dose of coronavac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
1,,681,SARS-CoV-2 specific antibody responses after third coronavac or bnt162b2 vaccine following two-dose coronavac vaccine regimen
1,,4351,Antibody responses to COVID-19 vaccines in older adults
1,,703,Coronavac induces lower neutralising activity against variants of concern than natural infection
1,,6117,Serum neutralising activity against SARS-CoV-2 variants elicited by coronavac
1,,878,Reactogenicity and immunogenicity after a late second dose or a third dose of chadox1 ncov-19 in the uk: A substudy of two randomised controlled trials (cov001 and cov002)
1,,373,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
1,,3647,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated SARS-CoV-2 vaccine in patients with sle: A case series"
1,,971,Intradermal chadox1 vaccine following two coronavac shots: A case report
1,,80,SARS-CoV-2 igg antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (coronavac) at phyathai 3 hospital
1,,2251,"Safety and immunogenicity of coronavac and chadox1 against the SARS-CoV-2 circulating variants of concern (alpha, delta, beta) in thai healthcare workers"
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,69,Immune responses against SARS-CoV-2 variants after heterologous and 479 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,3736,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after 483 receiving two-dose inactivated vaccines in healthy adults
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,3507,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,4880,Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,208,A serological assay to detect SARS-CoV-2 seroconversion in humans
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,1619,Correlates of protection 494 against symptomatic and asymptomatic SARS-CoV-2 infection
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3,4725,A SARS-CoV-2 surrogate virus 497 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 498 interaction
1248,Funding information WHO Regional Office for Europe,6049,"Confronting the Delta Variant of SARS-CoV-2, Summer 2021"
1248,Funding information WHO Regional Office for Europe,2377,Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review
1248,Funding information WHO Regional Office for Europe,2284,The nature and extent of COVID-19 vaccination hesitancy in healthcare workers
1248,Funding information WHO Regional Office for Europe,2146,COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates
1248,Funding information WHO Regional Office for Europe,463,Factors associated with COVID-19 vaccine hesitancy
1248,Funding information WHO Regional Office for Europe,953,SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
1248,Funding information WHO Regional Office for Europe,1628,Seasonal influenza vaccine dose distribution in 157 countries
1248,Funding information WHO Regional Office for Europe,746,Vaccination-Protection for those most at risk of Influenza Denmark: World Health Organization; 2022 [Protection for those most at risk of Influenza
1248,Funding information WHO Regional Office for Europe,5645,Barriers of influenza vaccination intention and behavior-a systematic review of influenza vaccine hesitancy
1248,Funding information WHO Regional Office for Europe,5792,Determinants of self-perceived health for Canadians aged 40 and older and policy implications
1248,Funding information WHO Regional Office for Europe,2651,Acceptability of vaccination against COVID-19 among healthcare workers in the Democratic Republic of the Congo. Pragmatic and Observational Research
1248,Funding information WHO Regional Office for Europe,3004,Vaccine hesitancy of the COVID-19 by health care personnel
1248,Funding information WHO Regional Office for Europe,3185,Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey
1248,Funding information WHO Regional Office for Europe,432,COVID-19 vaccine hesitancy among medical students
1248,Funding information WHO Regional Office for Europe,107,Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review
1248,Funding information WHO Regional Office for Europe,4945,Nurses' voices matter in decisions about dismissing vaccine-refusing families
1248,Funding information WHO Regional Office for Europe,972,Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system
1248,Funding information WHO Regional Office for Europe,4879,Factors associated with early uptake of COVID-19 vaccination among healthcare workers in Azerbaijan
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4272,"A comparative study between the severe acute respiratory syndrome-coronavirus-2, severe acute respiratory syndrome coronavirus, and the Middle East respiratory syndrome coronavirus"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1346,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1361,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1465,"Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4693,"Present variants of concern (VOC) and variants of interest (VOI) of SARS-CoV-2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape, and vaccines activity"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3066,Effectiveness of BNT162b2 vaccine against omicron variant in South Africa
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2193,How bharat biotech's vaccine works. The New York Times
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1535,Emerging SARS-CoV-2 variants: shooting the messenger
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,834,Identification of a novel coronavirus in patients with severe acute respiratory syndrome
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3679,Omicron SARS-CoV-2 variant: what we know and what we don't
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,579,COVID-19 vaccines: where we stand and challenges ahead
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5828,Evolution of antibody immunity to SARS-CoV-2
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2428,Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (basel)
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5582,Profiles of current COVID-19 vaccines
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4608,Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3534,History and recent advances in coronavirus discovery
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2175,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5186,A novel coronavirus associated with severe acute respiratory syndrome
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5176,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,83,"Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1682,Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4039,Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4244,A review on the effectivity of the current COVID-19 drugs and vaccines: are they really working against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants?
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5366,"A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,682,Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNTech and Moderna mRNA vaccines
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1444,A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3240,A brief outline of respiratory viral disease outbreaks: 1889-till date on the public health perspectives
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1025,"Recombinant protein vaccines, a proven approach against coronavirus pandemics"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4867,Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts-what is known so far
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,804,Advances in gene-based vaccine platforms to address the COVID-19 pandemic
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1282,"COVID-19 vaccine makers plan for annual boosters, but it's not clear they'll be needed"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4653,"Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil)"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4866,Abdel-Moneim AS (2021) Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2160,Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3342,Immunogenicity of the Ad26.COV2.S vaccine for COVID-19
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,1767,Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4018,SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4420,Cultivation of viruses from a high proportion of patients with colds
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,880,New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2458,Novavax vaccine delivers 89 % efficacy against COVID-19 in U.K.-but is less potent in South Africa
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,3099,Coronavirus diseases (COVID-19) Dashboard (2022) Updated on 5:13pm CET
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4743,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,6001,Situation report 1. World Health Organization
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4520,Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,118,The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,4682,Publisher's Note
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5729,Interim findings from firstdose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,3402,The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2908,I mmunosenescence and inflammaging: risk factors of severe COVID-19 in older people
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5342,Vaccination in the elderly: the challenge of immune changes with aging
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2025,Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,582,Plano Nacional de Operacionalização da Vacinação Contra a COVID-19
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,1569,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,4993,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5937,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2631,Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,4853,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyzes of routinely-collected data on vaccine coverage and mortality
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,726,Time interval between onset of symptoms and COVID-19 testing in Brazilian state capitals
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,6164,Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,1865,Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,3469,Small-area Deprivation Measure for Brazil: Data Documentation. University of Glasgow
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5796,R: A Language and Environment for Statistical Computing
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,4470,Efficacy and safety of highdose influenza vaccine in elderly adults: a systematic review and meta-analysis
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2127,Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,1738,Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,775,Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,1146,The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,5431,Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study,3599,Medidas de distanciamento social no controle da pandemia de COVID-19: potenciais impactos e desafios no Brasil
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,4094,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers, israel"
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,2740,Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19/bnt162b2 vaccination
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,2665,Neutralizing antibodies against the sars-cov-2 omicron variant following homologous and heterologous coronavac or bnt162b2 vaccination
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,3312,"Heterologous versus homologous covid-19 booster vaccination in previous recipients of two doses of coronavac covid-19 vaccine in brazil (rhh-001): A phase 4, non-inferiority, single blind, randomised study"
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,4469,"Antibody response to the inactivated sars-cov-2 vaccine among healthcare workers, indonesia"
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,2472,Waning antibody levels after vaccination with mrna bnt162b2 and inactivated coronavac covid-19 vaccines in hong kong blood donors
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,1934,Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,5173,"Safety and immunogenicity of seven covid-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,5945,Neutralizing antibodies against the sars-cov-2 delta and omicron variants following heterologous coronavac plus bnt162b2 booster vaccination
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,5519,Personalized vaccinology: A review
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,4657,Convalescent plasma anti-sars-cov-2 spike protein ectodomain and receptor-binding domain igg correlate with virus neutralization
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,2610,Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,3701,"Efficacy and safety of an inactivated whole-virion sars-cov-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey"
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine,4868,"Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,394,Surveillance on emerging coronavirus variant of concern (VOCs) on
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4290,WHO. WHO Coronavirus Disease (COVID-19) Dashboard
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4903,Thailand Guideline for COVID-19 vaccination 2021 second edition
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2608,COVID-19 Response in Thailand and Its Implications on Future Preparedness
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4506,"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,3089,CoronaVac induces lower neutralising activity against variants of concern than natural infection. The Lancet Infectious Diseases
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1519,Immunogenicity of a third dose viralvectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4788,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4898,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1857,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,4273,AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,3175,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,3631,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2581,Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2497,Laboratory diagnosis of COVID-192021
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1612,WHO International Standard for anti-SARS-CoV-2 immunoglobulin
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1920,Vaccine xxx (xxxx) xxx
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,964,Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2607,Abbott SARS-CoV-2 IgG II Quant for Use with ARCHITECT
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5790,cPass TM SARS-CoV-2 Neutralization Antibody Detection Kit. Instructions for Use
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2274,Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5027,Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,3962,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health -Europe
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,943,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,3137,The influence of sex and gender on the immune response
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5048,The effect of estrogen in coronavirus disease 2019
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1464,"Antibody titers against SARS-CoV-2 decline, but do not disappear for several months"
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,5107,Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,219,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2408,Interleukin-21 is a critical cytokine for the generation of virus-specific longlived plasma cells
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,2527,Vaccine sideeffects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers,1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2444,Maternal immunological adaptation during normal pregnancy
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5956,"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,1503,"Study to evaluate the safety, tolerability, and immunogenicity of SARS CoV-2 RNA vaccine candidate (BNT162b2) against COVID-19 in healthy pregnant women 18 years of age and older"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5215,Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low-and middle-income countries
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,6146,Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4993,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5910,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of Covid-19 in Brazil: test negative case-control study
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,1539,Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4012,Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4871,Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4305,SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2216,Brazilian Ministry of Health. Campanha Nacional de Vacinação contra a Covid-1. Décimo oitavo informe técnico
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4971,Nota Técnica N° 1/2021-DAPES/SAPS/MS -Vaccination for pregnant and postpartum women with comorbities
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,615,Nota Técnica N° 467/2021-CGPNI/DEIDT/ SVS/MS -Vaccination for pregnant and postpartum women without comorbidities
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4035,COVID-19 Vacinação Doses Aplicadas
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,3724,Coronavirus update (live) COVID-19 virus pandemic
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5305,"Impact of COVID-19 pandemic on time series of maternal mortality ratio in Bahia, Brazil: analysis of period 2011-2020"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4573,The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2259,"convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,712,Brazilian Ministry of Health
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2473,Genomic Surveillance of SARS-CoV-2 in Brazil
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,1644,Developing a Small-Area Deprivation Measure for Brazil
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5323,"Test-negative designs: differences and commonalities with other case-control studies with ""other patient"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2558,A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,3790,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,1991,"COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women"
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4175,Is the host viral response and the immunogenicity of vaccines altered in pregnancy? Antibodies (Basel)
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,2276,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,3601,Análise da qualidade das estatísticas vitais brasileiras: a experiência de implantação do SIM e do SINASC. Ciência & Saúde Coletiva
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,3202,WHO. The Sinovac-CoronaVac COVID-19 vaccine: what you need to know. 2021
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,4682,Publisher's Note
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series",1926,"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series",448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series",5250,Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series",4023,Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series",944,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebocontrolled phase 2 clinical trial"
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5660,Remdesivir for the Treatment of Covid-19 -Final Report
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2501,Dexamethasone in hospitalized patients with Covid-19
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,4818,Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5928,COVID-19 vaccine tracker
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,416,China's COVID vaccines have been crucial -now immunity is waning
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3125,COVID-19 vaccine trials in Africa
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,561,Africa's preparedness towards COVID-19 vaccines: Demand and acceptability challenges
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,4386,Interim statement on COVID-19 vaccination for children and adolescents
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,713,Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3178,The differential impact of pediatric COVID-19 between high-income countries and low-and middle-income countries: a systematic review of fatality and ICU admission in children worldwide
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5918,"World Health Organization. WHO coronavirus disease (COVID-19) Dashboard, data table, and detailed surveillance data"
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,4041,COVID-19) update: FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2455,FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2729,Philippines approves emergency use of Moderna's COVID-19 vaccine for 12-17 year olds
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3096,Covaxin shot recommended for children in India
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,1862,Hong Kong authorises Sinovac Covid vaccine for children aged 3 to 17
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5104,China approves emergency use of Sinopharm COVID-19 vaccine for children aged 3-17
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2064,China authorises CoronaVac Covid-19 vaccine for children above 3 years
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,919,COVID-19 vaccine Spikevax Approved for children aged 12 to 17 in EU
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3413,World Health Organization. COVID-19 vaccine Tracker and landscape
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2451,Regulation and Prequalification: Emergency Use Listing (EUL)-COVID-19 Vaccines
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5115,Children and COVID-19 vaccinations trends
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5076,US Centers for Disease Control and Prevention. COVID-19 vaccine booster Shots
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,497,Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3812,Available: https:// africacdc.org/download/covid-19-scientific-and-public-healthpolicy-update
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2515,Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-Saharan African countries
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5278,The critical need for pooled data on coronavirus disease 2019 in African children: an AFREhealth call for action through multicountry research collaboration
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5382,"African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study"
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2963,Strategy to achieve global COVID-19 vaccination by mid-2022
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2316,Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5232,"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) -highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts"
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,1906,Omicron-fuelled COVID-19 surge in African plateaus
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,1394,Vaccine Advocacy Infographics: What age groups do AU Member States need to target to reach 70% COVID-19 vaccination coverage?
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,4352,The Tribune. India gets its 1st vaccine for children above 12
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2291,Zydus's 3-dose ZyCoV-D approved
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,3670,Uganda to start inoculating children under 15 with Pfizer vaccine
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5732,Mauritius orders Covid-19 doses to cover remaining population
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,1494,Vaccination campaign for Seychellois children begins Friday
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,4547,SAHPRA update on section 21 Authorisation for Pfizer Comirnaty vaccine
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2795,Xinhuanet News. Namibia to start vaccinating teens against COVID-19
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,2008,Ghana: FDA authorizes Pfizer vaccine for 15 to 17-year-olds
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,841,"Egypt to vaccinate children aged between 15, 18 against COVID-19"
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5311,Egypt authorizes Pfizer's COVID-19 vaccine for 12 to 15 year-olds
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5863,NPHCDA: 16-year-olds can receive COVID vaccine if required for educational purposes
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola,5701,Zimbabwe starts vaccinating teens against COVID-19
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,6122,CoronaVac Induces Lower Neutralising Activity Against Variants of Concern Than Natural Infection
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,1298,Estimating the Early Impact of Vaccination Against COVID-19 on Deaths Among Elderly People in Brazil: Analyses of Routinely-Collected Data on Vaccine Coverage and Mortality
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3925,"High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in Over 75-Year-Olds, CearáState, Brazil"
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,847,Effectiveness of the CoronaVac Vaccine in the Elderly Population During a P.1 Variant-Associated Epidemic of COVID-19 in Brazil: A Test-Negative Case-Control Study
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2393,"Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?"
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,11,Antibody Response to Inactivated COVID-19 Vaccine (CoronaVac) in Immune-Mediated Diseases: A Controlled Study Among Hospital Workers and Elderly
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4150,Immunosenescence: Influenza Vaccination and the Elderly
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3957,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5049,AS03-Adjuvanted Versus Non-Adjuvanted Inactivated Trivalent Influenza Vaccine Against Seasonal Influenza in Elderly People: A Phase 3 Randomised Trial
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2725,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4323,A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5657,Immunodominant B Cell Epitope in a Hotspot Mutation Site and Mechanism of Immune Escape for SARS-CoV-2. medRxiv (2021)
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4274,Screening for SARS-CoV-2 Antibodies in Convalescent Plasma in Brazil: Preliminary Lessons From a Voluntary Convalescent Donor Program
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,1029,SARS-CoV-2 Isolation From the First Reported Patients in Brazil and Establishment of a Coordinated Task Network
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,369,Identification of Novel Consensus CD4 T-Cell Epitopes From Clade B HIV-1 Whole Genome That Are Frequently Recognized by HIV-1 Infected Patients
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3065,Algorithm AS 136 A K-Means Clustering Algorithm
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,1090,Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,861,Early Programming and Late-Acting Checkpoints Governing the Development of CD4 T-Cell Memory
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2920,Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5269,Male Sex Identified by Global COVID-19 Meta-Analysis as a Risk Factor for Death and ITU Admission
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5877,The X-Files in Immunity: Sex-Based Differences Predispose Immune Responses
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2622,Sex and Gender Differences in the Outcomes of Vaccination Over the Life Course
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2754,Immunosenescence and Human Vaccine Immune Responses
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,6034,Antibody Response to Influenza Vaccination in the Elderly: A Quantitative Review
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3276,Safety and Immunogenicity of
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,981,"Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial"
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5961,T-Cell Mediated Immunity After AZD1222 Vaccination: A Polyfunctional Spike-Specific Th1 Response With a Diverse TCR Repertoire
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5771,An mRNA Vaccine Against SARS-CoV-2 -Preliminary Report
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3738,Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,147,Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,605,Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,583,Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4407,Clinical Performance of a Standardized SARS-CoV-2 Interferon-g Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,5375,Interferon-gRelease Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4086,Spike Is the Most Recognized Antigen in the Whole-Blood Platform in Both Acute and Convalescent COVID-19 Patients
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,4442,Rapid Measurement of SARS-Cov-2 Spike T Cells in Whole Blood From Vaccinated and Naturally Infected Individuals
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,2480,Linhagens do SARS-CoV-2 Em Circulacão
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,1597,Influence of Age on the Effectiveness and Duration of Protection of Vaxzevria and CoronaVac Vaccines
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old,3859,A 'Mix and Match' Approach to SARS-CoV-2 Vaccination
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3291,"History of the COVID-19 pandemic: origin, explosion, worldwide spreading"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4642,A pneumonia outbreak associated with a new coronavirus of probable bat origin
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4130,SARS-CoV-2 was already spreading in France in late
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4863,Dating first cases of COVID-19
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3856,An mRNA vaccine against SARS-CoV-2 -preliminary report
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4792,Russia announces positive COVID-vaccine results from controversial trial
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2437,National Guiding Policy for Vaccination Against SARS-CoV-2 for the Prevention of COVID-19 in Mexico
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2058,"Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Ensanut 2020 Covid-19"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2796,"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3863,data. Coronavirus (COVID-19) Vaccinations. Available online at
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2335,Mexico -COVID-19 -Vaccines administered
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1315,Side effects after COVID-19 vaccinations among residents of Poland
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,127,Surveillance for Adverse Events After COVID-19 mRNA Vaccination
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2916,Coronavirus Vaccine -Weekly Summary of Yellow Card Reporting
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,236,Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,527,"Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,691,"The Janssen COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2673,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 Anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Re"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3111,Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1616,Mild adverse events of Sputnik V vaccine in Russia: social media content analysis of telegram via deep learning
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3168,Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2850,Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5391,Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,592,Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1514,Adverse Effects When Being Vaccinated Against Covid-19
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,442,Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5795,Side effects following administration of the first dose of Oxford-AstraZeneca's covishield vaccine in Bangladesh: a cross-sectional study
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1702,BMI-based body size guides for women and men: development and validation of a novel pictorial method to assess weight-related concepts
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1674,BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2186,Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,992,A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4110,Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,6037,Active monitoring of early safety of Sputnik V vaccine in
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3468,"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city"
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,2700,Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR -Product information (updated). (2021)
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,4227,Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: a systematic review and meta-analysis
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5500,Advisory Committee on Imunization Practices (ACIP) (2021)
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5021,Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,5966,Sex differences in immunity to viral infections
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3680,The Xs and Y of immune responses to viral vaccines
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,3991,Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,281,Population and Housing Census
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population,1605,National Health and Nutrition Survey 2020 on Covid-19. National results
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,3564,Coronavirus Disease (COVID-2019) Situation Reports. 2020. Available online
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,4421,Multiple forms of mass anxiety in coronavirus disease-2019 pandemic
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,2380,COVID-19 Vaccines vs. Variants-Determining How Much Immunity Is Enough
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,287,A strategic approach to COVID-19 vaccine R&D
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1378,Delivery Routes for COVID-19 Vaccines. Vaccines
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,331,Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,810,COVID-19 Vaccine Tracker and Landscape
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,464,COVID-19 vaccine hesitancy: A survey in a population highly compliant to common vaccinations
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,6012,"Challenges and Issues of Anti-SARS-CoV-2 Vaccines. Front. Med. 2021, 8, 664179"
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1192,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,99,Vacinas-COVID-19
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,4032,Sexual dimorphism in SARS-COV-2 infection
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,2258,Immune system and COVID-19 by sex differences and age. Women's Health
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1272,Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,4008,G-test of goodness-of-fit
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1289,Vacina Adsorvida COVID-19 (Inativada)
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,3461,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1953,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,6036,Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,3271,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,3551,Herd Immunity and Implications for SARS-CoV-2 Control
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,4063,Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,217,Sex-and age-specific clinical and immunological features of coronavirus disease 2019
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil,1586,Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion
5794,1 Special Administrative Region,416,China's COVID vaccines have been crucial -now immunity is waning
5794,1 Special Administrative Region,5827,COVID-19 vaccines: under evaluation
5794,1 Special Administrative Region,1987,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. Geneva: WHO; 2021
5794,1 Special Administrative Region,6150,Travel and covid: rules and restrictions. Brussels: Your Europe
5794,1 Special Administrative Region,3302,COVID-19: travel into the EU. Brussels: European Council 2022
5794,1 Special Administrative Region,1883,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses
5794,1 Special Administrative Region,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
5794,1 Special Administrative Region,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
5794,1 Special Administrative Region,3021,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
5794,1 Special Administrative Region,1125,Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
5794,1 Special Administrative Region,1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
5794,1 Special Administrative Region,629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
5794,1 Special Administrative Region,541,SARS-CoV-2 Testing in Elective Surgery Collaborators. A dual-antigen enzyme-linked immunosorbent assay allows the assessment of severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in a low-transmission setting
5794,1 Special Administrative Region,4116,"Optimization, comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich ELISA for measurement of human IL-23"
5794,1 Special Administrative Region,3983,The Government of Hong Kong Special Administrative Region. Hong Kong vaccination dashboard. Hong Kong: The Government of Hong Kong Special Administrative Region
5794,1 Special Administrative Region,2396,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
5794,1 Special Administrative Region,5212,"Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera"
5794,1 Special Administrative Region,1754,"License, supplementary material and copyright"
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,3036,Psoriasiform disorders. Fitzpatrick's Dermatology
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,1947,Possible triggering effect of influenza vaccination on psoriasis
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,268,"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4932,Widespread psoriasis flare following influenza vaccination
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,627,New onset guttate psoriasis following pandemic H1N1 influenza vaccination
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,1658,COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,750,Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4377,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4455,Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,5652,What do we know about India's Covaxin vaccine
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4763,Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,3039,Impact of yellow fever vaccine on patients with psoriasis: preliminary results
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,5739,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin. Dermatol Sin
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4373,"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments"
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,3317,Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine,4946,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4207,An Interactive Web-Based Dashboard to Track COVID-19 in Real Time
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,2655,A Novel Coronavirus From Patients With Pneumonia in China
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4111,Symptoms and Symptom Clusters Associated With SARS-CoV-2 Infection in Communitybased Populations: Results From a Statewide Epidemiological Study
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,563,SARS-CoV-2 Vaccines in Development
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4460,Covid-19. Draft Landscape of COVID-19 Candidate Vaccines
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3434,SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,2222,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1474,"Safety and Immunogenicity of the ChAdOx1 Ncov-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial"
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4918,Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4467,Genomic Survey of SARS-CoV-2 Vaccine Breakthrough Infections in Healthcare Workers From Kerala
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1190,Vaccine Breakthrough Infections With SARS-CoV-2 Variants
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1404,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,5817,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against Sars-Cov-2 in Healthy Chilean Adults in A Phase 3 Clinical Trial 2 3 Brief Title: Coronavac03cl Phase 3 Interim Analysis of Safety and Immunogenicity
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,5132,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,246,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,395,Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3891,WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3401,Statement -Older People are at Highest Risk From COVID-19
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1257,Comorbidities in the Elderly and Their Possible Influence on Vaccine Response
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3899,Clinical Features of COVID-19 in Elderly Patients: A Comparison With Young and Middle-Aged Patients
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1676,Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3332,Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1673,Risk of COVID-19 for Patients With Obesity
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3448,Clinical Characteristics of 30 Medical Workers Infected With New Coronavirus Pneumonia
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4901,Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,6076,Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3213,Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,1942,Risk and Course of SARS-CoV-2 Infection in Patients Treated for Hypothyroidism and Hyperthyroidism
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4582,Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4429,Multi-Omics Resolves a Sharp Disease-State Shift Between Mild and Moderate COVID-19
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,6111,Thyroid Disease Is Associated With Severe Coronavirus Disease 2019 (COVID-19) Infection
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,3421,Infectivity and Immune Escape of the New SARS-CoV-2 Variant of Interest Lambda
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,2840,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,5293,Evidence for Antibody as a Protective Correlate for COVID-19
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,6020,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,4598,Case Study of Two Post Vaccination SARS-CoV-2 Infections With P1 Variants in Coronavac Vaccinees in Brazil
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine,2296,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5633,The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,2534,"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5987,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3817,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3420,Clinical features of patients infected with 2019 novel coronavirus in
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4363,A Novel Coronavirus from Patients with Pneumonia in China
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3147,Clinical Characteristics of Coronavirus Disease 2019 in China
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4981,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4545,Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5196,Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3908,Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,1930,TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,2278,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,2595,An mRNA Vaccine against SARS-CoV-2-Preliminary Report
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3957,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,2194,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,532,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4124,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,1480,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5228,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4059,Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,5639,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4748,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,3051,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,945,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind"
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines,6148,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials
1,,5300,Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect? Hepatology
1,,2846,Autoimmune hepatitis after COVID-19 vaccination
1,,5044,Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: one or even several swallows do not make a summer
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",123,"Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",797,The interplay between HIV and COVID-19: Summary of the data and responses to date
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",928,HIV/SARS-CoV-2 coinfection: A global perspective
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",590,"Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2286,An updated meta-analysis on the association between HIV infection and COVID-19 mortality
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4003,Associations between HIV infection and clinical spectrum of COVID-19: A population level analysis based on US National COVID Cohort Collaborative (N3C) data
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",3351,Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4310,Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5900,Factors Associated with US Adults' Likelihood of Accepting COVID-19 Vaccination
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2993,COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",517,A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2228,COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5639,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4462,Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4904,Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",371,Guidelines for Standard Criteria for Adverse Events in Clinical Trials of Vaccines
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5355,Inference and missing data
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4444,Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5028,Complete Course COVID-19 Vaccinal Rate in Beijing Exceeded 90%
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2746,HIV-positive gay men's knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",1878,Predictors for and coverage of influenza vaccination among HIV-positive patients: A cross-sectional survey
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4603,"High prevalence of syphilis, HBV, and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",1523,COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4168,"COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5200,Severe Acute Respiratory Syndrome Coronavirus 2: Vaccine Hesitancy Among Underrepresented Racial and Ethnic Groups with HIV in
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5057,Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years-United States
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",4404,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",1620,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",311,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind"
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",223,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",3579,Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: Results from a cross-sectional survey among staff of a large Italian teaching hospital
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5150,Comparison of the effects of acute Influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",5592,COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2915,Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",900,Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",1596,Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity",2682,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adult
1,,5383,Effectiveness of an Inactivated SARS-CoV-2 Vaccine
1,,3531,Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant
1,,382,Heterologous Prime-Boost Vaccination
1,,2867,"India's Coronavirus Death Toll Tops 400,000 as the Delta Variant Spreads Globally, Including in the United States-The Washington Post"
1,,2184,Tracking SARS-CoV-2 Variants
1,,1091,AstraZeneca to Deliver Six Million COVID-19 Vaccine Doses in THAILAND
1,,1422,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 2021
1,,2102,"Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes"
1,,5733,The R Project for Statistical Computing
1,,3733,Pipe-Friendly Framework for Basic Statistical
1,,5471,DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus
1,,6090,The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series
1,,5969,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort
1,,122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
1,,2420,Cell Memory and Plasma Cell Development
1,,6101,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients
1,,3562,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
1,,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
1,,1046,Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay
1,,4326,Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose
1,,4338,Interim Recommendations for Heterologous COVID-19 Vaccine Schedules
1,,2157,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia"
1,,659,Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland
1,,4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,5144,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2. Vaccine in a Subgroup of Healthy Adults in Chile
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,5440,"T follicular helper cell differentiation, function, and roles in disease"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,1766,Omicron thwarts some of the world's most-used COVID vaccines
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,3653,SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,4459,"Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,3326,Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,884,Age-related changes in lymphocyte development and function
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2939,Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2669,Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,4223,Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,3964,Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2575,SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2443,"SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2214,Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,3799,MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,4849,T follicular helper cells in human autoimmunity
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,751,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind"
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination,2254,Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,1364,Clinical performance of different SARS-CoV-2 IgG antibody tests
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,2396,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,1564,SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,3932,SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. medRxiv
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,4608,Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,3869,SARS-CoV-2 Immunoassays: Advancing diagnostics of COVID-19
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,3852,Discrete SARS-CoV-2 antibody titers track with functional humoral stability
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,4050,Vaccines: correlates of vaccine-induced immunity
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,1588,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,3253,Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,805,A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers,1606,How to cite this article
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,4432,Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,3347,World Health Organization. Draft landscape of COVID-19 candidate vaccines
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,3027,The Turkish Ministry of Health Covid19 information page
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,3802,Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,3717,Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,6021,The use of social network in daily pediatric practice and education: Turkish pediatric atelier
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,3655,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,4321,Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,1958,Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,461,A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers,1989,What do we know about India's Covaxin vaccine?
1805,Citation,97,Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
1805,Citation,4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1805,Citation,5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
1805,Citation,110,"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial"
1805,Citation,31,"B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. arXiv 2021"
1805,Citation,5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
1805,Citation,5567,Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates
1805,Citation,2819,A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
1805,Citation,5369,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
1805,Citation,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
1805,Citation,1114,Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
1805,Citation,5558,"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study"
1805,Citation,2616,Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
1805,Citation,1410,Omicron: Call for updated vaccines
1805,Citation,4372,The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
1805,Citation,3270,Heterologous prime-boost vaccination
1805,Citation,2864,Heterologous prime-boost strategies for COVID-19 vaccines
1805,Citation,3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
1805,Citation,4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
1805,Citation,4132,BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
1805,Citation,2164,"BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced"
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,2695,Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,5956,"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis"
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,1112,Pregnancy and COVID-19
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,2140,Suspected COVID-19 case definition: a narrative review of the most frequent signs and symptoms among confirmed cases
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,43,Worldwide maternal deaths due to COVID-19: A brief review
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,5488,We have Vaccine for COVID-19! What to Recommend for Pregnant Women?
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,4239,Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,3393,Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,5797,Antigen-specific immune responses to influenza vaccine in utero
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,557,Impact of maternal immunization on influenza hospitalizations in infants
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report,5041,A Case Report to Assess Passive Immunity in a COVID Positive Pregnant Patient
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",4809,"Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",6028,First month of COVID-19 vaccine safety monitoring-United States
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",5622,"Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: A preliminary analysis"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",447,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",4810,"Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine-United States"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",5921,"The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study in the United States"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",1260,Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",1426,Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",1080,The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil",2144,International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. Milbank Q. 2021
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5903,Ministry of Public Health of Thailand. SARS-CoV-2 variants in Thailand
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5621,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5934,"Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2186,Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2710,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,3659,Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2391,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,354,Vaccine effectiveness against infection with the delta (B.1.617.2) variant
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,100,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance -eight U.S. locations
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4399,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant -national healthcare safety network
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,1346,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,3573,Online ahead of print
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5693,Guangdong's study of the effectiveness of China's inactivated vaccines against the SARS-CoV-2 B.1.617.2 (delta) variant
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,521,Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5954,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4640,Safety and immunological response following heterologous primary series of COVID-19 vaccination: the preliminary report focusing on the delta variant
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,3623,Evaluation of postintroduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4662,"Guidelines on diagnosis, treatment and prevention of Covid-19 in hospitals, the revised version"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4206,"Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 delta VOC in Guangzhou. China EClinicalMedicine"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,932,World Health Organization. COVID-19 clinical management: living guidance
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2631,Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,5831,Evaluation of COVID-19 vaccine effectiveness
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,1454,Waning immunity after the BNT162b2 vaccine in Israel
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2797,Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study,4043,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a singleblind, randomised, non-inferiority trial"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,2810,Sinovac: Coronavac. Inactivated Vaccine. Available online
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,2308,Effectiveness of an inactivated SARS-CoV-2 vaccine in chile
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,711,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,1801,"Immunogenicity and reactogenicity of bnt162b2 booster in chadox1-s-primed participants (combivacs): A multicentre, open-label, randomised, controlled, phase 2 trial"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5562,Intradermal vaccination: A potential tool in the battle against the COVID-19 pandemic? Risk Manag
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,3868,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: A systematic review and meta-analysis
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5607,Pseudotype neutralization assays: From laboratory bench to data analysis
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5840,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world. medRxiv 2021. preprint
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5553,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5585,"Daily Corona Virus Disease (COVID-19) Vaccine Situation Report. Department of Disease Control, Ministry of Public Health"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,1345,"Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (zycov-d): Results of an open-label, non-randomized phase i part of phase i/ii clinical study by intradermal route in healthy subjects in india"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5613,"Safety and immunogenicity of ino-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5811,safety and immunogenicity of intradermal delivery of a fractional dose mrna-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021. preprint
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,2065,"Immunogenic potential of DNA vaccine candidate, zycov-d against SARS-CoV-2 in animal models"
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,1099,Immunogenicity of a DNA vaccine candidate for COVID-19
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,3665,Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv 2021. preprint
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,1333,Thrombocytopenia and splenic platelet directed immune responses after intravenous chadox1 ncov-19 administration
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report,5684,The adjuvant gla-af enhances human intradermal vaccine responses
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,234,COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,2800,COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,2592,Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,290,COVID-19 infection in kidney transplant recipients: Disease incidence and clinical outcomes
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,227,Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,2357,Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,935,mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,6130,Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,4345,SARS-CoV-2 breakthrough infections in vaccinated kidney transplant recipients: an issue of concern
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,6003,Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,938,Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,1656,Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,6019,Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,1912,Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,3585,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,5412,SARS-CoV-2 vaccine
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,4489,Impaired humoral response in renal
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,5552,"Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients"
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,2588,COVID-19 vaccines: modes of immune activation and future challenges
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,3722,Effectiveness of an Inactivated SARS-CoV-2
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,4021,Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,1951,Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,4156,Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,3003,"Lymphocyte count, cells/L, median (IQR)"
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,3595,"Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate using CKD EPI Formula"
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant,5416,"Receptor Binding Domain of SARS-CoV-2 spike protein; SD, standard deviation"
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,2544,Transverse myelitis
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,4100,"Transverse myelitis: pathogenesis, diagnosis and treatment"
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3455,Acute transverse myelitis -A rare clinical manifestation of Lyme neuroborreliosis
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3571,Transverse myelitis after vaccination
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3371,Drug-induced interstitial lung disease: a systematic review
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3674,COVID-19 vaccine-related interstitial lung disease: a case study
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1356,Acute transverse myelitis following COVID-19 vaccination. Vaccines (Basel)
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,4649,Adverse events reported from COVID-19 vaccine trials: a systematic review
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3373,ANA investigates: neurological complications of COVID-19 vaccines
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1189,SARS-CoV-2 vaccinationinduced transverse myelitis
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,5321,Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature (PREPRINT)
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1219,COVID-19 vaccine induced interstitial lung disease
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,3557,A case of severe interstitial lung disease after COVID-19 vaccination
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1339,Acute exacerbation of idiopathic pulmonary fibrosis after pandemic influenza A (H1N1) vaccination
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,5031,Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,1231,Coronavirus vaccine-associated lung immunopathology-what is the significance
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine,4919,"Comparative systematic review and metaanalysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2418,COVID-19) Dashboard
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2346,COVID-19 Weekly Epidemiological Update Edition 68
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5501,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,4292,WHO. Interim statement on COVID-19 vaccine booster doses 2021
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,4773,WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 2021
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,1001,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5149,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2669,Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,3930,Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,1435,Optimize Prime/Boost Vaccine Strategies: trained Immunity as a New Player in the Game
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,4715,Prime-boost vaccine strategy against viral infections: mechanisms and benefits
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,1519,Immunogenicity of a third dose viralvectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,208,A serological assay to detect SARS-CoV-2 seroconversion in humans
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,3843,Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,220,"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations, WHO Technical Report Series 1004"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2344,Immunological memory cells
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,184,Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,303,To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,316,Coronavirus Pandemic (COVID-19) 2020
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,2992,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: a randomized controlled trial
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines,1671,Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
1805,Citation,4807,Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread
1805,Citation,5485,WHO Coronavirus (COVID-19) Dashboard. Available online
1805,Citation,4561,Hong Kong Special Administrative Region. CHP Local Situation Dashboard
1805,Citation,5532,Hong Kong Special Administrative Region. CHP Vaccination Dashboard
1805,Citation,770,Evaluation of the QuantiFERON SARS-CoV-2 interferon-G release assay in mRNA-1273 vaccinated health care workers
1805,Citation,3354,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently
1805,Citation,6073,Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
1805,Citation,1993,Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
1805,Citation,402,R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing
1805,Citation,306,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: Decline in antibodies 12 weeks after two doses
1805,Citation,5263,"Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine"
1805,Citation,1979,"RHH-001 study team. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
1805,Citation,122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
1805,Citation,6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
1805,Citation,5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
1805,Citation,2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
1805,Citation,2004,DMID 21-0012 Study Group
1805,Citation,1744,Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa
1805,Citation,4409,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
1805,Citation,45,Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
1805,Citation,4002,Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
1805,Citation,5714,The T cell immune response against SARS-CoV-2
1805,Citation,907,Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
1805,Citation,3524,"SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection"
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,1069,Global burden of COVID-19: situational analysis and review
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,2047,COVID-19 dynamics after a national immunization program in Israel
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,3950,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,2312,Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,777,IDSA clinical practice guideline for vaccination of the immunocompromised host
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,5225,"Clinical impact, reactogenicity, and immunogenicity after the first coronavac dose in kidney transplant recipients"
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,5250,Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants,3410,Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",3781,WHO. Coronavirus disease (COVID19): Vaccines. 2021
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",6043,Duration of protection against mild and severe disease by Covid19 vaccines
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",5203,Emergence of a novel SARSCoV2 variant in southern California
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",3444,"Safety and immunogenicity of seven COVID19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",1327,Protection of BNT162b2 vaccine booster against Covid19 in Israel
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4004,Interim recommendations for heterologous COVID19 vaccine schedules. Interim guidance
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",420,Highlights from the meeting of the strategic advisory group of experts (SAGE) on immunization
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",5484,SARSCoV2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",2358,A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4164,Heterologous AD5nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",128,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type5 vectorbased COVID19 vaccine (Ad5nCoV) in adults: preliminary report of an openlabel and randomised phase 1 clinical trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",2128,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type5 vectored COVID19 vaccine: a doseescalation, openlabel, nonrandomised, firstinhuman trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",3470,Notice of the state food and drug administration on issuing the guidelines for the grading standards for adverse events in clinical trials of prophylactic vaccines
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4950,Heterologous primeboost immunization with CoronaVac and Convidecia
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",431,"Development of an inactivated vaccine candidate, BBIBPCorV, with potent protection against SARSCoV2"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",322,"Immunogenicity and safety of a recombinant adenovirus type5vectored COVID19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebocontrolled, phase 2 trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",766,Quantifying adenovirusneutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",273,Correlates of protection against symptomatic and asymptomatic SARSCoV2 infection
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",752,Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4465,"Safety and immunogenicity of CpG 1018 and aluminium hydroxideadjuvanted SARSCoV2 S2P protein vaccine MVCCOV1901: interim results of a large scale, doubleblind, randomised, placebocontrolled phase 2 trial in Taiwan"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",2851,Clover's COVID19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",2034,"Immunogenicity, safety, and reactogenicity of heterologous COVID19 primary vaccination incorporating mRNA, viralvector, and proteinadjuvant vaccines in the UK (ComCOV2): a singleblind, randomised, phase 2, noninferiority trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",767,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID19 vaccine (ComCOV): a singleblind, randomised, noninferiority trial"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",1043,Heterologous ChAdOx1 nCoV19 and mRNA1273 vaccination
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4941,Respiratory mucosal delivery of nextgeneration COVID19 vaccine provides robust protection against both ancestral and variant strains of SARSCoV2
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",5800,T resident helper cells promote humoral responses in the lung
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",5809,Mucosal vaccines-fortifying the frontiers
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",4120,"Safety, mucosal and systemic immunopotency of an aerosolized adenovirusvectored vaccine against SARSCoV2 in rhesus macaques"
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",133,T cell immunity to SARSCoV2 following natural infection and vaccination
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",3348,Considerable escape of SARSCoV2 Omicron to antibody neutralization
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial",189,mRNAbased COVID19 vaccine boosters induce neutralizing immunity against SARSCoV2 Omicron variant
5896,Erythema multiforme after SARS-CoV-2 vaccine,4067,Localized cutaneous reaction to an mRNA COVID-19 vaccine
5896,Erythema multiforme after SARS-CoV-2 vaccine,1051,New-onset cutaneous lichen planus triggered by COVID-19 vaccination
5896,Erythema multiforme after SARS-CoV-2 vaccine,4231,Erythema multiforme after Corona-Vac vaccination
5896,Erythema multiforme after SARS-CoV-2 vaccine,4334,Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2097,Psychobehavioral responses and likelihood of receiving COVID-19 vaccines during the Pandemic
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5936,Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5071,Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance? Eur
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1515,Thromboembolic events in the South African Ad26.COV2.S vaccine study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5588,Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1030,Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5985,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2138,COVID-19 vaccine and myocarditis
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5805,The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1868,Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,13,Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4870,Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,854,"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3124,"Multimorbidity in middle age predicts more subsequent hospital admissions than in older age: A nine-year retrospective cohort study of 121,188 discharged in-patients"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4318,Sociodemographic moderation of the association between depression and stroke incidence in a retrospective cohort of 0.4 million primary care recipients with hypertension
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2814,"Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1963,"Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5248,"Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,816,Learning from the past: development of safe and effective COVID-19 vaccines
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1755,Age and multimorbidity predict death among COVID-19 patients
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2282,COVID-19 Vaccination Programme
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,132,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1245,Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,591,Centre for Health Protection. Hong Kong Vaccination Dashboard
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3526,Evaluation of the safety profile of COVID-19 vaccines: a rapid review
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2641,Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,555,Coverage of COVID-19 Vaccines In Electronic Healthcare Databases: A Protocol Template From The ACCESS Project
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5941,Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4054,"COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, and other serious comorbid conditions: a cross-sectional internet-based survey"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3833,Differential impacts of multimorbidity on COVID-19 severity across the socioeconomic ladder in Hong Kong: a syndemic perspective
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2318,An evaluation of universal vouchers as a demand-side subsidy to change primary care utilization: a retrospective analysis of longitudinal services utilisation and voucher claims data from a survey cohort in Hong Kong
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,2457,Redistribution or horizontal equity in Hong Kong's mixed public-private health system: a policy conundrum
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,5616,Cardiovascular outcomes associated with use of clarithromycin: population based study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3145,Prenatal antidepressant use and risk of attention-deficit/ hyperactivity disorder in offspring: population based cohort study
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,3741,Influenzarelated hospitalizations among children in Hong Kong
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,1363,Methods for identifying 30 chronic conditions: application to administrative data
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4038,Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,4862,Entropy balancing is doubly robust
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong,6009,Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study
1,,2203,World Health Organization. Coronavirus Disease (COVID-19) Dashboard
1,,1287,Our World in Data. Coronavirus (COVID-19) Vaccinations
1,,488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
1,,3569,China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine | Reuters
1,,2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
1,,1183,Plan Nacional de Vacunación contra COVID-19
1,,1730,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
1,,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1,,3378,"Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud Recomendaciones basadas en consenso de expertos e informadas en la evidencia"
1,,4540,World Health Organization. Clinical management of COVID-19
1,,3545,COVID-19 vaccine: critical questions with complicated answers
1,,1536,Sinovac Announces Phase III Results of Its
1,,4836,"New mutations raise specter of ""immune escape"
1,,3819,"COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations"
1,,3884,"Reporte COVID-19: Vacuna CoronaVac tiene un 90,3% de efectividad para prevenir el ingreso a UCI"
1,,3123,El virus se adaptó para transmitirse rápidamente
1,,4682,Publisher's Note
1,,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,44,References: 'metafor' P. Package 'metafor'
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,3143,National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4765,Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1816,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4985,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,3618,Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5054,Vaccination in the elderly: The challenge of immune changes with aging
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1970,mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2209,Effectiveness of COVID-19 vaccines: From clinical trials to real life
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4796,Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4166,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel)
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1171,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using 19 national surveillance data"
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1927,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5971,Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2522,Spread of a Variant SARS-CoV-2 in
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2009,Long-Term Care Facilities in England
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1396,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4344,Interpreting vaccine effectiveness trial results for infection and transmission
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,3547,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults 20 in England: test negative case-control study"
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,3224,Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2062,AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5938,The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5428,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Effectiveness and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4438,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4947,FDA-authorized mRNA COVID-19 vaccines are effective per 21
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5295,real-world evidence synthesized across a multi-state health system
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2170,A systematic review assessing the under-representation of elderly adults in COVID-19 trials
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5618,Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2762,Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,5539,Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2838,VIVALDI): a prospective cohort study. The Lancet Infectious Diseases
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,1084,Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2376,Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2445,Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,408,"-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4512,The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,825,Tracking SARS-CoV-2 variants
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2885,Retrieved
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,2363,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,241,BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4209,The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis,4309,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
5327,"To cite: Saygılı ES, Karakilic E",1020,Mini-Review Discussing the reliability and efficiency of COVID-19 vaccines
5327,"To cite: Saygılı ES, Karakilic E",649,Subacute thyroiditis following seasonal influenza vaccination
5327,"To cite: Saygılı ES, Karakilic E",653,Clinical characteristics of 852 patients with subacute thyroiditis before treatment
5327,"To cite: Saygılı ES, Karakilic E",1602,Viruses and thyroiditis: an update
5327,"To cite: Saygılı ES, Karakilic E",4048,Thyroiditis and SARS-CoV-2 pandemic: a review
5327,"To cite: Saygılı ES, Karakilic E",2434,Diagnostic value of nuclear medicine imaging and ultrasonography in subacute thyroiditis
5327,"To cite: Saygılı ES, Karakilic E",2679,Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis
5327,"To cite: Saygılı ES, Karakilic E",4335,Endocrine significance of SARS-CoV-2's reliance on ACE2
5327,"To cite: Saygılı ES, Karakilic E",1141,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
5327,"To cite: Saygılı ES, Karakilic E",625,Sars vaccines: where are we?
5327,"To cite: Saygılı ES, Karakilic E",3901,Occurrence of subacute thyroiditis following influenza vaccination
5327,"To cite: Saygılı ES, Karakilic E",5555,Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female
5327,"To cite: Saygılı ES, Karakilic E",4504,Subacute thyroiditis following the H1N1 vaccine
5327,"To cite: Saygılı ES, Karakilic E",732,Subacute thyroiditis after hepatitis B vaccination
5327,"To cite: Saygılı ES, Karakilic E",5791,Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)
5327,"To cite: Saygılı ES, Karakilic E",4275,Asia syndrome and endocrine autoimmune disorders
5327,"To cite: Saygılı ES, Karakilic E",1626,Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination Asia syndrome
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5770,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3861,SARS-CoV-2 vaccines: status report
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2799,E.a. The COVID-19 pandemic and global environmental change: emerging research needs
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3672,"Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1424,Immunotoxicity and environment: immunodysregulation and systemic inflammation in children
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1234,Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1144,Elevated biomarkers of sympatho-adrenomedullary activity linked to ewaste air pollutant exposure in preschool children
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2882,The role of air pollution (PM and NO2) in COVID-19 spread and lethality: a systematic review
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5360,Systemic inflammatory markers associated with cardiovascular disease and acute and chronic exposure to fine particulate matter air pollution (PM2.5) among US NHANES adults with metabolic syndrome
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4521,Evaluation of masks' internal and external surfaces used by health care workers and patients in coronavirus-2 (SARS-CoV-2) wards
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4009,Investigation of SARS-CoV-2 virus in environmental surface
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1891,"Co-variance nexus between COVID-19 mortality, humidity, and air quality index in Wuhan, China: new insights from partial and multiple wavelet coherence"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4997,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5032,Source apportionment and health risk assessment of air pollution particles in eastern district of Chengdu
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2570,"SARS-CoV-2 in municipal wastewater treatment plant, collection network, and hospital wastewater"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3067,Moradi-Asl E (2021b) Investigation of SARS-CoV-2 virus on nozzle surfaces of fuel supply stations in North West of Iran
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4412,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1879,Decreased vaccine antibody titers following exposure to multiple metals and metalloids in e-waste-exposed preschool children
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3875,"Considerable decrease of antibody titers against measles, mumps, and rubella in preschool children from an e-waste recycling area"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3650,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2386,Air pollution exposure and COVID-19: a look at mortality in Mexico City using individual-level data
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5823,Elevated inflammatory Lp-PLA2 and IL-6 link e-waste Pb toxicity to cardiovascular risk factors in preschool children
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4833,"Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2702,Air pollution by NO 2 and PM 2.5 explains COVID-19 infection severity by overexpression of angiotensinconverting enzyme 2 in respiratory cells: a review
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2858,Spike in pollution to ignite the bursting of COVID-19 second wave is more dangerous than spike of SAR-CoV-2 under environmental ignorance in long term: a review
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,327,Characterization of water soluble inorganic ions and their evolution processes during PM2.5 pollution episodes in a small city in southwest China
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1741,Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5193,Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1901,Investigating the relationship between occupation and SARS-CoV2
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2103,A study on the effects of meteorological and climatic factors on the COVID-19 spread in Canada during 2020
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5912,Effects of climatological parameters on the outbreak spread of COVID-19 in highly affected regions of Spain
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5359,Does environmental quality and weather induce COVID-19: case study of Istanbul
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5010,Fluctuations in environmental pollutants and air quality during the lockdown in the USA and China: two sides of COVID-19 pandemic
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4723,"Lamon-Fava S (2021) EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3954,COVID-19 and air pollution and meteorology-an intricate relationship: a review
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,3031,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5740,Links between air pollution and COVID-19 in England
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5167,Long-term residential exposure to air pollution is associated with hair cortisol concentration and differential leucocyte count in Flemish adolescent boys
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1452,Investigation of SARS-CoV-2 in hospital indoor air of COVID-19 patients' ward with impinger method
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1783,"Seasonal characteristics, formation mechanisms and source origins of PM<sub>2.5</sub> in two megacities in Sichuan Basin"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4778,"Combined toxicity of outdoor air pollution on kidney function among adult women in Mianyang City, southwest China"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2418,COVID-19) Dashboard
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5646,"Children and increased susceptibility to environmental carcinogens: evidence or empathy? Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2904,"SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: what is the connection?"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4821,Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4601,Decreased blood hepatitis B surface antibody levels linked to ewaste lead exposure in preschool children
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,1576,Inflammatory response to fine particulate air pollution exposure: neutrophil versus monocyte
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5139,Assessing the mechanism of DNA damage induced by lead through direct and indirect interactions
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5219,Analysis of efficacy of intervention strategies for COVID-19 transmission: a case study of Hong Kong
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2573,"Particulate air pollution and respiratory Haemophilus influenzae infection in Mianyang, southwest"
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2647,Ambient fine particulate matter inhibits innate airway antimicrobial activity in preschool children in e-waste areas
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,24,The association of PM2.5 with airway innate antimicrobial activities of salivary agglutinin and surfactant protein D
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2559,Associations between air pollution and COVID-19 epidemic during quarantine period in China
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,4204,Ambient air heavy metals in PM2.5 and potential human health risk assessment in an informal electronic-waste recycling site of China
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,2461,Association between short-term exposure to air pollution and COVID-19 infection: evidence from China
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine,5768,Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,4013,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,3310,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5401,Ministry of Health
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5819,WHO. Coronavirus disease (COVID-19): Vaccines
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5542,The Capacity of the Indonesian Healthcare System to Respond to COVID-19
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,650,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5019,WHO. Coronavirus disease (COVID-19
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5545,Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,1250,The complementary roles of Phase 3 trials and postlicensure surveillance in the evaluation of new vaccines
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,547,Real world effectiveness of covid-19 vaccines
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,5380,WHO. Interim statement on COVID-19 vaccine booster doses
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,1461,Turkish Society of Clinical Microbiology and Infectious Diseases
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,3113,"Vaccination status, acceptance, and knowledge toward a COVID-19 vaccine among healthcare workers: a cross-sectional survey in China"
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,2373,"Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey"
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers,3848,"Hazal Cansu Acar, Sumeyye Nur Aydin et al. Vaccine xxx (xxxx) xxx"
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",811,"), and National Institute of Allergy and Infectious Diseases (ZIA AI001273). JDS, LRG and BMA have received postdoctoral fellowships by the Brazilian Ministry of Health while conducting this study. References Artic Network"
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",87,The importance and challenges of identifying SARS-CoV-2 reinfections
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3214,"Centers for Disease Control and Prevention, 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel"
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2142,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",1701,2020. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",4576,Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",4855,Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3176,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3690,ModelFinder: fast model selection for accurate phylogenetic estimates
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",1781,Longitudinal analysis of human memory T-cell response according to the severity of illness up to 8 months after SARS-CoV-2 infection
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",4825,Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2355,A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2206,"Oxford University Hospitals Staff Testing, G, 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers"
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2547,SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",5867,SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",1406,Portal do COVID-19 -Coronavírus Brasil
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",1016,Three SARS-CoV-2 Reinfection Cases by the New Variant of Concern (VOC) P.1/501Y.V3. PREPRINT Available at Research Square
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",1648,IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",250,"CoG-UK), o.b.o.C.-G.C.U, 2020. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations"
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2561,Rede Genômica Fiocruz. Presença das linhagens por estado
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2218,SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",607,Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3203,Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",3820,Detection of a SARS-CoV-2 variant of concern in South Africa
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",2646,Genomic evidence for reinfection with SARS-CoV-2: a case study
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil",5512,"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil"
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1064,reactive T cells in healthy donors and patients with COVID-19
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5229,Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2200,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2719,Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,737,Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2084,Adaptive immunity to SARS-CoV-2 and COVID-19
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5970,Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2432,Correlates of protection from SARS-CoV-2 infection
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5077,"A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients"
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,3152,Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5777,Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,894,Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,3621,Antibody titres decline 3-month post-vaccination with BNT162b2
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1596,Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2262,Enhanced SARS-CoV-2 neutralization by dimeric IgA
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1562,Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2254,Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,4223,Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1386,Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,5054,Vaccination in the elderly: The challenge of immune changes with aging
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,2190,Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine,1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4509,An interactive web-based dashboard to track COVID-19 in real time
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2598,Age-specific mortality and immunity patterns of SARS-CoV-2
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2393,"Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1633,Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2196,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4525,Projeções populacionais por sexo e idade para pequenas áreas no Brasil
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4118,"Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1073,"Case-control vaccine effectiveness studies: Data collection, analysis and reporting results"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,3637,Definition of COVID-19 cases and recommendations for COVID-19 surveillance in Brazil
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1284,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1692,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,587,COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,507,Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1187,Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,1244,Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4486,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,6102,"Supplementary Figure 1. Reported RT-PCR or Antigen confirmed COVID-19 in the general population of the São Paulo State, Brazil from"
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study,400,"Reported RT-PCR or Antigen confirmed COVID-19 rates in the general population of the São Paulo State, Brazil from"
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,5091,Dominance of alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,2007,Covid-19 breakthrough infections in vaccinated health care workers
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,3288,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,4176,"Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections"
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers,501,Antibody status and incidence of SARS-CoV-2 infection in health care workers
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",4572,"Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",887,"Aging in COVID-19: vulnerability, immunity and intervention"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",3242,Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",5815,Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",976,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2630,Socioeconomic inequalities associated with mortality for COVID-19 in Colombia: a cohort nationwide study
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",3824,"COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",694,Public health surveillance for COVID-19. Interim guidance
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",821,Pan American Health Organization. Case definitions for COVID-19 surveillance
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",1076,Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",5754,Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2511,mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",6091,Preparing for a pandemic: accelerating vaccine availability
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",3790,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",4933,Frailty: implications for clinical practice and public health
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2978,Immunosenescence and human vaccine immune responses
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2148,Effectiveness of the CoronaVac vaccine in the elderly population during a gamma variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2811,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",2898,Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222)
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort",5135,Introduction to the analysis of survival data in the presence of competing risks
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6141,Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",648,A rare case of shingles after covid-19 vaccine: is it a possible adverse effect?
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5309,Myocarditis following COVID-19 vaccination
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4319,Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4860,The 2020 pandemic: current SARS-CoV-2 vaccine development
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5625,The proximal origin of SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4117,Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6151,Cancer immunology and canine malignant melanoma: a comparative review
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4389,AZD1222 US Phase III primary analysis confirms safety and efficacy
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3184,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1434,Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",702,Review on up-to-date status of candidate vaccines for COVID-19 disease
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1279,The 2019-new coronavirus epidemic: evidence for virus evolution
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1672,Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5759,Evolutionary reversion of live viral vaccines: can genetic engineering subdue it? Virus Evol
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5736,Combinatorial nano-bio interfaces
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2676,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3612,"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3392,"Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4199,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.3.5.1 variants and severe COVID-19 disease in Qatar
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5965,The world health organization international clinical trials registered organization registered platform
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2383,Chinese COVID-19 vaccine candidate the first to start phase 3 clinical trials worldwide-Global Times
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6119,Reported orofacial adverse effects of COVID-19 vaccines: the knowns and the unknowns
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3207,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals-Full Text View-ClinicalTrials.gov
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4174,Aurisicchio L (2020) Are genetic vaccines the right weapon against COVID-19?
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1969,SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1579,Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in nonhuman primates
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2240,Covid-19 Latest News: Sinopharm Virus Vaccine Safe in Testing-Bloomberg
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3002,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection-Full Text View-ClinicalTrials.gov. (2021)
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2560,Personalized medicine case report a rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",623,West Nile virus: recent trends in diagnosis and vaccine development
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4737,Eong Ooi E (2020) A single dose of self-transcribing and replicating RNA based SARS-CoV-2 1 vaccine produces protective adaptive immunity
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",955,A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5338,Polyethylene glycol and polysorbate testing in twelve patients prior to or after COVID-19 vaccine administration
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1719,Singledose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2215,Tuberculosis vaccine: a journey from BCG to present
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4837,"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",842,Recent advances in design of immunogenic and effective naked DNA vaccines against cancer
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2195,SARS-CoV-2 variants and ending the COVID-19 pandemic
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",908,Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2997,Nonviral delivery of self-amplifying RNA vaccines
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3319,Rapid COVID-19 vaccine development
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1223,A decade after SARS: strategies for controlling emerging coronaviruses
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1517,Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4428,A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",237,Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2728,Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5708,Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B117 variant
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3948,Cytokine gene expression in epidermis with biological effects following injection of naked DNA
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2352,Lymphadenopathy associated with the COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2048,DNA vaccines-how far from clinical use?
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4722,The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1564,SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4243,Recognizing vaccine-induced immune thrombotic thrombocytopenia
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5726,COVID-19 spike-host cell receptor GRP78 binding site prediction
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2576,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial (2021) https:// trial siten ews. com/ indon esia-testi ng-locat ion-forchinas-sinov ac-phase-3-clini cal-trial/. Accessed 30 Mar 2021 Investigating a Vaccine Against COVID-19-Full Text View-Clini-calTrials.gov
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2955,COVID-19: a review of therapeutic strategies and vaccine candidates
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5095,An mRNA vaccine against SARS-CoV-2-preliminary report
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",963,Preparation of viruslike particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2556,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2552,Role of nanotechnology behind the success of mRNA vaccines for COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3760,COVID-19 vaccination and glomerulonephritis
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1226,Montefiori DC (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6080,Status report on COVID-19 vaccines development. Curr Infect Dis Rep
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5664,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4220,Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1249,Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against middle east respiratory syndrome coronavirus challenge
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",576,How could a COVID vaccine cause blood clots? Scientists race to investigate
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4356,Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4069,SARS-CoV-2 and viral sepsis: observations and hypotheses
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1921,Pseudo-anaphylactic reactions to pfizer bnt162b2 vaccine: report of 3 cases of anaphylaxis post pfizer bnt162b2 vaccination
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4528,Vaccines against COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2279,Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2912,Epitopes for a 2019-nCoV vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4914,Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1760,Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3462,"AstraZeneca vaccine: blood clots are ""extremely rare"" and benefits outweigh risks, regulators conclude"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",370,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5155,India's DNA COVID vaccine is a world firstmore are coming
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",684,Cationic liposome-mediated RNA transfection
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2923,Skeletal muscle cells: from local inflammatory response to active immunity
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",344,Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices-United States
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5331,Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1038,"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4519,Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2305,Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: a case report
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4779,Unilateral axillary adenopathy in the setting of COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3669,"SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2021,Live attenuated vaccines: historical successes and current challenges
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6011,Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: a clinical dilemma for clinicians and patients
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3033,Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B.1.351)
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5262,Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2306,Nanotechnology shows promise for nextgeneration vaccines in the fight against COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5667,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. medRxiv (p. 2020.06.30
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3675,Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",914,Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5252,mRNA vaccinesa new era in vaccinology
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4427,Non-viral COVID-19 vaccine delivery systems
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1162,Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3280,"COVID-19 vaccine anaphylaxis : IgE, complement or what else ? A reply to"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",6110,"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4590,Phase I/II study of intracutaneous inoculation of COVID-19 DNA vaccine (AG0302-COVID19)
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",491,Phase II/III Study of COVID-19 DNA Vaccine (AG0302-COVID19)-Full Text View-ClinicalTrials.gov
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1134,SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",352,Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",725,Single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2185,Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2715,A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1559,Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1590,Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",778,Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",645,Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3640,Safety and efficacy of single-dose Ad26COV2S vaccine against covid-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5307,DNA and mRNA vaccination against allergies
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3804,ANCA glomerulonephritis after the Moderna COVID-19 vaccination
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4656,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioN-Tech mRNA COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3379,An overview of vaccine development for COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4800,ANCA-associated vasculitis following pfizer-BioNTech COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3867,A review of the progress and challenges of developing a vaccine for COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3198,COVID-19 vaccination in developing nations: challenges and opportunities for innovation
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",153,A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3090,Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine-United States
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1505,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",748,COVID-19 vaccine development and a potential nanomaterial path forward
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4861,Generation of influenza A viruses as live but replication-incompetent virus vaccines
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1256,Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3195,The clinical development process for a novel preventive vaccine: an overview
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3967,Sinovac says its Covid-19 vaccine generated immune responses-STAT
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3160,Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5158,Orofacial adverse effects of COVID-19 vaccines exist but are rare
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3342,Immunogenicity of the Ad26.COV2.S vaccine for COVID-19
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1654,The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4415,A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1518,Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2554,Emerging vaccine delivery systems for COVID-19: functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3904,Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1334,COVID-19: learning from lessons to guide treatment and prevention interventions
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",544,"The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",437,"SARS-CoV-2/ COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",868,Understanding Viral Vector COVID-19 Vaccines|CDC
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1838,Engineering attenuated virus vaccines by controlling replication fidelity
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2120,Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1102,Neurological complications of COVID-19: guillain-barre syndrome following pfizer COVID-19 vaccine
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4434,Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",244,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",799,"Veesler D (2020b) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1061,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4999,A human monoclonal antibody blocking SARS-CoV-2 infection
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1532,SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1271,Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4085,Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1017,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3577,Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",718,Neutrilizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patients cohort and their implications
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1450,"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2691,An infectious cDNA clone of SARS-CoV-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1000,Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2425,Childhood vaccination: implications for global and domestic public health
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2568,Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3311,Wilson IA (2020) A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1565,Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",3515,Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2233,Progress and prospects on vaccine development against sars-cov-2
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",4212,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, doubleblind, and placebo-controlled phase 2 clinical trial"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5063,Assessment of the immune responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan nanoparticles before and after Treponema pallidum challenge in rabbits
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",5730,A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review",1608,Single-cell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3485,A novel coronavirus from patients with pneumonia in China
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4758,COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,207,"Vaccine Development, Testing, and Regulation | History of Vaccines"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4159,The SARS-CoV-2 spike glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3200,COVID-19 vaccine tracker and landscape
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,1733,Safety and efficacy of single-dose Ad2.6COV2.S vaccine against COVID-19
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5528,Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3409,Current advances in the development of SARS-CoV-2 vaccines
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,670,SARS-CoV-2 vaccines in development
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,914,Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3853,"Molecular sciences mRNA vaccine era-mechanisms, drug platform and clinical prospection"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5545,Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4788,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,132,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2175,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,1903,"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2167,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2076,Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,6161,Network meta-analysis: an introduction for clinicians
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2628,Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,6106,Systematic reviews and meta-analyses CHECK LIST: The PRISMA statement
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3081,Rayyan-a web and mobile app for systematic reviews
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3503,The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5731,The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2494,"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4395,Fluoroquinolones and cardiovascular risk: a systematic review Meta-analysis and Network Meta-analysis
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,2597,Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) during pregnancy and the risk for autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in the offspring: A true effect o
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4208,"Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,913,Ranking treatments in frequentist network meta-analysis works without resampling methods
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,5611,Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4921,Janssen Vaccines & Prevention B.V. A Study of Ad26.COV2.S in Adults
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3270,Heterologous prime-boost vaccination
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,262,Novavax COVID-19 Vaccine Demonstrates 89 . 3 % Efficacy in UK Phase 3 Trial
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,137,Vaccines and Related Biological Products Advisory Committee
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,4558,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. www. thela ncet"
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,3206,Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis,79,mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,538,COVID-19) Dashboard with Vaccination Data
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,428,Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. InSeminars in Arthritis and Rheumatism
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,1065,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,1280,"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. Rmd Open"
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,5751,Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,1402,Lb0003 Immunogenicity and Safety of the BNT162B2 mRNA Covid-19 Vaccine in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Population: a Multicenter Study
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,41,"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis"
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,446,Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2381,Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2877,Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3411,Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,895,"but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases"
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3110,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2382,The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2968,Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2248,Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,5807,American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,1325,COVID-19 vaccination and antirheumatic therapy
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3726,rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2753,The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,5835,"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate"
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,990,Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3309,Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3813,Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,5422,"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomized controlled, non-inferiority trial"
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,2463,A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,275,Draft Guidelines for Adverse Event Reporting and Learning Systems
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE,3645,Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2972,2021. 2. WHO. Draft Landscape and Tracker of COVID-19 Candidate Vaccines
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1625,Efficacy and SAFETY of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,5842,CoV-2 Variant Classifications and Definitions
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2110,Lineage Assignment in An Emerging Pandemic as An Epidemiological Tool
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3159,COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,578,"Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice"
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,125,BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1142,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,114,"MAFFT online service: Multiple sequence alignment, interactive sequence choice and visualization"
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,171,Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,560,"Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: A systematic review and meta-analysis"
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,4363,A Novel Coronavirus from Patients with Pneumonia in China
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,4726,the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,477,who-director-general-s-opening-remarks-at-the-media-briefing-on-covid
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1534,Informativo da Sociedade Brasileira de Infectologia: Primeiro Caso Confirmado de Doença Pelo Novo Coronavírus (COVID-19) No Brasil-26/02/2020. Soc. Bras. Infectol. Sao Paulo Brasil 2020
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,608,Explosion in mortality in the Amazonian epicenter of the COVID-19 epidemic 19. Cad
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1214,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,4479,Have deaths from COVID-19 in Europe plateaued due to herd immunity?
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1034,Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3082,"Ministério da Saúde: Brazilia, Brazil"
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1443,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1228,Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,4486,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,689,Spike mutation D614G alters SARS-CoV-2 fitness
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,4283,SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2366,Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,1646,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3323,Plano Nacional da Operacionalização da Vacinação Contra a COVID-19
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2969,A systematic review of SARS-CoV-2 vaccine candidates
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3510,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3283,A cross-country database of COVID-19 testing
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,3461,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil,511,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: A retrospective analysis of nationwide data"
1,,3420,Clinical features of patients infected with 2019 novel coronavirus in
1,,1324,Did pangolins spread the China coronavirus to people? Nature 2020
1,,4422,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster
1,,2959,World Health Organization Draft Landscape of COVID-19 Candidate Vaccines
1,,101,The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
1,,1432,COVID-19 vaccine: Where are we now and where should we go?
1,,5953,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVİD-19
1,,2582,Five things to know about: Mixing and Matching Coronavirus Vaccines
1,,3747,Oxford Vaccine Group COM-COV Comparing COVID-19 Vaccine Schedule Combinations
1,,3881,Southampton University COV-BOOST Evaluating COVID-19 Vaccine Boosters
1,,3372,BioNTech Product Monograph including Patient Medication Information Comirnaty(R) COVID-19 Vaccine
1,,4566,Diagnostic Snibe MAGLUMI 2019-nCoV IgM/IgG Immunoassay 2020
1,,6093,Snibe Diagnostic Fact Sheet for Healthcare Providers-MAGLUMI 2019-nCoV IgM/IgG 2020
1,,5833,COVID-19) Emergency Use Authorizations for Medical Devices; Food and Drug Administration
1,,1242,Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data
1,,5810,R-Pharm) Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
1,,2227,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial"
1,,2824,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: A prospective cohort study. medRxiv 2021"
1,,4920,Mixing COVID-19 Vaccines Appears to Boostİmmune Responses
1,,3479,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant ınfections among ıncarcerated persons in a federal prison-Texas
1,,1544,Breakthrough ınfections of SARS-CoV-2 gamma variant in fully vaccinated gold miners
1,,334,"COVID-19-associated hospitalizations mong vaccinated and unvaccinated adults ≥18 years -COVID2 NET, 13 states"
1,,75,Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study
1,,4915,Prevention and attenuation of COVİD-19 with the BNT162b2 and mRNA-1273 Vaccines
1,,2360,Royal College of Physicians. National Early Warning Score (NEWS) 2. 2021. Available online
1,,1094,World Health Organization. WHO R&D Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis
1,,593,BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
1,,1694,Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
1,,3664,COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): A prospective cohort study
1,,552,Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
1,,4416,Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2
1,,1824,Clinical characteristics of hospitalized COVID-19 patients who received at least one dose of COVID-19 vaccine
1,,3934,Virological and serological kinetics of 1 SARS-CoV-2 Delta variant vaccine breakthrough infections: A multi-center cohort study
1,,3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
1,,5349,"Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections"
1,,1047,The overlooked superpower of mRNA vaccines
1,,260,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
1,,4224,Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
1,,2269,Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants
1,,180,Waning ımmune humoral response to BNT162b2 COVİD-19 vaccine over 6 months
1,,764,Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study
1,,4599,Waning of BNT162b2 vaccine protection against SARS-CoV-2 ınfection in Qatar
1,,3943,Prediction of long-term kinetics of vaccine-elicitedneutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
1,,1599,SARS-CoV-2 infection in fully vaccinated individuals of old age strongly boosters the humoral immune response
1,,4740,Vaccine breakthrough ınfections with SARS-CoV-2 variants
1,,1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
1,,4700,Anti-SARS-CoV-2 antibody levels measured by the AdviseDx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing ımmunity
1,,2891,SARS-CoV-2 breakthrough infections in fully vaccinated individuals
1,,6032,Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
1,,2183,COVİD-19 breakthrough ınfections in vaccinated health care workers
1,,968,Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant
1,,2977,"No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups ınfected with SARS-CoV-2 delta variant"
1,,5737,The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
1,,4858,Effectiveness of an ınactivated SARS-CoV-2 vaccine in Chile
1,,5943,Effectiveness of an ınactivated SARS-CoV-2 vaccine
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4484,Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1574,Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,3777,SARS-CoV-2 infection in patients with systemic autoimmune diseases
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,5568,Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4518,A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4641,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2257,Leveraging the United States Epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1277,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4840,Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1548,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1677,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,662,Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,61,Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,5856,The REDCap consortium: building an international community of software platform partners
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,20,Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,5264,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,333,World Health Organization. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,5012,Systemic lupus erythematosus disease activity index
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1718,The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1286,SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,4061,Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,987,Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,3535,One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2895,Dynamics of inactivated SARS-CoV-2 vaccine antibody response in SARS-CoV-2-seropositive autoimmune rheumatic disease patients
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2052,Sex differences in vaccine-induced humoral immunity
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,3624,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers"
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus,1842,Immunological considerations for COVID-19 vaccine strategies
413,The immunogenicity and safety of different COVID-19 booster vaccination following 1,1428,"*The post primary series GMC was derived from the study in the same setting as the current study 620 (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against 621 the SARS-CoV-2 Circulating Variants of Concern"
413,The immunogenicity and safety of different COVID-19 booster vaccination following 1,1050,The post primary series GMC 623 (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5824,Ethics and execution of developing a 2nd wave COVID vaccine-Our interim phase I/II VSV-SARS-CoV2 vaccine experience
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1446,COVID-19 vaccine trial ethics once we have efficacious vaccines
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4249,Threat assessment brief: emergence of SARS CoV 2 B. 1.617 variants in India and situation in the EU/EEA
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2757,Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2675,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2367,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5397,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2873,Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,6031,Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5975,"SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,915,Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5466,Strategies for vaccine prioritization and mass dispensing
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,3476,"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2738,Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2537,Intradermal vaccination: a potential tool in the battle against the COVID-19 pandemic? Risk Manag
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4337,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A systematic review and meta-analysis
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5491,Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1403,Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,800,Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2028,Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5072,COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2927,SARS-CoV-2 antibody response in persons with past natural infection
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,723,T cell response to SARS-CoV-2 infection in humans: a systematic review
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,96,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1556,"Ministry of Public Health, a goverment organization. The Coronavirus disease 2019 situation"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1437,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4387,The race to a COVID-19 vaccine: opportunities and challenges in development and distribution
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1273,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,150,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,3774,Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2634,Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,143,Mechanisms of innate events during skin reaction following intradermal injection of seasonal influenza vaccine
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4957,Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2704,Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,730,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2175,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4378,Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4169,SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,4513,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1116,T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1482,Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,3494,Immune system and COVID-19 by sex differences and age
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population,1306,Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",2520,"5′-TCGTTTCGGAAGAGA-CAGGT-3′; reverse primer, 5′-GCGCAGTAAGGATGGCTAGT-3′. gradient centrifugation, and peripheral blood mononuclear cells (PBMCs) were isolated using conventional Ficoll-Hypaque density-gradient centrifugation (GE Healthcare"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",677,"Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) microscope. For IHC staining, to identify the expression of SARS-CoV-2 S protein"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",7,dehydrated paraffin sections (3-4 µm in thickness) were treated with an antigen retrieval kit
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",5620,"After blocking in 1% normal goat serum for 1 h at 37°C, the sections were stained with anti-SARS-CoV-2 rabbit monoclonal antibody at 4°C overnight, followed by incubation with a horseradish peroxidase HRP-labeled goat anti-rabbit IgG secondary antibody (ZDR-5306, 1:200; ZSGB Bio) for 1 h at 37°C. Finally, the sections were visualized by incubation with 3,3′-diaminobenzidine tetrahydrochloride (DAB) and viewed carefully by an Olympus microscope. CT Macaques were anesthetized with 2% isoflurane. CT imaging was conducted by using an IRIS XL-260 CT scanner"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3761,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",1148,Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",1659,Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",4859,Analysis of the delta variant B.1.617.2 COVID-19
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",423,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3344,Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",154,mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",942,Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",539,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",518,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",4049,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",5647,Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Sequential immunizations confer cross-protection against variants of
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",1952,"two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",2078,Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3910,Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",646,Transcriptome-wide off-target effects of steric-blocking oligonucleotides
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",5151,Heavily mutated Omicron variant puts scientists on alert
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",1032,Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",4736,micron extensively but incompletely escapes Pfizer BNT162b2 neutralization
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",240,Culture and identification of a Deltamicron SARS-CoV-2 in a three cases cluster in southern France
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",2098,The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",3780,Primary exposure to SARS-CoV-2 protects against reinfection in Rhesus macaques
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",924,Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques",4511,"which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5629,Infective endocarditis in adults
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,337,Acute pericarditis
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1466,"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2217,Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1765,Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5907,Myocarditis following COVID-19 mRNA vaccination
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,3539,"Myocarditis following mRNA vaccination against SARS-CoV-2, a case series"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4850,Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4647,C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5681,Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5051,Myocarditis with COVID-19 mRNA vaccines
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2454,Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4610,Approval letter-Comirnaty. Accessed atwww.fda.gov/media/151710/download on 10
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5985,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2288,"CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4727,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5052,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: ORIGINAL RESEARCH"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2783,Carditis Risk After Messenger RNA and Inactivated Virus Vaccination a population-based cohort study
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5616,Cardiovascular outcomes associated with use of clarithromycin: population based study
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4502,EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,5974,Myocarditis/pericarditis case definition
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1316,The Government of the Hong Kong Special Administrative Region. Hong Kong vaccination dashboard
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1278,Analysis of matched case-control studies
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,399,Unconditional or Conditional logistic regression model for age-matched case-control data. Front Public Health
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1913,"C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,989,"CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, openlabel, randomised, controlled, phase 2 trial"
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4081,Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2138,COVID-19 vaccine and myocarditis
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,3840,Gender differences in myocarditis: a nationwide study in Finland
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,558,Association between COVID-19 and myocarditis using hospital-based administrative data -United States
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1476,Characterising the background incidence rates of adverse events of special interest for Covid-19 vaccines in eight countries: multinational network cohort study
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2026,Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,4895,Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,1928,Critical revision of the article for important intellectual content
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci,2023,Collection and assembly of data
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,3689,COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,4647,C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,5756,Chilean Ministry of Health. Daily official report
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,5398,Effectiveness of the SARS-CoV-2 vaccine program
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,2872,"Monitoring incidence of COVID-19 cases, and deaths, by vaccination status 13 US jurisdictions"
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,309,World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,1664,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults,6089,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study. SSRN [Preprint
1131,63rd ASH Annual Meeting Abstracts ONLINE PUBLICATION ONLY 632.CHRONIC MYELOID LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients,2689,"COVID-19 incidence was higher in the CML than in the MPN population, probably because MPN patients were less exposed, and the older pts were the rst to receive vaccines"
1131,63rd ASH Annual Meeting Abstracts ONLINE PUBLICATION ONLY 632.CHRONIC MYELOID LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients,2350,"Pagnano: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Membership on an entity's Board of Directors or advisory committees"
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,4721,World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,5627,Association between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,4011,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled"
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,6063,Evaluation of mRNA-1273 SARS-CoV-2
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,5165,Vaccine in Adolescents
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2414,Evaluation of the BNT162b2
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,4986,Covid-19 Vaccine in Children 5 to 11 Years of Age
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,1329,Clinical and epidemiological features of 36 children
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,4835,China: an observational cohort study
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,3384,Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,1284,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2339,World medical association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,1735,"Clinical validation of the Siemens All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers"
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,3584,Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2725,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,3453,2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,5385,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Front Immunol
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile,2681,Impact of SARS-CoV-2 variants on the
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5988,The Covid-19 world-Are we there yet?
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4510,Characterization of the Second Wave of COVID-19 in India
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4263,World Health Organization. Tracking SARS-CoV-2 variants
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5576,SARS-CoV-2 variants of concern and variants under investigation in England-Technical briefing 17
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5299,"Population Movement, City Closure in Wuhan, and Geographical Expansion of the COVID-19 Infection in China in"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5064,Countries of origin of imported COVID-19 cases into China and measures to prevent onward transmission
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5074,Guangzhou Municipal Health Commission. COVID-19 situation update in Guangzhou on 21
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5437,US Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4438,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",529,Suspending social vaccination against COVID-19 and concentrating on case findings
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",6121,National Health Commission of the People's Republic of China. Diagnosis and treatment protocols of pneumonia caused by a novel coronavirus (trial version 8)
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",3735,Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",301,Serial Interval of COVID-19 among Publicly Reported Confirmed Cases
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4531,A new framework and software to estimate time-varying reproduction numbers during epidemics
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4400,How generation intervals shape the relationship between growth rates and reproductive numbers
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1929,Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",3482,Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4568,The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2807,International Expansion of a Novel SARS-CoV-2 Mutant
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1152,Does incubation period of COVID-19 vary with age? A study of epidemiologically linked cases in Singapore
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2755,Forward-looking serial intervals correctly link epidemic growth to reproduction numbers
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5594,Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5130,"Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5960,Transmission dynamics and epidemiological characteristics of Delta variant infections in China
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2399,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5159,Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2: a national case-control study
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2442,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 14
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",30,Serial interval of novel coronavirus (COVID-19) infections
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",738,"Transmission dynamics of the delta variant of SARS-CoV-2 infections in Daejeon, South Korea"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1723,Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5477,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1347,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1804,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",3159,COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2210,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",4965,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",5940,"Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",1438,Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study",2761,COVID-19 Outbreak Associated with Air Conditioning in Restaurant
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,4702,Correlates of protection against symptomatic and 185 asymptomatic SARS-CoV-2 infection
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,2739,Longer intervals and extra doses of ChAdOx1 188 nCoV-19 vaccine
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,3091,"SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, 192 placebo-controlled, phase 1/2 clinical trial"
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,4300,Effectiveness of an Inactivated SARS-CoV-2 196
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,1015,IgA dominates the early neutralizing antibody 199 response to SARS-CoV-2
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,2287,Role of Immunoglobulin M and A Antibodies in the 202
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,667,Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1,5065,Enhanced SARS-CoV-2 neutralization by 205 dimeric IgA
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2320,SARS-CoV-2 vaccines: a triumph of science and collaboration
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",803,"A review of novel coronavirus disease ( COVID -19 ): based on genomic structure , phylogeny , current shreds of evidence , candidate vaccines , and drug repurposing"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",722,SARS-CoV-2 vaccines: Lights and shadows
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2982,Biochemical characterization of SARS-CoV-2 nucleocapsid protein
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",5093,Evaluation of the performance of SARS-CoV--2 antibody assays for the longitudinal population-based study of COVID-19 spread in
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3131,Single-domain antibodies make a difference. Science (80-)
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",4391,SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",1549,Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",864,Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",829,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: Comparison with neutralization titers
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",4035,COVID-19 Vacinação Doses Aplicadas
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",756,Immunity to SARS-CoV-2: Lessons Learned. Front Immunol
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2280,The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",245,Coronavirus disease (COVID-19) advice for the public
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",4563,"Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3504,Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3849,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3939,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3717,Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2125,Suppression of normal immune responses after treatment with rituximab
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2950,Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",5259,"Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",3362,The Effects of Heterologous Immunization with Prime-Boost
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2271,Vaccination against SARS-CoV-2. Vaccines
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",5119,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",6137,"Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern, Emerging Microbes & Infections"
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",1561,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for",2833,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,3605,Autorização de Uso Emergencial de Vacinas contra a COVID-19
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,3295,A Primer on Effectiveness and Efficacy Trials
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,5640,Dados abertos. Registro de casos e óbitos por município e data de notificação no Estado de São Paulo
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,5586,Adesão ao isolamento social em SP. Available at: synthesized across a multi-state health system
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,2886,Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,2991,13-Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,1982,"Science in 5. Episode #31-Vaccines, variants & doses"
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,507,Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,340,Covid-19 deaths in Africa: prospective systematic postmortem surveillance study
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report,1695,Tracking excess deaths associated with the COVID-19 epidemic as an epidemiological surveillance strategy-preliminary results of the evaluation of six Brazilian capitals
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",4096,Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",1828,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel)
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",1125,Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",921,"The impact of Vaccination worldwide on SARS-CoV-2 infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",3890,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2157,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",6002,Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",815,Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerg Infect Dis
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",1036,The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",5970,Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",6068,Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",190,Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",3056,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines (Basel)
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",3386,Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",683,Months After SARS-CoV-2 Infection. Front Immunol
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",3982,"Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",4336,The COVID-19 pandemic: major risks to healthcare and other workers on the front line
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2235,Evaluation of antibody response after COVID-19 vaccination of healthcare workers
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2091,"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2418,COVID-19) Dashboard
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",2964,Vaccination drive against coronavirus begins with health care workers in Turkey
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",5821,COVID-19 Vaccine National Implementation Strategy
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination",1291,COVID-19 (SARS-CoV-2 INFECTION) LABORATORY BIOSAFETY GUIDE
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,6069,Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1299,"Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4485,CMMID COVID-19 Working Group
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5220,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2142,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2027,Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2366,Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4403,"Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1161,"Local Transmission of SARS-CoV-2 Lineage, B.1.1.7, Brazil"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1860,"Epidemic Spread of SARS-CoV-2 Lineage, B.1.1.7 in Brazil"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3510,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2194,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3655,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3404,Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3530,COVID-19: Medical community split over vaccine interval policy as WHO recommends six weeks
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,239,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4770,Evaluation of COVID-19 vaccination strategies with a delayed second dose
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,959,Hospitalisation among vaccine breakthrough COVID-19 infections
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,73,Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5547,Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3822,Evolution and epidemic spread of SARS-CoV-2 in Brazil
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3229,Accurate spliced alignment of long RNA sequencing reads
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4696,Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1142,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,313,Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5718,MAFFT multiple sequence alignment software version 7: Improvements in performance and usability
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4697,IQ-TREE: A fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3630,Fast model selection for accurate phylogenetic estimates
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2411,RDP4: Detection and analysis of recombination patterns in virus genomes
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,711,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1699,Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2605,AdviseDx SARS-CoV-2 IgG II
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2179,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5828,Evolution of antibody immunity to SARS-CoV-2
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5291,Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,4422,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5298,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5161,Connecting clusters of COVID-19: An epidemiological and serological investigation
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1845,Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1692,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5994,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,1033,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,2708,SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,3380,"Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors-A prospective community cohort study (Virus Watch)"
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,6148,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines,5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,5221,"Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,806,Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,5589,Current and innovative methods for the diagnosis of COVID 19 infection (Review)
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4664,World Health Organization. COVID-19 Weekly Epidemiological Update-Edition 64
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2226,World Health Organization. COVID-19 Vaccine Tracker and Landscape
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,368,What do we know about China's covid-19 vaccines?
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1083,Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1229,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1953,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4180,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2870,World Health Organization. Considerations for Evaluation of COVID-19 Vaccines
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4944,Looking beyond COVID-19 vaccine phase 3 trials
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,3237,Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (delta) variant
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2276,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,426,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1357,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4084,Considerations in boosting COVID-19 vaccine immune responses
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4539,COVID-19 Vaccine Tracker. Sinovac: CoronaVac. Available online
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,6,World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 Vaccine
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2865,Open data on Malaysia's National COVID-19 Immunisation Programme
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,278,COVID-19 Situation Report for the Western Pacific Region #70: 8-14
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1200,Kenyataan Media Pejabat Perdana Menteri
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4139,The Special Committee for Ensuring Access to COVID-19 Vaccine
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1627,Open Data on the COVID-19 Epidemic in Malaysia
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4954,"Sirotkin, B. Field evaluation of vaccine efficacy"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1076,Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1348,Estimating rotavirus vaccine effectiveness in Japan using a screening method
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,3795,An assessment of the screening method to evaluate vaccine effectiveness: The case of 7-valent pneumococcal conjugate vaccine in the United States
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,5404,Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,196,Confounding by indication in non-experimental evaluation of vaccine effectiveness: The example of prevention of influenza complications
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1160,Government of Chile. Effectiveness of the SARS-CoV-2 Vaccination Program
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4735,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2491,Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2433,World Health Organization. Tracking SARS-CoV-2 Variants
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,377,"COVID-19 Epidemic in Malaysia: Epidemic Progression, Challenges, and Response. Front. Public Health"
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,3739,Malaysia's third COVID-19 wave-a paradigm shift required
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,4676,World Health Organization. COVID-19 in Malaysia Situation Report 45
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,2906,Institute for Public Health (IPH); National Institutes of Health; Ministry of Health Malaysia
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,6127,Evidence Used to Update the List of Underlying Medical Conditions that Increase a Person's Risk of Severe Illness from COVID-19
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,1088,National Pharmaceutical Regulatory Agency (NPRA); Ministry of Health Malaysia. Frequently Asked Questions (FAQ) about COVID-19 Vaccine
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio,597,A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1187,Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,507,Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,587,COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1427,Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3. In Review
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4191,COVID-19 data in Brazil
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1214,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,3562,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,2079,Antibody evasion by the P.1 strain of SARS-CoV-2
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,5284,Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4486,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,2002,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. Infectious Diseases (except HIV/AIDS)
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,5001,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)-SINOVAC -Supply Vaccines to Eliminate Human Diseases
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4118,"Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1073,"Case-control vaccine effectiveness studies: Data collection, analysis and reporting results"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,3466,Fundação de Vigilância em Saúde do Amazonas. BOLETIM DIÁRIO COVID-19 NO AMAZONAS
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,2173,Brazilian Ministry of Health. Definition of COVID-19 cases and recommendations for COVID-19
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4509,An interactive web-based dashboard to track COVID-19 in real time
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1692,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4923,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1244,Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,1650,Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC -Supply Vaccines to Eliminate Human Diseases
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
2750,Erythema multiforme after CoronaVac vaccination,2958,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
2750,Erythema multiforme after CoronaVac vaccination,5009,"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist"
2750,Erythema multiforme after CoronaVac vaccination,323,"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination"
2750,Erythema multiforme after CoronaVac vaccination,5782,"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations"
2750,Erythema multiforme after CoronaVac vaccination,856,Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy
2750,Erythema multiforme after CoronaVac vaccination,1358,Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases
2750,Erythema multiforme after CoronaVac vaccination,3980,Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination
2750,Erythema multiforme after CoronaVac vaccination,4233,Vaccine allergies
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2774,Herd immunity: understanding COVID-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4829,Herd immunity or suppression strategy to combat COVID-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4075,Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2568,Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3854,The hallmarks of COVID-19 disease
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5625,The proximal origin of SARS-CoV-2
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,651,Bats as reservoirs of severe emerging infectious diseases
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,693,"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,544,"The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3319,Rapid COVID-19 vaccine development
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1017,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5079,"The Mysterious Disappearance of the First SARS Virus, and Why we need a Vaccine for the Current One But Didn't for the Other"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2295,The reproductive number of COVID-19 is higher compared to SARS coronavirus
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5696,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5007,Cells Found in COVID-19 Patients Bode Well for Long-Term Immunity
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,6087,Sentinel surveillance of SARS-CoV-2 in waste water anticipates the occurrence of COVID-19 cases. medRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1938,"SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1270,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4320,Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. medRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3304,Immunology of COVID-19: current state of the science
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1550,Twoyear prospective study of the humoral immune response of patients with severe acute respiratory syndrome
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,940,Coronavirus vaccines leap through safety trials -but which will work is anybody's guess
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2660,Clinical vaccine development
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3195,The clinical development process for a novel preventive vaccine: an overview
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3801,Are genetic vaccines the right weapon against COVID-19?
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,12,The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,958,Draft Landscape of COVID-19 Candidate Vaccines
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,287,A strategic approach to COVID-19 vaccine R&D
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,197,Developing Covid-19 vaccines at pandemic speed
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5890,Coronavirus Vaccine Tracker
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,6107,Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1522,Available online at
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,148,COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4562,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3856,An mRNA vaccine against SARS-CoV-2 -preliminary report
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1445,An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2230,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4194,"Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4476,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1115,Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4822,Vaccine Boosts Immune Response In Pigs
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3671,"A phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1168,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1108,Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with and without HIV-Infection
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3582,Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4068,A Phase III Study to Investigate a Vaccine Against COVID-19
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,485,"Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3018,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3405,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3092,CanSino's COVID-19 Vaccine Candidate Approved for Military use in China
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5316,"Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3223,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,67,Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero cells). (2020)
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5153,Sinopharm Says Second Covid Vaccine Found to Be Safe
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,469,Chinese COVID-19 Vaccine Candidate the First to Start Phase 3 Clinical Trials Worldwide
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1354,Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5887,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,6138,Sinovac Says Early Data Show its Covid-19 Vaccine Generated Immune Responses
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1201,"Immunogenicity and Safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial. medRxiv"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3546,Available online at: https:// www.gatesfoundation.org/Media-Center/Press-Releases/2020/04/Gates-Foundation-Expands-Commitment-to-COVID-19-Response-Calls-for-International-Collaboration
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5509,Fear Mounts Trump May Pressure FDA to Rush Covid-19 Vaccine by Election
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2436,Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,2407,Russia's fast track coronavirus vaccine draws outrage over safety
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1408,A review of Dengvaxia R : development to deployment
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4929,COVID-19 human challenge studies: ethical issues
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5163,"From Oxford to an Italian Lab, One Race for Coronavirus Vaccine is gaining Backers"
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4789,Multivalue ethical framework for fair global allocation of a COVID-19 vaccine
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1922,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5301,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,237,Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1777,The improbability of the rapid development of a vaccine for SARS-CoV-2
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4620,Coronavirus Vaccine Developers Wary of Errant Antibodies
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3028,The COVID-19 vaccine development landscape
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3114,US Anti-Vaxxers Aim to Spread Fear Over Future Coronavirus Vaccine
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,6085,Half of Americans would get a COVID-19 Vaccine
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4365,Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1448,Ensuring uptake of vaccines against SARS-CoV-2
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5368,Older Adults May Be Left Out Of Some COVID-19 Trials
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,3305,What you always needed to know about electroporation based DNA vaccines
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,1140,Global Vaccine Summit 2020
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,4083,Accelerating development of SARS-CoV-2 vaccines -the role for controlled human infection models
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,186,Coronavirus disease pandemic (COVID-19): challenges and a global perspective
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19,5166,"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5830,WHO. WHO coronavirus disease (COVID-19) dashboard. 2021
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",4482,"Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5034,European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",3527,"Children and adolescents with SARS-CoV-2 Infection: epidemiology, clinical course and viral loads"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",3431,COVID-19 in children and young people
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",3059,COVID-19 vaccine development: a pediatric perspective
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5581,Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",2625,The importance of advancing SARS-CoV-2 vaccines in children
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",194,Association of age with SARS-CoV-2 antibody response
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",4268,Draft landscape of COVID-19 candidate vaccines
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5780,SARS-CoV-2 vaccines
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",4433,COVID-19 vaccines in children: research to guide your news coverage
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5671,National Institutes of Health. Safety and immunogenicity study of inactivated vaccine for prevention of COVID-19
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5183,Pfizer-Biontech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",6113,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",2687,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5218,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",1841,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",1281,Guidelines for grading standards of adverse events in clinical trials of preventive vaccines
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",616,"Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial"
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",528,Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adults
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5474,Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",5721,An effective COVID-19 vaccine needs to engage T cells
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",1129,SARS-CoV-2-Specific T cell responses in patients with COVID-19 and unexposed individuals
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4959,"SARS-CoV-2 variants, spike mutations and immune escape"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4297,The biological and clinical significance of emerging SARS-CoV-2 variants
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,1823,SARS-CoV-2 variants and vaccines
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4506,"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3923,Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,1184,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coron-aVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3010,Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,5481,SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3885,Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2155,Protection of BNT162b2 vaccine booster against COVID-19 in Israel
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3596,Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2519,Homologous and heterologous COVID-19 booster vaccinations
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,1844,mRNAbased COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,5847,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4417,Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households. medRxiv
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4451,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,357,SARS-CoV-2 spreads through cell-to-cell transmission
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2187,The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,6162,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4588,Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4865,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2828,Molecular basis of receptor binding and antibody neutralization of Omicron
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4537,Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,5982,The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,934,SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2705,Is there a link between the pathogenic human coronavirus envelope protein and immunopathology? A review of the literature
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,5820,Antibody evasion properties of SARS-CoV-2 Omicron sublineages
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,3702,"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4293,"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,1362,"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, doubleblind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)"
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,4578,Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,5089,Universal coronavirus vaccines-an urgent need
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,336,Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant,2656,Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization",4262,CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization",707,Development of an inactivated vaccine candidate for 484 SARS-CoV-2
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization",3428,"Safety, tolerability, and immunogenicity of an 486 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a 487 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization",1936,"vaccine (CoronaVac) in healthy adults aged 60 years and older: a 491 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization",6083,Sinovac's coronavirus vaccine candidate approved for emergency use in 494
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3619,Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,495,Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,6139,Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2769,Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3226,Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,4806,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,4451,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2727,Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,6162,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3606,An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3792,Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3328,Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,692,SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,258,T cell responses to SARS-CoV-2 spike cross-recognize Omicron
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1689,Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2986,Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines. medRxiv
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2074,SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3135,T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,2,T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,240,Culture and identification of a Deltamicron SARS-CoV-2 in a three cases cluster in southern France
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1640,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,5696,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,4967,Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1014,Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,318,Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1126,Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,3764,Vaccine booster efficiently inhibits entry of SARS-CoV-2 Omicron variant
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,602,Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1806,Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron variant of concern
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,4440,HLA common and well-documented alleles in China. HLA
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,34,NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1,1151,Understanding T-cell responses to COVID-19 is essential for informing public health strategies
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,6017,COVID-19 Vaccine Surveillance Report-Week 41
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,3105,The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1909,International Vaccine Access Center's. COVID-19 Vaccine Effectiveness Forest Plots
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1166,Vaccine breakthrough infections with SARS-CoV-2 variants
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1388,Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,483,COVID-19 Vaccine Tracker
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1885,Weekly Epidemiological Update on COVID-19 -31
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,5195,A cluster of the new SARS-CoV-2 B1621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,4001,Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1522,Available online at
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,425,Analysis by real-time pcr of five transport and conservation medium of nasopharyngeal swab samples to covid-19 diagnosis in Santiago of Chile
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,3266,Coronavirus disease (covid-19) associated mucormycosis (CAM): case report and systematic review of literature
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,5379,Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex TM 2019-nCoV assay
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,4098,Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,1361,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,600,Effectiveness of covid-19 vaccines against the B16172 (Delta) variant
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,4055,SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,2627,Arterial hypertension as a risk comorbidity associated with covid-19 pathology
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,5260,Identification of symptoms prognostic of COVID-19 severity: multivariate data analysis of a case series in Henan Province
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,6071,"Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity"
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,3865,SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
1,,3432,Vaccines: Correlates of vaccine-induced immunity
1,,168,Beyond binding: Antibody effector functions in infectious diseases
1,,3786,SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
1,,2658,"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv"
1,,4493,Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv
1,,3435,Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
1,,907,Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
1,,29,Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
1,,1790,Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
1,,923,Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection
1,,4720,"Alter, A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus"
1,,1563,Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
1,,5140,Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
1,,6072,Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
1,,5844,COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
1,,4559,"The Fcmediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody"
1,,4960,"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo"
1,,2852,Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
1,,3523,Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
1,,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
1,,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1,,4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
1,,1057,IgG subclasses and allotypes: From structure to effector functions
1,,4703,Mouse and human FcR effector functions
1,,1121,CD107a as a functional marker for the identification of natural killer cell activity
1,,1311,SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
1,,2727,Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
1,,3606,An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
1,,1675,T cell responses to SARS-CoV-2 spike crossrecognize Omicron
1,,4269,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study
1,,4953,Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland
1,,6007,"Beigel; mRNA-1273 Study Group, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report"
1,,1397,Distinct conformational states of SARS-CoV-2 spike protein
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,5108,Rapid epidemic expansion of the SARS-CoV-2
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,5702,Omicron variant in southern Africa
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,1063,"SARS-CoV-2 variants, spike mutations and 384 immune escape"
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,2925,Omicron escapes the majority of existing SARS-CoV-2 386 neutralizing antibodies
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,819,Striking antibody evasion manifested by the Omicron 388 variant of SARS-CoV-2
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,4832,Increased risk of SARS-CoV-2 390 reinfection associated with emergence of Omicron in South Africa
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,205,Omicron (BA. 1) and Sub-Variants (BA
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3622,BA. 2 and BA. 3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative 394
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,4907,Sequence and Structural-based Computational Assessment
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,4257,Overview of Variants/Mutations
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,1453,Accessed 16
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3566,Efficacy of Antibodies and Antiviral 399 Drugs against Covid-19 Omicron Variant
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,2145,Efficacy of Antiviral Agents against the 401
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,89,Waning immune humoral response to BNT162b2
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,2438,Covid-19 vaccine over 6 months
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,2033,Neutralizing antibody levels are highly 405 predictive of immune protection from symptomatic SARS-CoV-2 infection
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,6159,Considerable escape of SARS-CoV-2 Omicron to 408 antibody neutralization
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3850,Safety and immunogenicity of seven COVID-19 412 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,1902,"BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, 414 phase 2 trial"
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,5372,Correlates of protection against SARS-CoV-2 in 416 rhesus macaques
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,4655,Antigen-specific adaptive immunity to
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,5346,SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3633,Divergent SARS CoV-2 Omicron-421
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3243,reactive T-and B cell responses in COVID-19 vaccine recipients
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,3803,T cell responses to SARS-CoV-2 spike cross-424 recognize Omicron
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5,5766,"Age in years (mean, IQR) in age between groups using one-way ANOVA. c represents the comparison in dosing 473 interval between groups using Kruskal-Wallis H test"
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,2047,COVID-19 dynamics after a national immunization program in Israel
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,5276,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,247,The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,6004,Tracking Coronavirus Vaccinations Around the World
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,1218,The New York Times
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,4990,Plano nacional de operacionalização da vacinação contra a covid-19: 9ª edição
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,2848,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv"
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1346,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3844,Protection of BNT162b2 vaccine booster against Covid-19 in Israel
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4313,Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,2332,CoVariants: SARS-CoV-2 Mutations and Variants of Interest
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,202,Department of Statistics Malaysia
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,960,Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1454,Waning immunity after the BNT162b2 vaccine in Israel
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4084,Considerations in boosting COVID-19 vaccine immune responses
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,499,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled"
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4033,Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4784,Expert Committee on COVID-19 Vaccination: Updated Recommendation on Use of COVID-19 Vaccines
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3459,Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,2865,Open data on Malaysia's National COVID-19 Immunisation Programme
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1638,Ministry of Health Malaysia
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3400,Open Data on COVID-19 in Malaysia
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3204,Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3014,Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,454,the USA: a retrospective cohort study
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,3399,Association between mRNA vaccination and COVID-19 hospitalization and disease severity
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,483,COVID-19 Vaccine Tracker
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,1803,World Health Organization. Considerations for evaluation of Covid-19 vaccines
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study,5127,"World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,807,Accessed on 22 nd February 2022 499 2. The New York Times. Tracking Coronavirus Vaccinations Around the World
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,72,How COVID vaccines shaped 2021 in eight powerful charts
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,2694,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a 505 systematic review and meta-analysis
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,142,mRNA-based COVID-19 vaccine boosters induce 507 neutralizing immunity against SARS-CoV-2 Omicron variant
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,1472,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3573,Online ahead of print
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3011,The immunogenicity and safety of different COVID-19 512 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,2930,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3012,vaccine for preventing severe outcomes in Israel: an observational study
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,1199,Neutralizing antibody levels are highly predictive of immune and Hospitalizations Among Adults During Periods of Delta and Omicron Variant 570
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,1944,10 States
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,896,Heterologous versus homologous COVID-19 booster 573 vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in 574
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,324,"RHH-001): a phase 4, non-inferiority, single blind, randomised study"
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3257,Neutralizing antibodies against the SARS-CoV-2 Omicron variant 577
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,4308,BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3233,Neutralizing antibodies against the SARS-CoV-2 Delta and 580
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,1105,Omicron variants following heterologous CoronaVac plus BNT162b2 booster 581 vaccination
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3888,"Department of Health and Human Services, Food and Drug Administration"
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,1412,Guidance for Industry Toxicity Grading 584
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,5047,Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 585
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,2529,A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine 587
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,3558,Elicits Potent Immune Responses in a Mouse Model
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,5563,Interferon-γ Release Assay for Accurate Detection of Severe Acute 589
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,489,Respiratory Syndrome Coronavirus 2 T-Cell Response
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,139,Commercialized kit to assess T-cell responses against SARS-592
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics,698,CoV-2 S peptides. A pilot study in Health Care Workers
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",135,High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1207,SARS-CoV-2 B.1.1.529 (Omicron) Variant -United States
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",5836,Plasma neutralization of the SARS-CoV-2 Omicron variant
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",4327,Virus isolation and quantitation
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",3720,Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1609,Screening for SARSCoV-2 antibodies in convalescent plasma (CCP) in Brazil: preliminary lessons from a voluntary convalescent donor program
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",3265,Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1797,Essential medical statistics. 2 nd ed. Massachusetts: Blackwell Science
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",4022,Generalized linear models. 2 nd ed
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",5741,Applied linear statistical models. 4 th ed. Ilinois: Richard D. Irwing
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",2969,A systematic review of SARS-CoV-2 vaccine candidates
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1361,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1323,Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",6053,Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",1821,"SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster"
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",3512,Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",4409,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination",4731,Understanding neutralizing antibodies against SARS-CoV-2 and their implications in clinical practice
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,4841,Special features of SARS-CoV-2 in daily practice
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5979,Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2973,Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,3658,Current and innovative methods for the diagnosis of COVID19 infection (Review)
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,3474,"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape"
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1562,Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2313,Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2213,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,423,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1791,COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1604,Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,894,Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2015,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1114,Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5558,"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study"
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2616,Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,4152,Serum Antibody Profile of a Patient With Coronavirus Disease
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,3438,COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,6157,B cell memory: Understanding COVID-19
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5317,Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,4802,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1396,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,4097,Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,508,Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,3449,Factsheet on COVID-19 Vaccination for Persons with Prior COVID-19 Infection
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,198,The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1974,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,632,Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2172,SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,2818,Assessing Immune Response to SARS-CoV-2 Infection
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,330,"Evaluating ELISA, Immunofluorescence, and Lateral Flow Assay for SARS-CoV-2 Serologic Assays"
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1447,Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant,1855,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
4631,To appear in: Vaccine,2418,COVID-19) Dashboard
4631,To appear in: Vaccine,3800,What can the world learn from China's response to covid-19?
4631,To appear in: Vaccine,2985,Interpretation of the Protocol for Prevention and Control of COVID-19 in China
4631,To appear in: Vaccine,1347,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
4631,To appear in: Vaccine,65,National Health Commission of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
4631,To appear in: Vaccine,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
4631,To appear in: Vaccine,6079,Sinopharm's BBIBP-CorV vaccine effectiveness on preventing hospital admission and deaths: results from a retrospective study in the Emirate of Abu Dhabi
4631,To appear in: Vaccine,2584,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
4631,To appear in: Vaccine,5981,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded"
4631,To appear in: Vaccine,2863,Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples
4631,To appear in: Vaccine,3697,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison -Texas
4631,To appear in: Vaccine,2210,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings"
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",5024,Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3878,Emergence of Omicron third lineage BA.3 and its importance
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",1374,Transmission of SARS-CoV-2 Omicron VOC subvaraints BA.1 and BA.2: Evidence from from Danish households
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",4128,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",1274,Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",5847,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",5179,Does the world need an Omicron vaccine? What researchers say
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",2347,SARS-CoV-2 variants of concern and variants under investigation in England
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",4621,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variantdependent manner
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",50,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",103,A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",393,Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3805,Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3021,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",5820,Antibody evasion properties of SARS-CoV-2 Omicron sublineages
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",2100,Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",2793,"COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variants, spike mutations and immune escape"
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",280,An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",5322,Virological characteristics of SARS-CoV-2 BA.2 variant.2022. February152022
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",994,Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",2584,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",2532,Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",539,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3608,Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",1526,SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3555,COVID-19) in the UK. Updated Wednesday 27
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",478,Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",3328,Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022",1754,"License, supplementary material and copyright"
5832,To appear in: Public Health,3347,World Health Organization. Draft landscape of COVID-19 candidate vaccines
5832,To appear in: Public Health,670,SARS-CoV-2 vaccines in development
5832,To appear in: Public Health,933,The race for coronavirus vaccines: a graphical guide
5832,To appear in: Public Health,287,A strategic approach to COVID-19 vaccine R&D
5832,To appear in: Public Health,4495,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial"
5832,To appear in: Public Health,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
5832,To appear in: Public Health,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5832,To appear in: Public Health,456,SARS-CoV-2 immunity: review and applications to phase 3
5832,To appear in: Public Health,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
5832,To appear in: Public Health,3927,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study"
5832,To appear in: Public Health,213,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
5832,To appear in: Public Health,5995,The role of antibody testing for SARS-CoV-2: is there one?
5832,To appear in: Public Health,3628,A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations
5832,To appear in: Public Health,1370,Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID19 patients
5832,To appear in: Public Health,1283,SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
5832,To appear in: Public Health,1546,Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
5832,To appear in: Public Health,116,Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation
5832,To appear in: Public Health,5595,A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
5832,To appear in: Public Health,2771,Phase 1-2 trial of a SARSCoV-2 recombinant spike protein nanoparticle vaccine
5832,To appear in: Public Health,5185,Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
5832,To appear in: Public Health,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5832,To appear in: Public Health,3572,Diagnostic accuracy of serological tests for Covid-19: systematic review and metaanalysis
5832,To appear in: Public Health,4674,mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2-preliminary report
5832,To appear in: Public Health,4477,Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
5832,To appear in: Public Health,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5832,To appear in: Public Health,4396,Humoral immune response to SARS-CoV-2 in Iceland
5832,To appear in: Public Health,4434,Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
5832,To appear in: Public Health,3947,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)"
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,1247,"Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes"
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,863,Vaccinations in patients with immunemediated inflammatory diseases
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,575,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,776,National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,4763,Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,2338,Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,362,IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report,2922,Th17 cytokines and vaccineinduced immunity
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4162,Director-General's opening remarks at the media briefing on COVID-19 -11
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",228,COVID-19 (Novel Coronavirus 2019) -418 recent trends
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",2081,"Morphology, Genome Organization, Replication, 421 and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",904,Covid-19 Vaccine Tracker: Latest Updates -The New York Times
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4425,Overview of the Main Anti-SARS-CoV-429 2 Vaccines: Mechanism of Action
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",3296,STROBE 432 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 433 statement: guidelines for reporting observational studies
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4626,Safety of SARS-CoV-2 436 vaccines: a systematic review and meta-analysis of randomized controlled trials
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",5494,Clinical and Analytical Performance of an
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4047,Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4494,One dose of 443 SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from 444 symptomatic COVID-19
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4354,The antibody response to SARS-CoV-2 infection persists over at least 448 8 months in symptomatic patients
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",3578,Immunogenicity and Safety of the COVID-19 Vaccines Compared With 458 Control in Healthy Adults: A Qualitative and Systematic Review
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",3217,Comparing the clinical efficacy of 461 COVID-19 vaccines: a systematic review and network meta-analysis
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",5210,Robust spike antibody responses and 464 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA 465 vaccine
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",606,Antibody Responses in Seropositive 468 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4279,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers 472 Previously Infected With SARS-CoV-2
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",4651,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 476 against Covid-19
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",5124,BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",952,Safety and efficacy of an 483 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis 484 of a randomised controlled phase 3 trial in Russia
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",1712,Age-sex population adjusted analysis of disease severity 487 in epidemics as a tool to devise public health policies for COVID-19
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",169,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 491 administered in a prime-boost regimen in young and old adults (COV002): a single-blind, 492 randomised, controlled, phase 2/3 trial"
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4",2394,The dependent variable is the delta of antibodies. Time and personal variability are 602 random effects. Reference group BNT162b2 mRNA
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1825,World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,2663,World Health Organization. Coronavirus disease (COVID-19) pandemic
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1564,SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,2679,Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5002,"Endocrinology adult and pediatric, 7th edn"
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5806,"Subacute (de Quervain's) thyroiditis: association with HLA-Bw35 antigen and abnormalities of the complement system, immunoglobulins and other serum proteins"
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,2613,Subacute thyroiditis after SARS-CoV-2 infection
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5449,COVID-19-associated subacute thyroiditis: evidence-based data from a systematic review
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,710,Potential ınteraction between SARS-CoV-2 and thyroid: a review. Endocrinology
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1778,Subacute thyroiditis after mRNA vaccine for COVID-19
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,141,Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,3106,Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1680,Williams textbook of endocrinology
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1365,American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,3331,Graves' disease following acute (subacute) thyroiditis
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,3895,Graves' disease with thyrotoxicosis following subacute thyroiditis
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5038,Occurrence and spontaneous remission of Graves' hyperthyroidism preceded by painless thyroiditis
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,3100,Clinical characteristics of subacute thyroiditis is different than it used to be -current state based on 15 years own material
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5438,"Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study"
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,4210,Recurrence of subacute thyroiditis over 10 years after the first attack in three cases
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1477,COVID-19 autopsy cases: detection of virus in endocrine tissues
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5335,Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,3088,Case Report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,1141,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,2639,Evidence refuting the existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,724,"Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality"
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,570,ASIA syndrome and endocrine autoimmune disorders
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,4468,CDC Centre for Disease Control and Prevention. Adjuvants and Vaccines
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,2765,European Centre for Disease Prevention and Control. Types of seasonal influenza vaccine
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5775,Efficacy and safety of COVID-19 Vaccines: a systematic review and meta-analysis of randomized clinical trials
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs,5700,COVID-19 bilgilendirme platformu
1,,1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
1,,3318,Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
1,,1454,Waning immunity after the BNT162b2 vaccine in Israel
1,,1736,Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
1,,2068,Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa
1,,4097,Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
1,,1468,SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
1,,4865,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
1,,690,Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
1,,5836,Plasma neutralization of the SARS-CoV-2 Omicron variant
1,,1078,Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
1,,5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
1,,5134,Real-time public health communication of local SARS-CoV-2 genomic epidemiology
1,,5763,A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
1,,5128,"designed, managed and monitored the quality of the epidemiological data collected in the REDCap database"
1,,2888,secured funds and supervised the project
1,,204,"Vaccinated participants plasma reactivity to RBD measured by ELISA. b, Plasma neutralization titers measured at baseline, previously to BNT162b2 booster shot against ancestral virus, Delta and Omicron variants. Regression lines are shown over time as days post 2 CoronaVac dose vaccination, as purple (ancestral), dark green (Delta) and light green (Omicron)"
1,,1706,"Extended Data Table 1 | Patient data: Dominican Republic SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
1,,3871,"Extended Data Table 2 | Patient data: Yale healthcare worker SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,4509,An interactive web-based dashboard to track COVID-19 in real time
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2212,Vaccines Against RNA Viruses
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,3686,Keeping track of the SARS-CoV-2 vaccine pipeline
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2398,"Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines"
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,5653,Differential chemokine expression following respiratory virus infection reflects 1-or 2-biased immunopathology
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,4791,e cytokine storm and COVID-19
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,4474,SARS-CoV-2 viral load is associated with increased disease severity and mortality
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,816,Learning from the past: development of safe and effective COVID-19 vaccines
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,6015,Antibody-dependent enhancement of coronavirus
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2060,COVID-19 vaccines: should we fear ADE
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2345,Dexamethasone in hospitalized patients with covid-19
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2465,Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,6070,Socio-demographic and health factors drive the epidemic progression and should guide vaccination strategies for best COVID-19 containment
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,4780,Optimal governance and implementation of vaccination programmes to contain the COVID-19 pandemic
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,5202,Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19,183,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,4642,A pneumonia outbreak associated with a new coronavirus of probable bat origin
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,4654,A new coronavirus associated with human respiratory disease in China
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,4426,WHO. 2022. WHO Coronavirus (COVID-19) Dashboard
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,3723,COVID-19 Vaccine Effectiveness
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,2546,"Vaccine efficacy, effectiveness and protection"
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,3706,Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,5284,Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,3790,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,5598,The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 $7 days after the 2nd dose
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,692,SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine,2523,Fomites and the environment did not have an important role in COVID-19 transmission in a Brazilian mid-sized city
1,,4564,Lastest news. COVID-19 Coronavirus pandemic
1,,1696,"Keinan-Boker, L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data"
1,,4286,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant
1,,5713,Thailand Medicines Regulation Division
1,,4613,SARS-CoV-2 IgG antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (CoronaVac) at Phyathai 3 Hospital
1,,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
1,,6092,Safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern
1,,5599,Confronting the Delta variant of SARS-CoV-2
1,,5883,Delta to dominate world
1,,3745,Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
1,,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
1,,3609,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
1,,5815,Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1,,5812,Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals
1,,3759,Boosting immunity to COVID-19 vaccines
1,,668,China's COVID vaccines have been crucial-Now immunity is waning
1,,2317,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study
1,,5445,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)
1,,647,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: Interim results from a double-blind, randomized"
1,,77,The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine
1,,5489,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
1,,1941,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
1,,1377,Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
1,,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
1,,721,Humoral responses and serological assays in SARS-CoV-2 infections
1,,3788,Human IgG and IgA responses to COVID-19 mRNA vaccines
1,,1960,The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus
1,,192,A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
1,,1647,A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein
1,,5914,Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
1,,3339,T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
1,,629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
1,,5151,Heavily mutated Omicron variant puts scientists on alert
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3485,A novel coronavirus from patients with pneumonia in China
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,551,Covid-19: a brief overview of the discovery clinical trial
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,6132,The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,188,Naming the coronavirus disease (COVID-19) and the virus that causes it
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3597,Global public health COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5302,"Access to COVID-19 vaccines and medicines-a Global Public Good Zur Verfügung Gestellt in Kooperation Mit/ provided in cooperation with: GIGA German Institute of Global and Area Studies Vaccines and Medicines -a Global Public Good. (GIGA Focus Global, 4)"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3698,Mental health and the covid-19 pandemic
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,704,WHO declares COVID-19 a pandemic
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3200,COVID-19 vaccine tracker and landscape
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,825,Tracking SARS-CoV-2 variants
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,343,Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2199,US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5860,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4543,safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine -United States
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2917,COVID-19 Vaccine Janssen: Guillain-Barré Syndrome Listed as a Very Rare Side Effect. European Medicines Agency
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3694,Reactive arthritis after COVID-19 vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2231,Myocarditis and pericarditis after mRNA COVID-19 vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,564,Electron microscopy of SARS-CoV-2: a challenging task
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3984,One year update on the COVID-19 pandemic: where are we now?
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2096,SARS and MERS: recent insights into emerging coronaviruses
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,319,Origin and evolution of pathogenic coronaviruses
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3409,Current advances in the development of SARS-CoV-2 vaccines
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4608,Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1725,"Structure, function, and evolution of coronavirus spike proteins"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2302,Structure analysis of the receptor binding of 2019-nCoV
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3867,A review of the progress and challenges of developing a vaccine for COVID-19
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3657,Structural insights into coronavirus entry
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5625,The proximal origin of SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1279,The 2019-new coronavirus epidemic: evidence for virus evolution
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4642,A pneumonia outbreak associated with a new coronavirus of probable bat origin
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5272,The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4958,"Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,999,A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3681,Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein 1 triggers recent massive expansion of SARS-Cov-2 variants 2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,998,Identification of a SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1972,Covid-19: what new variants are emerging and how are they being investigated?
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,423,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2661,Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2072,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the Severe acute respiratory syndrome coronavirus 2 501Y Variant 1 and Variant 2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2088,The British variant of the new coronavirus-19 (SARS-CoV-2) should not create a vaccine problem
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4500,"Origin, evolution and global spread of SARS-CoV-2"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,6095,D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3742,Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5559,Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation FDA = Food and Drug Administration VOC = Variant of Concern VTM = Viral Transport Media
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5476,Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3382,SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5473,Influenza vaccine: where are we and where do we go
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4385,"Polio vaccination: past, present and future"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2709,Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankaravectored Ebola vaccines: a randomized clinical trial
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2182,Ebola vaccine trials: progress in vaccine safety and immunogenicity
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,526,A comparison of plasmid DNA and mRNA as vaccine technologies
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,111,RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4245,Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1035,Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis b vaccine with a novel adjuvant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3397,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1841,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2620,Safety and efficacy of singledose Ad26.COV2.S vaccine against covid-19
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5590,Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2175,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4294,The arrival of Sputnik V
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3827,COVID vaccine excitement builds as Moderna reports third positive result
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5190,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Artic Lancet Infect Dis"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2623,Safety and immunogenicity of two RNA-based covid-19 vaccine candidates
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,6112,Safety and efficacy of NVX-CoV2373 covid-19 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1416,"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,719,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4079,ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4478,Early-stage trial data on AstraZeneca COVID-19 vaccine due Monday -Lancet. Race for a cure
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2827,Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2452,Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5689,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1484,Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,6044,A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4742,NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4018,SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1622,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3721,Brazil: the PROFISCOV study
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1771,Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3856,An mRNA vaccine against SARS-CoV-2 -preliminary report
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3181,Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2967,Susceptibility of circulating SARS-CoV-2 variants to neutralization
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1347,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5218,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4978,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine 1 (BBV152): a, double-blind, randomised"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,983,Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural infection and vaccination
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,822,Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1817,Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4065,Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5722,Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2822,Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil. medRxiv
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,568,Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,251,"Sweden joins Germany, France, and 15 other countries in suspending AstraZeneca's vaccine over possible side effects"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3183,Expert suspects causal link between AstraZeneca jab and rare blood clots
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3667,Prothrombotic immune thrombocytopenia after COVID-19 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1705,COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4418,A one-shot COVID-19 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,312,Thrombotic thrombocytopenia after Ad26.COV2.S vaccination -response from the manufacturer
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3870,COVID-19 vaccine-induced myocarditis: case report with literature review
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,259,Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,397,"Russia's Sputnik V shot around 90% effective against Delta variant, developers say. Reuters"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4453,SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1857,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2474,Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3415,Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,855,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3206,Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,461,A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2329,Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,902,BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2138,COVID-19 vaccine and myocarditis
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2965,Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3298,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,149,"Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3857,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""EpiVacCorona"" vaccine for the prevention of COVID-19"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1886,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4037,CureVac's mRNA-based vaccine candidate against COVID-19. CureVac; 2021
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5223,Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4551,"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4842,Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,112,mRNA vaccine CVnCoV protects nonhuman primates from SARS-CoV-2 challenge infection
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4828,mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3506,Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2835,Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4095,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India-NC-ND license. EClini-calMedicine"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,5580,Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4405,China's single-dose COVID vaccine has efficacy similar to Johnson & Johnson's. Fortune
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,4824,"s first COVID-19 vaccine for those above 12, gets nod. The Hindu"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,1678,"Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, randomised, observer-blinded, placebocontrolled clinical trial in ten countries in Europe and Latin America"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,2489,Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine,3132,How to cite this article: Hadj Hassine I. Covid-19 vaccines and variants of concern: A review
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,4666,WHO (2022) WHO director-general's opening remarks at the media briefing on COVID-19
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,5783,Republic of Turkey Ministry of Health (2022) COVID-19 vaccination information platform
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,4396,Humoral immune response to SARS-CoV-2 in Iceland
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,2677,"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study"
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,2897,SARS-CoV-2 variant classifications and definitions
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,3974,World Health Organization (2022) Variants of concern (VOC)
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,6038,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a testnegative case-control study. The Lancet Regional Health -Americas. 1:100025
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,4014,Establishment of the WHO International standard and reference panel for anti-SARS-CoV-2 antibody
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,1976,Dynamic of humoral response to SARS-CoV-2 anti-nucleocapsid and spike proteins after CoronaVac vaccination
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,2586,Waning antibody levels after vaccination with mRNA BNT162b2 and inactivated CoronaVac COVID-19 vaccines in Hong Kong blood donors
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,1858,"Shortterm immune response after inactivated SARS-CoV-2 (CoronaVac ® , Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria ® , Oxford-AstraZeneca) vaccinations in health care workers"
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,3981,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,5517,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required,1561,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,4509,An interactive web-based dashboard to track COVID-19 in real time
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,51,Status of COVID-19 vaccines within WHO EUL/PQ evaluation process
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5634,COVID-19 WHO Thailand Situation Reports
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3397,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,1651,Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 vaccine
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3588,Department of Disease Control MoPH. Thailand. a guide to COVID-19 vaccines in Thailand
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2770,A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,9,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdox1 nCov-19/bnt162b2 vaccination
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,1684,Correlation between commercial anti-RBD IgG titer and neutralization titer against SARS-CoV-2 beta variant
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,1959,Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,951,WHO international standard for anti-SARS-CoV-2 immunoglobulin
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5192,Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2760,COVID-19 antibody tests and their limitations
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3773,Effectiveness of heterologous ChAdox1 nCov-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2731,Immunogenicity and efficacy of heterologous ChAdox1-BNT162b2 vaccination
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3270,Heterologous prime-boost vaccination
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2675,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2024,Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,1585,HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3860,Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2782,Adenovirus vector-based vaccine for infectious diseases
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2844,Cross-Presentation by dendritic cells
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2924,Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus? Front Immunol
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,418,"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group"
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5424,Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,838,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2078,Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3019,Is prime boost strategy a promising approach in HIV vaccine development?
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,1130,From vaccines to memory and back
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,2054,Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,3457,Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines,539,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,2418,COVID-19) Dashboard
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3139,Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv : the preprint server for health sciences
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3587,Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3157,Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,4638,Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,412,Will Omicron finally overpower China's COVID defences?
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,5676,Provisional Analysis of the First 6748 Reported Death Cases in the 5th Wave
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,966,Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,1042,COVID-19 vaccines and vaccine administration
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3957,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3711,"Aging in COVID-19: Vulnerability, immunity and intervention"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3360,Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,4155,A global survey of potential acceptance of a COVID-19 vaccine
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,5460,"Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,224,Acceptance of COVID-19 Vaccination during the COVID-19
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3832,Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,5230,"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,506,BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,1481,Immunogenicity and safety of two doses of the
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,5757,CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,5408,Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,3249,Influence of a COVID-19 vaccine&#x2019;s effectiveness and safety profile on vaccination acceptance
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,1600,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,1173,A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,6128,Vaccines and related biological products advisory committee meeting
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study,831,COVID-19 Vaccination for People with Comorbidities
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,1915,"Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4450,Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,6023,Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,243,C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5799,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5251,Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4624,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2:e423
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,3685,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,1097,Half-vs full-dose trivalent inactivated influenza vaccine
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5933,Genetic control of the CD4/CD8 T-cell ratio in humans
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,2069,Sex differences in autoimmune disease
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4311,Correlation of Side Effects and Neutralizing Antibody mSphere
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4982,Reactogenicity following receipt of mRNA-Based COVID-19 vaccines
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5658,Age-and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5199,Prevalence and risk factors of coronavac side effects: an independent cross-sectional study among healthcare workers in Turkey
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,2067,Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,1898,Comparative reactogenicity of enhanced influenza vaccines in older adults
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5463,"Systemic IL-15, IFN-gamma, and IP-10/ CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients"
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,5433,The how's and what's of vaccine reactogenicity
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines,4820,Performance of a surrogate SARS-CoV-2-neutralizing antibody assay in natural infection and vaccination samples
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3492,Covid-19 vaccines: where we stand and challenges ahead
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,351,Covid-19 vaccine tracker
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4388,"Coronavac has overall efficacy of 50.4 percent, says butantan"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3321,Técnicos da anvisa recomendam uso emergencial da vacina de oxford
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,5880,Vacinas contra a covid-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4594,"The brazilian health system: history, advances, and challenges"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4198,Brazil's unified health system: the first 30 years and prospects for the future
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,286,Programa nacional de imunizações (pni) e covid-19: desafios a uma história de quase meio século de sucesso | cee fiocruz
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,39,São paulo passa para fase vermelha a partir de hoje
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,2031,Update i. a systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for covid-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,5458,Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (sarscov-2) infection: a randomized clinical trial
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,289,Mapa da vacinação contra covid-19 no brasil
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,411,Informes e notas técnicas
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,617,Estados · observatório covid-19 br
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4121,Infectivity of asymptomatic versus symptomatic covid-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4668,Spread and dynamics of the covid-19 epidemic in italy: Effects of emergency containment measures
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4381,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sarscov-2)
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,5750,The implications of silent transmission for the control of covid-19 outbreaks
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,1393,Temporal dynamics in viral shedding and transmissibility of covid-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3480,"Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, japan, 2020"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4548,"Asymptomatic and presymptomatic sarscov-2 infections in residents of a long-term care skilled nursing facility-king county, washington"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,4787,Estimation of the asymptomatic ratio of novel coronavirus infections (covid-19)
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,2389,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-covidnet, 14 states"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,882,Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -united states
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,2440,"The novel coronavirus, 2019-ncov, is highly contagious and more infectious than initially estimated"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,1981,"Clinical course and outcomes of critically ill patients with sars-cov-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,1113,"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (covid-19): a review"
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,1320,Coronavírus -dados completos
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,5549,Plano nacional de operacionalização da vacinação contra a covid-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,948,Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the covid-19 era
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3336,Aspectos demográficos e socioeconômicos dos adultos brasileiros e a covid-19: uma análise dos grupos de risco a partir da pesquisa nacional de saúde
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3704,Threequarters attack rate of sars-cov-2 in the brazilian amazon during a largely unmitigated epidemic
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,3205,Access to vaccines in brazil and the global dynamics of the health economic-industrial complex
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,5993,Knowledge about cervical cancer and hpv immunization dropout rate among brazilian adolescent girls and their guardians
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach,1296,"Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, united states"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5434,CDC. Vaccines: The Basics. Available online
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4113,Population Ages 0-14 (% of Total Population)
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",787,Vaccines 2021
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4125,Efficacy and safety of COVID-19 vaccines: A systematic review
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",2353,Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1926,"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",2720,Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4705,COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals)-A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3041,Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients with Autoimmune Rheumatic Diseases
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1395,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4312,Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3015,Should We Mandate a COVID-19 Vaccine for Children?
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",2361,Guidelines for the Management of Children and Adolescent with COVID-19: Protocol for an update
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3783,Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1734,Cochrane Handbook for Systematic Reviews of Interventions
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3503,The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3495,The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5324,Methodological quality and synthesis of case series and case reports
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5846,Checklist for Analytical Cross Sectional Studies
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3162,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4289,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",871,BNT162b2 mRNA COVID-19 Vaccine in AYA with cancer: A monocentric experience
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3648,Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1686,Recurrence of Acute Myocarditis Temporally Associated With Receipt of the mRNA COVID-19 Vaccine in an Adolescent Male
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",2400,Myopericarditis in a Previously Healthy Adolescent Male Following COVID-19 Vaccination: A Case Report
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4719,Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1196,Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3710,A systematic review of factors affecting vaccine uptake in young children
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4876,The burden of seasonal and pandemic influenza in infants and children
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5411,Safety of pandemic H1N1 vaccines in children and adolescents
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1340,Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4254,Hyperinflammatory shock in children during COVID-19 pandemic
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1728,SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3787,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4342,Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4554,A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",792,Kawasaki disease and immunisation: A systematic review
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",867,Vaccines Candidates by Trial Phase
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5543,Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",2506,"World Health Organization. Interim Recommendations for Use of the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing: Interim Guidance, First Issued"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3678,COVID-19 Vaccines for Children and Teens
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",3029,"Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization; US Department of Health and Human Services, Food and Drug Administration: Silver Spring"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5727,The Canadian Paediatric Society. COVID-19 Vaccine for Children
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",4724,COVID-19 Vaccine Spikevax Approved for Children Aged 12 to 17 in EU
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",973,Interim Public Health Considerations for COVID-19 Vaccination of Adolescents in the EU/EEA
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",1175,Factors Associated with Parents' Willingness to Enroll Their Children in Trials for COVID-19 Vaccination
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",666,"Vaccine Hesitancy: COVID-19 and Influenza Vaccine Willingness among Parents in Wuxi, China-A Cross-Sectional Study"
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review",5711,"A Systematic Review of Methods to Improve Attitudes towards Childhood Vaccinations. Cureus 2019, 11, e5067"
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,4443,"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment"
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,1740,Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,2911,Flare of rheumatoid arthritis after COVID-19 vaccination
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,2143,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested casecontrol study
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,1156,Association of risk of suicide attempts with methylphenidate treatment
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,5237,The Government of the Hong Kong Special Administrative Region. COMIRNATY COVID-19 mRNA vaccine (BNT162b2) 2021
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,5016,Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,5719,Statistical power analysis for the behavioral sciences
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,3694,Reactive arthritis after COVID-19 vaccination
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,1292,Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,283,Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,403,"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges"
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,3737,Factors associated with COVID-19-related death using OpenSAFELY
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,3997,Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong,5113,COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases 2021
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,346,Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines (Basel)
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,4364,Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,5287,An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,3550,The changing acceptance of COVID-19 vaccination in different epidemic phases in china: a longitudinal study
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,2976,but the intention of immediate vaccination declined substantially due to concerns about the vaccine's safety. The results implied that information about vaccination safety was important in addressing vaccine hesitancy and promoting successful herd immunity for the general population in China
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,5541,Willingness to receive novel coronavirus vaccine and factors influencing willingness among healthcare workers in Zhejiang province. Zhongguo Yi Miao He Mian Yi
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,104,The low acceptance rate of COVID-19 vaccines suggested that both the public and health professionals need to sufficient evidence and accurate information about COVID-19 vaccines to boost confidence in vaccination
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,3963,Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,5909,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,2324,This phase 3 clinical trial conducted in healthcare professionals in Brazil demonstrated that the inactivated CoronaVac vaccine has a good safety profile and is efficacious against any symptomatic SARS-CoV-2 infections and highly protective against moderate and severe COVID-19
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,3994,Draft landscape and tracker of COVID-19 candidate vaccines-30
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,2456,"Oxford COVID vaccine trial group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,216,"Oxford COVID vaccine trial group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,3054,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,5773,A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,383,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,4103,mRNA vaccines -a new era in vaccinology
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,4299,BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,6125,C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China,3941,COVE study group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2690,The impact of the COVID-19 pandemic on cancer patients
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,4475,"Centre for Health Protection, Hong Kong Department of Health. Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings"
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2502,COVID-19 Vaccines for Moderately or Severely Immunocompromised People
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,4452,Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,4930,Cancer patients' willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1937,Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines (Basel)
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,3662,COVID-19 vaccination acceptance and its associated factors among cancer patients in Tunisia
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2092,COVID-19 vaccine safety in cancer patients: a single centre experience
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,70,Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1874,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,3514,Immunogenicity and safety of the coronavac vaccine in patients with cancer receiving active systemic therapy
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1868,Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1335,Safety of COVID-19 mRNA vaccines in patients with cancer enrolled in early-phase clinical trials
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1557,Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective singlecenter study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2642,"Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: a multicenter, prospective, observational study. Thorac Cancer"
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2599,Commentary: SARS-CoV-2 vaccines and cancer patients
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,276,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study. SSRN
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,2860,Bell's Palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,3445,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case-control study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,3264,Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,5604,Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,3358,Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,161,Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,6047,COVID-19 Vaccines: Safety Surveillance Manual
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,1030,Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †,4402,"Report on Evaluation of Safety, Efficacy and Quality of Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection"
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1850,World Health Organization. Coronavirus (COVID-19) dashboard
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,3521,"Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how?"
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,4376,Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,3437,Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5304,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,60,Interim statement on COVID-19 vaccine booster doses
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,3610,FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,824,World Health Organization Reference Panel. First WHO international reference panel for anti-SARS-CoV-2 immunoglubulin NIBSC code: 20/268 instructions for use
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1492,Humoral immune response in inactivated SARS-CoV-2 vaccine: when should a booster dose be administered? medRxiv
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,328,Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5600,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,292,COVID-19: why we can't use antibody tests to show that vaccines are working
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1618,Impact of age and sex on antibody response following the second dose of COVID-19
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,4816,BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1096,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5465,"Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI"
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,3621,Antibody titres decline 3-month post-vaccination with BNT162b2
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,6051,HLA does not impact on shortmedium-term antibody response to preventive anti-SARS-Cov-2 vaccine
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5851,Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,1269,Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,145,A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,303,To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey,5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,706,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A testnegative case-control study"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,577,Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel) 2021
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3807,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4119,"Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines (Basel) 2020"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1589,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3097,World Health Organization. Polio vaccines: WHO position paper
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,5070,World Health Organization. Rabies vaccines: WHO position paper
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,2011,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,6018,Intradermal vaccine delivery: will new delivery systems transform vaccine administration?
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,208,A serological assay to detect SARS-CoV-2 seroconversion in humans
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3843,Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4337,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A systematic review and meta-analysis
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4805,T cell-oriented strategies for controlling the COVID-19 pandemic
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4623,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,26,Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3809,Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,5216,Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,2784,"Immunogenicity and safety of two-visit, intradermal preexposure rabies prophylaxis simultaneously administrated with chimeric liveattenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,375,Rapid healing with topical INH powder
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1639,Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,193,Key roles of adjuvants in modern vaccines
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3300,Sanctioned countries in the global COVID-19 vaccination campaign: the forgotten 70
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,5178,Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4845,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4772,Coronavirus Pandemic (COVID-19): Our World in Data
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1493,"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,4146,Intradermal covid-19 vaccination could solve supply problems
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3494,Immune system and COVID-19 by sex differences and age
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,516,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,3614,A simple protein-based surrogate neutralization assay for SARS-CoV-2
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1920,Vaccine xxx (xxxx) xxx
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,2890,Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,6067,Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac,1698,Testing fractional doses of COVID-19 vaccines
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5662,Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5193,Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",3334,Joint investigation of 2-month post-diagnosis IgG antibody levels and psychological measures for assessing longer term multi-faceted recovery among COVID-19 cases in northern Cyprus
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",4714,Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",4959,"SARS-CoV-2 variants, spike mutations and immune escape"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5774,"COVID-19: structural considerations for virus pathogenesis, therapeutic strategies and vaccine design in the novel SARS-CoV-2 variants era"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",2450,Under the COVID-19 lockdown: rapid review about the unique case of north Cyprus
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",2495,Effectiveness of COVID-19 vaccines against omicron or delta infection
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",2052,Sex differences in vaccine-induced humoral immunity
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5468,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",1601,Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",3825,COVID-19 breakthrough infections in vaccinated health care workers
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5397,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",1182,Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",4993,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",6077,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5669,SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",3103,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",5765,Heterologous primeboost vaccination with ChAdOx1 nCoV-19 and BNT162b2
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study",1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
1,,3164,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (Coronavacâ) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1,,5789,Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
1,,3443,Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4509,An interactive web-based dashboard to track COVID-19 in real time
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5174,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, doubleblind, placebo-controlled, phase 1/2 trial"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3242,Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,877,Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5624,Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,1570,Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4480,Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4270,"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2119,"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3598,Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4200,Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2404,Hospital Authority. Hospital Authority Statistical Report
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5616,Cardiovascular outcomes associated with use of clarithromycin: population based study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3473,Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5492,"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5855,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5548,Clinical characteristics of coronavirus disease 2019 in China
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2300,Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,381,"Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes"
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4091,Department of Health and Human Services NIH National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.0
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,3757,Self-controlled case series studies: A modelling guide with R
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4701,MMR vaccine and idiopathic thrombocytopaenic purpura
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4005,Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,343,Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,2093,Surveillance for adverse events after COVID-19 mRNA vaccination
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5527,Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,6040,Vaccination induced neutropenia
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,5169,Hematologic toxicity of sodium valproate
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,747,Delayed onset of clozapineinduced leucopenia
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,4943,Benign ethnic neutropenia
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study,890,Population By-census-Thematic Report: Ethnic Minorities
1,,2662,Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic
1,,350,"European Centre for Disease Prevention and Control. COVID-19 Situation Update Worldwide, as of Week 49"
1,,2101,COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
1,,5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
1,,2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
1,,5059,The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out
1,,5367,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study
1,,4959,"SARS-CoV-2 variants, spike mutations and immune escape"
1,,5297,Available online
1,,1176,"COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence"
1,,387,SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network
1,,2332,CoVariants: SARS-CoV-2 Mutations and Variants of Interest
1,,580,Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
1,,5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
1,,2079,Antibody evasion by the P.1 strain of SARS-CoV-2
1,,711,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
1,,25,Host genetic factors determining COVID-19 susceptibility and severity
1,,3695,The potential danger of suboptimal antibody responses in COVID-19
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",1690,COVID-19 Vaccine Technical Working Group. Technical vaccination recommendations for COVID-19 vaccines in China
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",2936,Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 8)
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",1541,Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",3397,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",1995,BBIP-CorV vaccine effectiveness for preventing infection and death of health workers
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",2327,Effectiveness of an inactivated SARS-CoV-2 vaccine
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",5801,Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Guangdong
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021",3227,Effectiveness of COVID-19 vaccines against the B. 1.617.2 (Delta) variant
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,1990,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,4383,Brazilian Ministry of Health. COVID-19 vaccination applied doses
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,3535,One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,987,Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,4362,First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,270,Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5102,Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,1521,Persistence and evolution of SARS-CoV-2 in an immunocompromised host
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5495,Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,3411,Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,808,Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5798,A new SARS-CoV-2 dualpurpose serology test: highly accurate infection tracing and neutralizing antibody response detection
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,3155,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. Geneva: World Health Organization
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5348,Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5698,Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,4410,Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,893,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,2927,SARS-CoV-2 antibody response in persons with past natural infection
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,1277,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,501,Antibody status and incidence of SARS-CoV-2 infection in health care workers
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,1456,Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,5154,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokinetreated patients with immune-mediated inflammatory diseases"
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,174,Antibody responses in COVID-19: a review
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,4994,Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study,191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,134,WHO. WHO Coronavirus (COVID-19). 2022. Accessed
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,6123,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4612,Transmission of SARS-CoV-2 variant B. 1.1. 7 among vaccinated health care workers
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,579,COVID-19 vaccines: where we stand and challenges ahead
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,132,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,1750,Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,476,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight US locations"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4348,Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks-Connecticut
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,2847,Turkey begins mass COVID-19 vaccination with Sinovac's jabs. 2021
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4237,Turkey OKs emergency use of Sputnik-V vaccine
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,1509,Anadolu Agency.1st Doses of Pfizer-BioNTech Jab Administered in Turkey
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,471,C4591001 clinical trial group: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,5545,Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,3369,Early evidence of the effect of SARS-CoV-2 vaccine at one medical center
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,3825,COVID-19 breakthrough infections in vaccinated health care workers
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,5534,Healthcare workers should be recieved with the highest effective vaccine available
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4437,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18−59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,2106,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: a test-negative case-control study. medRxiv
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,3399,Association between mRNA vaccination and COVID-19 hospitalization and disease severity
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4309,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,2659,Predictors for severe COVID-19 infection
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,3898,Correlations of clinical and laboratory characteristics of COVID-19: a systematic review and meta-analysis
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,2510,Ferritin as prognostic marker in COVID-19: the FerVid study
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,6154,"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,954,"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis"
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics,4507,Respiratory support for adult patients with COVID-19
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,5105,WHO coronavirus (COVID-19) dashboard
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,157,A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,3763,"Swords and Shields"" against COVID-19 for patients with cancer at ""clean"" and ""pandemic"" hospitals: are we ready for the second wave?"
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,1366,Impact of coronaphobia on treatment and follow-up compliance of cancer patients
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2551,The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,49,• Discusses the importance of COVID-19 vaccines in patients with cancer
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,1441,• Discusses phase I and II CoronaVac trial results
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,108,Discusses news about approval of CoronaVac by WHO
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,533,Seasonal influenza vaccine in immunocompromised persons
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,1630,Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,1185,Turkish Medical Oncology Society COVID-19 pandemic advisory board updated recommendations for medical oncologists: included vaccination
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,4458,ESMO statements for vaccination against COVID-19 in patients with cancer
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2839,Siemens Healthcare Diagnostics Atellica IM SARS-CoV-2 total (COV2T) ELISA assay for the detection of total antibodies to SARS-CoV-2
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,3668,Discusses the immunogenicity of CoronaVac in patients with rheumatological disease receiving immunomodulator drugs
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,4680,Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,1848,Discusses the immunogenicity of mRNA vaccines in cancer patients
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,773,Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,3358,Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,4355,Influenza vaccines in immunosuppressed adults with cancer
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,3177,"Aging, cancer, and antitumor immunity"
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,2988,Allocation of COVID-19 vaccination: when public prioritisation preferences differ from official regulations
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,3920,Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy,5913,Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
1177,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience,2787,CoronaVac (2x) DR + Pfizer (1x) DR
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,1964,A novel coronavirus outbreak of global health concern
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4207,An Interactive Web-Based Dashboard to Track COVID-19 in Real Time
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4499,data. Coronavirus (COVID-19) Vaccinations. Available online
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5668,World Health Organization. Ten Threats to Global Health in 2019
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3688,"SAGE Working Group on Vaccine Hesitancy Vaccine hesitancy: Definition, scope and determinants"
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,603,Understanding Vaccine Hesitancy around Vaccines and Vaccination from a Global Perspective: A Systematic Review of Published Literature
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5631,"The Royal Society and The British Academy. Covid-19 Vaccine Deployment: Behaviour, Ethics, Misinformation and Policy Strategies"
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4182,The Policy Institute. Coronavirus: Vaccine Misinformation and the Role of Social Media
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4252,Covid-19: Global Attitudes towards a COVID-19 Vaccine
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3484,International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,304,"Compulsory COVID-19 Vaccination? Only as a Policy of Last Resort. Voices Bioeth. 2020, 6"
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3979,Incentives for Immunity-Strategies for Increasing Covid-19 Vaccine Uptake
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3287,Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3905,Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5081,Department of Health. Hong Kong Vaccination Dashboard
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5649,"Office of the Communications Authority. The Numbering Plan for Telecommunications Services in Hong Kong (SAR), China. Available online"
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4908,The Census and Statistics Department of the Hong Kong Government
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3625,Our World in Data: Statistics and Research-Cornavirus (COVID-19) Vaccinations
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3499,"Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. Front. Med. 2021, 8, 644300"
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5435,COVID-19: Wäre eine Impfpflicht rechtlich möglich?
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4602,Will COVID-19 Vaccinations End Discrimination against COVID-19 Patients in China?
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,3613,Vaccine hesitancy: The next challenge in the fight against COVID-19
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,1910,Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,2723,A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,2266,Department of Health
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,5603,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,4136,Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses,791,Populist politics and vaccine hesitancy in Western Europe: An analysis of national-level data
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5127,"World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,4974,Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,3866,Comparative systematic review and meta-analysis of reactogenicity. immunogenicity and efficacy of vaccines against SARS-CoV-2 npj Vaccines
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,465,The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,1757,Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,2278,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5802,Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,4161,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-Sprimed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5033,Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,1804,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5674,"Understanding the Prevalence and Associated Factors of Behavioral Intention of COVID-19 Vaccination Under Specific Scenarios Combining Effectiveness, Safety, and Cost in the Hong Kong Chinese General Population"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,854,"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,2953,Measures of multimorbidity and morbidity burden for use in primary care and community settings: A systematic review and guide
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,1946,Sample size for binary logistic prediction models: Beyond events per variable criteria
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,5408,Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,3351,Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring,1914,What can countries learn from Hong Kong's response to the COVID-19 pandemic?
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1813,Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4788,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,132,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3651,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -eight U.S. locations"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2713,Evolution of the COVID-19 vaccine development landscape
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2606,Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2503,Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4451,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1382,Multiple SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2676,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5112,SARS-CoV-2 variants of concern in the United States-challenges and opportunities
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2897,SARS-CoV-2 variant classifications and definitions
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1823,SARS-CoV-2 variants and vaccines
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2160,Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2675,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,775,Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2521,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5841,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3419,Effectiveness of COVID-19 vaccines against Delta variant (B.1.617.2): a metaanalysis
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1059,Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1948,Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3503,The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1179,RoB 2: a revised tool for assessing risk of bias in randomised trials
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4512,The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3831,Meta-analysis in clinical trials
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5980,Interpretation of subgroup analyses in systematic reviews: a tutorial
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5612,Measuring inconsistency in meta-analyses
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5935,"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5989,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1542,Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,268,"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5528,Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5670,"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HER-ALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3567,Final analysis of efficacy and safety of single-dose Ad26.COV2.S
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2710,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2180,Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4801,Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel)
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1368,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance -eight U.S. locations
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4704,"Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,436,"Effectiveness of inactivated COVID-19 vaccines against illness caused by the B.1.617.2 (Delta) variant during an outbreak in Guangdong, China: a cohort study"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4972,Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4951,An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,6103,Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 years -Arizona
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2471,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant -National Healthcare Safety Network
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2410,Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4798,Effectiveness of BNT162b2 vaccine against Delta variant in adolescents
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3008,Comparative effectiveness of COVID-19 vaccines against the Delta variant
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2834,"Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3080,COVID-19 outbreak associated with a SARS-CoV-2 P.1 lineage in a longterm care home after implementation of a vaccination program -Ontario
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2056,"Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the Delta variant: real world study and evidence -China"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2736,Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3663,"Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2462,Duration of protection against mild and severe disease by Covid-19 vaccines
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3522,Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1516,"Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4991,"Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1857,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5937,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1907,"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance -VISION Network, 10 States"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1376,Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance -nine states
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4187,"Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5008,Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2040,"Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years -VISION Network, 10 States"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5270,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3456,Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4073,Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1569,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,3048,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2259,"convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4238,"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses"
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,6139,Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2236,Considerations for evaluation of COVID19 vaccines
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4806,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,57,Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2027,Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,1558,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,15,SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,2079,Antibody evasion by the P.1 strain of SARS-CoV-2
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4449,Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,4682,Publisher's Note
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis,5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2482,The SARS-CoV-2 outbreak: What we know
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1379,Epidemiology and public health in the COVID-19 epidemic
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4591,Depression and Anxiety in Hong Kong during COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4812,Mental health outcomes of the CoViD-19 pandemic
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5227,Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4147,Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1716,"SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,407,The Architecture of SARS-CoV-2 Transcriptome
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4109,A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3999,Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3281,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2685,Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1040,Structural basis of receptor recognition by SARS-CoV-2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4550,SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1085,The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4987,Properties of Coronavirus and SARS-CoV-2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5347,Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1141,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3121,"Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1383,The pulmonary pathology of COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2252,COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2579,COVID-19 and non-communicable diseases
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5043,COVID-19 and comorbidities: Deleterious impact on infected patients
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,386,Maternal and Perinatal Outcomes in Patients with Suspected COVID-19 and Their Relationship with a Negative RT-PCR Result
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5442,The Profile of the Obstetric Patients with SARS-CoV-2 Infection according to Country of Origin of the Publication: A Systematic Review of the Literature
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,903,Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,916,IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5014,The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3244,Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2794,Antibody responses to SARS-CoV-2 in patients with COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3127,Why the immune system fails to mount an adaptive immune response to a COVID-19 infection
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2829,A Predictive Model and Risk Factors for Case Fatality of COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4926,COVID-19 treatment: Close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4071,Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1866,Brief History of Pandemics (Pandemics Throughout History). In Psychiatry of Pandemics
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1814,"The last major outbreak of smallpox (Yugoslavia, 1972): The importance of historical reminders"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1294,"The swine flu vaccine, public attitudes, and researcher interpretations: A systematic review of qualitative research"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5504,Countering Vaccine Hesitancy
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4036,Historical aspects of immunization and vaccine safety communication
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1049,Vaccine Safety: Evidence-based research must prevail
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4089,The state of vaccine safety science: Systematic reviews of the evidence
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2010,"Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,970,Herd Immunity: Understanding COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4349,Immunological mechanisms of vaccination
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1753,Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network-12 States
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5344,Animal models for highly pathogenic emerging viruses
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3836,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2165,Duration of Antibody Responses after Severe Acute Respiratory Syndrome
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3165,Lessons for COVID-19 Immunity from Other Coronavirus Infections
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3516,Barriers to Vaccination for COVID-19 Control-Experience from the United States
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4241,Intention to Receive the COVID-19 Vaccination in China: Application of the Diffusion of Innovations Theory and the Moderating Role of Openness to Experience
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1932,COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1351,"Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3142,Tanzania refuses COVID-19 vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3398,Impact of COVID-19 Pandemic on Flu and COVID-19 Vaccination Intentions among University Students
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3613,Vaccine hesitancy: The next challenge in the fight against COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2921,Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2756,COVID-19 vaccines: Breaking record times to first-in-human trials
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2896,COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2856,The clinical development process for a novel preventive vaccine: An overview
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1655,"Covid-19, and the debunking of conspiracy theories"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3775,The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1138,A Rapid Systematic Review of Public Responses to Health Messages Encouraging Vaccination against Infectious Diseases in a Pandemic or Epidemic
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3396,The US Regulatory System and COVID-19 Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2723,A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,979,"Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2285,The plight of essential workers during the COVID-19 pandemic
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3711,"Aging in COVID-19: Vulnerability, immunity and intervention"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5142,Genetics of healthy aging and longevity
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1807,The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5962,Making a COVID-19 vaccine that works for everyone: Ensuring equity and inclusivity in clinical trials
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4302,Is there a role for childhood vaccination against COVID-19? Pediatr
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5878,Coronavirus Disease 2019 and Vaccination of Children and Adolescents: Prospects and Challenges
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3483,Vaccinating Children against Covid-19-The Lessons of Measles
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,714,Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine. Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4557,"Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1842,Immunological considerations for COVID-19 vaccine strategies
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4894,CDC's COVID-19 Vaccine Rollout Recommendations | CDC
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2126,Covid-19: Vaccine roll out could take a year and will require difficult prioritisation decisions
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5694,Israel's rapid rollout of vaccinations for COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4565,Covid-19 vaccination rollout: A commentary from England
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,741,Who should be vaccinated first? Comparing vaccine prioritization strategies in Israel and European countries using the Covid-19 Health System Response Monitor
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1013,What can we learn from Israel's rapid roll out of COVID-19 vaccination?
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1054,"Covid-19: How the UK vaccine rollout delivered success, so far"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2213,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,435,The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2717,Landscape of COVID-19 Candidate Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5396,"A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5004,COVID-19 Vaccination: From Interesting Agent to the Patient. Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5314,Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1432,COVID-19 vaccine: Where are we now and where should we go?
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1584,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,170,Direct gene transfer into mouse muscle in vivo
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3789,Developing mRNA-vaccine technologies
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,6110,"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3502,Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3472,Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,735,mRNA vaccines-A new era in vaccinology
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2328,Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4339,The Use of Nanobiotechnology in Immunology and Vaccination
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1919,Nanomaterial Delivery Systems for mRNA Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2680,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,6135,COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1478,Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2989,Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,967,"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5565,SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1205,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2974,"A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? Vaccines 2020, 8, 220"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4562,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2499,Development of mRNA Vaccines: Scientific and Regulatory Issues. Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1624,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2595,An mRNA Vaccine against SARS-CoV-2-Preliminary Report
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3957,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1661,Allergische Reaktionen auf COVID-19-Impfstoffe-Evidenz und praxisorientiertes VorgehenAllergic reactions to COVID-19 vaccines: Evidence and practice-oriented approach
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1881,Severe allergic reactions to the COVID-19 vaccine-Statement and practical consequences
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1232,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4480,Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4129,The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,266,"Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021, 372, n743"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5524,Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3377,Adenoviruses as vaccine vectors
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1380,Novel viral vectors in infectious diseases
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2566,Chimpanzee-origin adenovirus vectors as vaccine carriers
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3998,A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3810,Effects of a SARS-associated coronavirus vaccine in monkeys
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4285,Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2590,Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,532,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5228,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4124,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5860,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3511,Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1178,WHO Statement on AstraZeneca COVID-19 Vaccine Safety Signals
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3939,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1662,Inactivated Virus Vaccine-An Overview | ScienceDirect Topics
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4483,Inactivated Viral Vaccines
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3797,"Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3388,Development of an inactivated vaccine candidate for SARS-CoV-2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1961,Adjuvantation helps to optimise COVID-19 vaccine candidate
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2947,Immunogenicity and safety of a SARS-CoV-2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3876,SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,945,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5734,Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,585,"Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy"
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1265,Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,4710,Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3536,Structural and functional analysis of a potent sarbecovirus neutralizing antibody
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2513,Rational Vaccine Design in the Time of COVID-19
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3270,Heterologous prime-boost vaccination
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2635,Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,1897,Comparing COVID-19 Vaccine Schedule Combinations-Com-COV
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3262,Disposable face masks and reusable face coverings as non-pharmaceutical interventions (NPIs) to prevent transmission of SARS-CoV-2 variants that cause coronavirus disease (COVID-19): Role of new sustainable NPI design innovations and predictive mathematical modelling
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5444,Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,6065,Physical activity: Benefits and challenges during the COVID-19 pandemic. Scand
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,3693,Sleeping when the world locks down: Correlates of sleep health during the COVID-19 pandemic across 59 countries
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,2601,COVID-19: Imbalanced Immune Responses and Potential Immunotherapies
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times,5991,Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2418,COVID-19) Dashboard
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,1984,International Nonproprietary Names Programme. Messenger RNA Encoding the Full-Length SARS-CoV-2 Spike Glycoprotein. World Health Organization (2020)
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,1404,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2222,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,4536,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against SARS-CoV-2 in Healthy Chilean Adults in a Phase 3 Clinical Trial. medRxiv
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,4046,Comparative Immunogenicity of mRNA and Inactivated Vaccines Against COVID-19
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2141,Serological Response to mRNA and Inactivated COVID-19 Vaccine in Healthcare Workers in Hong Kong: Preliminary Results
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2053,BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,3381,mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,720,Comprehensive Assessment of Humoral Response After Pfizer BNT162b2 mRNA Covid-19 Vaccination: A Three-Case Series
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2371,IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,3829,Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,401,SARS-CoV-2 Detection by Nasal Strips: A Superior Tool for Surveillance of Paediatric Population
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,4689,Molecular Diagnosis of a Novel Coronavirus (2019-Ncov) Causing an Outbreak of Pneumonia
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,3951,Inhalable Nanovaccine With Biomimetic Coronavirus Structure to Trigger Mucosal Immunity of Respiratory Tract Against COVID-19
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,5609,Bronchus-Associated Lymphoid Tissue (BALT) Is Not Present in the Normal Adult Lung But in Different Diseases
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,1081,"Lymphocyte Homing to Bronchus-Associated Lymphoid Tissue (BALT) Is Mediated by L-Selectin/PNAd, Alpha4beta1 Integrin/VCAM-1, and LFA-1 Adhesion Pathways"
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,1483,Regional Induction of Adhesion Molecules and Chemokine Receptors Explains Disparate Homing of Human B Cells to Systemic and Mucosal Effector Sites: Dispersion From Tonsils
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2061,Mucosal Immunity in COVID-19: A Neglected But Critical Aspect of SARS-CoV-2 Infection
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2707,Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,4730,Systemic and Mucosal Antibody Responses Specific to SARS
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,2485,During Mild Versus Severe COVID-19
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation,5626,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-Spike Protein-Protein Interaction
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1420,Effectiveness 476 of an Inactivated SARS-CoV-2 Vaccine in Chile
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,848,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1326,"Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1776,Health Am 2021:100025
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4854,CoronaVac induces lower neutralising activity against variants of concern 484 than natural infection
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,121,"Safety and 486 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral 487 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-488 inferiority trial"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4436,ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses 491 among Health Care Workers. Vaccines (Basel) 2021
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5000,Intradermal Vaccination: 493 A Potential Tool in the Battle Against the COVID-19 Pandemic?
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4969,Vaccination into the Dermal Compartment: Techniques
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3346,Vaccines (Basel) 2020
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,2496,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: 499 A Systematic Review and Meta-analysis
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1489,World Health O. Polio vaccines: WHO position paper
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5392,505 12. World Health O. Rabies vaccines: WHO position paper
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4553,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4134,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 510 2021:2021.07.27.21261116
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3507,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4880,Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5146,All rights reserved. No reuse allowed without permission
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3541,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 14"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4288,Vaccine Following Two CoronaVac Shots: A Case Report
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,208,A serological assay to detect SARS-CoV-2 seroconversion in humans
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,2113,Correlates of protection 523 against symptomatic and asymptomatic SARS-CoV-2 infection
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,10,A SARS-CoV-2 surrogate virus 526 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 527 interaction
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5623,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 530
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4024,Vaccine Clinical Trials
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,98,Correlates of protection 533 against symptomatic and asymptomatic SARS-CoV-2 infection
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,2364,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A 537 systematic review and meta-analysis
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4526,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5688,COVID-19 pandemic
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,187,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4905,Multiplex 549 analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5073,Evidence of 552 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3528,SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months 556 after the infection
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,492,"Immunogenicity and safety of two-visit, intradermal pre-exposure rabies 559 prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis 560 vaccine in children living in rabies and Japanese encephalitis endemic country"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5417,Comparison of intradermal and 565 intramuscular administration of hepatitis B vaccine in neonates
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1401,Sanctioned countries in the global COVID-19 568 vaccination campaign: the forgotten 70
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4246,Inequalities in 571 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3153,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in 574 Brazilian elderly
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3303,Our World in Data
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,1338,"A focused 581 review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,4146,Intradermal covid-19 vaccination could solve supply problems
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,5959,A comparison study of SARS-CoV-2 IgG 589 antibody between male and female COVID-19 patients: A possible reason underlying different 590 outcome between sex
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,282,A simple 592 protein-based surrogate neutralization assay for SARS-CoV-2
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3460,Validation and 595 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4,3447,Evaluation of a commercially-available surrogate virus neutralization test for severe acute 599 respiratory syndrome coronavirus-2 (SARS-CoV-2)
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",802,Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4498,"Understanding the epidemiology, diagnosis and management of"
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",620,Cancer treatment during COVID-19 pandemic
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",3387,"COVID-19 in patients with sickle cell disease: A single center experience from Ohio, United States"
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4902,The severity of COVID-19 among pregnant women and the risk of adverse maternal outcomes
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",2984,COVID-19 Vaccines: Special Considerations for the Obese Population
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",3156,Risk for SARS-CoV-2 infection in healthcare workers
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",2776,Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4195,Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",3652,SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",2775,Airborne or droplet precautions for health workers treating COVID-19?
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",1062,Peraturan Presiden Republik Indonesia Nomor 14 Tahun 2021
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",2983,Interim national immunization technical advisory group for covid-19 vaccines resolution no
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4956,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4795,Sinovac reports positive data from Phase I/II trials of CoronaVac
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",203,Sinovac Biotech Limited; 2020. Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",1957,Current state of the first covid-19 vaccines
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",1748,Glossopharyngeal nerve and vagus nerve palsies associated with influenza vaccination
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",4682,Publisher's Note
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia",5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,85,Cultivation of a novel type of common-cold virus in organ cultures
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5554,Human Coronavirus Types
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2096,SARS and MERS: recent insights into emerging coronaviruses
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1749,"FDA, Coronavirus Treatment Acceleration Program (CTAP)"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5145,Clinical efficacy of antivirals against novel coronavirus (COVID-19): a review
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3146,Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2099,A summary of the SARS-CoV-2 vaccines and technologies available or under development
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5328,Spontaneous abortion following COVID-19 vaccination during pregnancy
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,661,Safety of COVID-19 vaccines administered in the EU: should we be concerned?
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3182,e epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2207,Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,818,"COVID-19: progress in diagnostics, therapy and vaccination"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4924,Recent advances in mRNA vaccine technology
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5241,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3223,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5590,Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3451,Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,6025,B and T cell immune responses elicited by the BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in nursing home residents
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4289,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2276,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,6000,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2331,Effectiveness of CoronaVac in the setting of high SARS
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3117,1 variant transmission in Brazil: a test-negative case-control study
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1188,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,37,rombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5068,1 skewed immune response of whole virion inactivated SARS cov 2 vaccine and its safety evaluation
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1841,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4093,A Tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,383,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4359,Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4744,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""Epi-VacCorona"" vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II)"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4667,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5689,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,345,Ad26 vectorbased COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1771,Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3712,Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5834,romboembolic events in the South African Ad26.COV2.S vaccine study
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1566,"Safety and immunogenicity of the Chadox1 ncov-19 vaccine against SARS-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4562,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,906,"Development of an inactivated vaccine candidate, BBIBP-corv, with potent protection against SARS-cov-2"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3215,Effects of COVID-19 and mRNA vaccines on human fertility
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,505,Efficacy of Important COVID-19 Vaccine in Real-World
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1135,Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4189,Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,3634,COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,176,Mix-and-match COVID vaccines trigger potent immune response
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1237,Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,4471,COVID-19 vaccine response in pregnant and lactating women: a cohort study
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2626,e vaccine-elicited immunoglobulin profile in milk after COVID-19 mRNA-based vaccination is IgGdominant and lacks secretory antibodies
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,2119,"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,1723,Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5332,Antibody response after second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among health care workers in India: final results of cross-sectional coronavirus vaccine
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,164,Module 2: Types of Vaccine and Adverse Reactions
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines,5675,"CDC, Vacines and immunizations. Local Reactions, Systemic Reactions, Adverse Events, And Serious Adverse Events: Janssen COVID-19 Vaccine"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1353,Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2698,Unequal Impact of
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4143,Structural Health Determinants and Comorbidity on COVID-19 Severity and Lethality in Older Mexican Adults: Considerations Beyond Chronological Aging
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3911,The Impact of Vaccination on
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4575,COVID-19) Outbreaks in the United States
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3649,Efficacy and Safety of the mRNA-1273
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2901,SARS-CoV-2 Vaccine
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3170,Safety and Efficacy of the BNT162b2
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1530,mRNA Covid-19 Vaccine
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2178,Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2849,Safety and efficacy of the ChAdOx1
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5451,"nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,549,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4314,COVID-19 Vaccine: Promoting Vaccine Acceptance
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4898,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4923,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1224,Impact and effectiveness of mRNA
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3615,"BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2374,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of longterm care facilities in England (VIVALDI): a prospective cohort study
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1774,Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel -33
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2083,Comparative Effectiveness of Moderna
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3211,Hospitalizations Among Adults Without Immunocompromising Conditions -United States
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1155,Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2842,"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4281,Effectiveness of the first component of
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3501,"Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,991,CoV-2 Vaccine in Chile
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4438,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4635,Coronavirus Pandemic (COVID-19)
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3303,Our World in Data
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5011,Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,6035,Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2020,Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,307,Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,3355,Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,4760,"CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2180,Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1111,Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2743,Epidemiology of diabetes mellitus in Mexico
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,996,Profiling Cases With Nonrespiratory Symptoms and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Mexico City
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,206,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,911,Omicron and Delta Variants
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,2767,"Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States"
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,6055,Protection against SARS-CoV-2 after Covid-19
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico,1044,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5824,Ethics and execution of developing a 2nd wave COVID vaccine-Our interim phase I/II VSV-SARS-CoV2 vaccine experience
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1446,COVID-19 vaccine trial ethics once we have efficacious vaccines
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1508,The granting of emergency use designation to COVID-19 candidate vaccines: Implications for COVID-19 vaccine trials
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2926,Threat Assessment Brief: Emergence of SARS CoV 2 B. 1.617 Variants in India and Situation in the EU/EEA
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,269,Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,3093,"Neutralising antibody activity against SARS-CoV-2 VOCs, B.1.617.2 and B.1.351 by BNT162b2 vaccination"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,3007,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: Aprospective, single-centre, longitudinal cohort study in health-care workers"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2612,Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4963,Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4571,"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,915,Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,398,Strategies for Vaccine Prioritization and Mass Dispensing. Vaccines
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,109,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2289,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination-A systematic review and meta-analysis
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5491,Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1403,Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2640,Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1328,Safety and Immunogenicity of Intradermal Delivery of a Fractional Dose mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults as a Dose Sparing Strategy
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,321,T cell response to SARS-CoV-2 infection in humans: A systematic review
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1953,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1927,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4672,The Coronavirus Disease
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1437,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1093,The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1258,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4633,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,3774,Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,2634,Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5037,Targeting skin dendritic cells to improve intradermal vaccination
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,3919,Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines 2021
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5734,Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4378,Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,4513,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1116,T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population,1996,T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1104,World Health Organization. WHO Coronavirus (COVID-19) Dashboard.; 2021
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2179,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1086,Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",3590,Is one vaccine dose enough if you've had COVID? What the science says
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1319,SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",641,SARS-CoV-2 Omicron Has Extensive but Incomplete Escape of Pfizer BNT162b2 Elicited Neutralization and Requires ACE2 for
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",3477,Increased Risk of SARS-CoV-2 Reinfection Associated with Emergence of the Omicron Variant in South Africa
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",853,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",494,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination -Kentucky
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",349,Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections versus Breakthrough Infections
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",6082,Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1089,Effectiveness and Durability of Protection against Future SARS-CoV-2 Infection Conferred by COVID-19 Vaccination and Previous Infection; Findings from the UK SIREN Prospective Cohort Study of Healthcare Workers
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",178,Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2816,Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",416,China's COVID vaccines have been crucial -now immunity is waning
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2945,Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",376,Welcome to the Tidyverse
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2378,MatchIt: Nonparametric Preprocessing for Parametric Causal Inference
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2484,Simultaneous inference in general parametric models
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",965,A Package for Survival Analysis in R.; 2021
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1005,Coronavirus: Vaccination
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2653,Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",5292,Stratégie de Vaccination Contre Le SARS-CoV-2 -Vaccination Des Personnes Ayant Un Antécédent de Covid-19.; 2021
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",4777,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. The Lancet Microbe
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",4687,T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",2292,Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. The Lancet Rheumatology
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",3166,Evaluation of COVID-19 Vaccine Effectiveness: Interim Guidance
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",4322,Categorical variables reported as number (%)
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5677,The psychological impact of quarantine and how to reduce it: rapid review of the evidence
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5540,"COVID-19 and the workplace: implications, issues, and insights for future research and action"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",3826,"Health inequity and the effects of COVID-19: assessing, responding to and mitigating the socioeconomic impact on health to build a better future"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4167,COVID-19 exacerbating inequalities in the US
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5505,COVID-19 vaccines: a review of the safety and efficacy of current clinical trials
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",2711,Inactivated COVID-19 vaccines to make a global impact
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",670,SARS-CoV-2 vaccines in development
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",3409,Current advances in the development of SARS-CoV-2 vaccines
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4020,"double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5955,Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR -/-mice
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",3388,Development of an inactivated vaccine candidate for SARS-CoV-2
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5870,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",458,Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5218,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",1841,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",809,"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4013,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4574,Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5803,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",4912,Safety and efficacy of singledose Ad26.COV2.S vaccine against COVID-19
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",3404,Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",5343,Functional responsiveness of memory T cells from COVID-19 patients
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,4104,Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,4563,"Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil"
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,3504,Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,3849,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,3939,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,3717,Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,2125,Suppression of normal immune responses after treatment with rituximab
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,2773,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,5271,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days,2880,"No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,6074,Coronavirus biology and 393 replication: implications for SARS-CoV-2
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,1893,Tracking changes in SARS-CoV-2 spike: evidence that 395 D614G increases infectivity of the COVID-19 virus
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2808,mRNA vaccination boosts cross-variant 397 neutralizing antibodies elicited by SARS-CoV-2 infection
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,574,Convergent antibody responses to SARS-400
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2854,CoV-2 in convalescent individuals
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2855,Mapping neutralizing and immunodominant sites on the 402 SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,338,Emerging SARS-CoV-2 variants reduce neutralization 405 sensitivity to convalescent sera and monoclonal antibodies
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2388,D614G mutation of SARS-CoV-2 spike protein enhances 408 viral infectivity. bioRxiv
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,4186,"Public Health Scotland and the EAVE 410 II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital 411 admission, and vaccine effectiveness"
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,181,Evidence for increased breakthrough rates of SARS-413
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,4527,CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,5767,Vaccine breakthrough infections with SARS-CoV-2 variants. 416
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3952,Changes in the humoral immunity response in SARS-CoV-2 418 convalescent patients over 8 months
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2794,Antibody responses to SARS-CoV-2 in patients with COVID-19
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3632,Vpr is required for efficient replication of human 422 immunodeficiency virus type-1 in mononuclear phagocytes
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,1745,A rapid and efficient screening system for neutralizing antibodies and 424 its application for SARS-CoV-2. Front Immunol
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,5006,Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and 426 its immune cross-reactivity with SARS-CoV
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,4534,Development of cell-based Pseudovirus entry 428 assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,1527,Comparison of lentiviral 431 vector titration methods
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,295,Cell entry mechanisms of SARS-CoV-2
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,5147,Key residues of the receptor binding motif in the spike protein of SARS-435
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,264,CoV-2 that interact with ACE2 and neutralizing antibodies
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3798,SARS-CoV-2 variant B.1.617 is resistant to 437 bamlanivimab and evades antibodies induced by infection and vaccination
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2792,SARS-CoV-2 spike L452R variant evades 440 cellular immunity and increases infectivity
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,5906,SARS-CoV-2 spike P681R mutation enhances and 442 accelerates viral fusion
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2168,1.617.2 and B.1.351 by BNT162b2 vaccination
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3537,Rapid displacement of SARS-CoV-2 variant B.1.1.7 447 by B.1.617.2 and P.1 in the United States. medRxiv
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3367,Reduced neutralization of SARS-CoV-2 B.1.617 449 by vaccine and convalescent serum
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3971,BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 451 variants
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,789,Infection and vaccine-induced neutralizing-antibody 453 responses to the SARS-CoV-2 B.1.617 variants
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2871,Emerging SARS-CoV-2 variants of 455 concern evade humoral immune responses from infection and vaccination
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2809,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-458 elicited antibodies
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2699,Serum neutralizing activity elicited by mRNA-1273 vaccine
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,391,Complete mapping of mutations to the SARS-CoV-2 spike 462 receptor-binding domain that escape antibody recognition
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,3489,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 464
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,4556,SARS-CoV-2 variants B.1.351 and P.1 escape 466 from neutralizing antibodies
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2109,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune 468 escape
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,2741,Antibody neutralization to SARS-CoV-2 and variants after one year 470 in Wuhan
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,1977,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 472 variant of concern
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant,4267,"Transmission, infectivity, and neutralization of a 474 spike L452R SARS-CoV-2 variant"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,595,WHO Coronavirus (COVID-19) Dashboard
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,609,Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,82,Viral targets for vaccines against COVID-19
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3254,Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4567,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,5415,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,2726,"Interim report: Safety and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4976,immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3816,"Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4532,The role of IgA in COVID-19
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,1583,"Comprehensive assessment of humoral response after Pfizer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4869,Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms. medRxiv
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4140,Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3666,Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4923,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,390,Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,1884,SARS-CoV-2 detection by nasal strips: A superior tool for surveillance of paediatric population
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3236,Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4732,"Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by Lselectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,727,Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,5039,Preclinical and Clinical Demonstration of Immunogenicity by mRNA 25
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,1261,Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4875,Mucosal Immunology
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3058,Sinovac says a booster shot for COVID-19 would increase antibody response tenfold within one week
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,4935,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days. medRxiv
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3993,Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,329,SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,6067,Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines,3565,"RWYC Writing -original draft: SL, JYC, RWYC Writing -review & editing"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",596,"Public Health Service (PHS), Centers for Disease Control (CDC) /Food and Drug Administration (FDA)"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1337,Coronavirus vaccine weekly summary of yellow card reporting
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2430,Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5289,Varicellazoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",27,Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1890,"Bern aldez A, Rodr ıguez-Jim enez P. Varicella zoster virus reactivation and mRNA vaccines as a trigger"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",6096,Reactivation of herpesvirus infections after vaccinations?
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3937,Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3077,Increased risk of stroke after a herpes zoster attack
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",4769,Analysis of vascular event risk after herpes zoster from 2007 to 2014 US insurance claims data
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5985,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",487,Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3734,"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2946,The cost-effectiveness of universal varicella vaccination in Italy: a model-based assessment of vaccination strategies
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1058,The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2758,Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",32,Thematic household survey report no. 58. Hong Kong
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1829,Multimorbidity and adverse events of special interest associated with CoronaVac (Sinovac) and Comirnaty
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3129,Carditis following Covid-19 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a case-control study
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1997,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5616,Cardiovascular outcomes associated with use of clarithromycin: population based study
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2115,Tutorial in biostatistics: the self-controlled case series method
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",4200,Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1637,Self controlled case series methods: an alternative to standard epidemiological study designs
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",3753,The self-controlled case series method
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2730,Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",5869,Advances in mRNA vaccines for infectious diseases
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",2322,Toll-like receptor sensing of human herpesvirus infection
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",389,Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",158,Thematic household survey report no
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",879,Prevention of dabigatranrelated gastrointestinal bleeding with gastroprotective agents: a population-based study
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region",1243,Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
1,,5968,COVID-19) Dashboard; 2021. World Health Organization
1,,4826,"efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
1,,3958,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet"
1,,439,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet
1,,637,Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treatment Guidelines; 2021. National Institute of Health
1,,2539,"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States"
1,,4955,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"
1,,86,Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease
1,,1306,Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
1,,5506,Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
1,,5710,First report of SARS-CoV-2 gamma variant in Turkey
1,,4965,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
1,,4728,"Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine"
1,,1369,Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
1,,5358,Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,5194,Neutralizing activities against the omicron variant after a heterologous booster in healthy 248 adults Receiving Two Doses of CoronaVac Vaccination
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,2722,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and 251 necessary measures for global immunity
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,5030,Will the COVID-19 pandemic end with the delta and omicron variants? 254
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,4253,Breakthrough 256 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,6100,Severe breakthrough
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,1864,COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,3750,Immunogenicity and safety of an intradermal BNT162b2 mRNA 263 vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,5990,The immunogenicity against variants of concern and reactogenicity of four COVID-19
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,3273,booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,883,Safety and efficacy 270 of the BNT162b2 mRNA Covid-19 vaccine
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,1916,An mRNA 273 vaccine against SARS-CoV-2 -Preliminary Report
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,3491,Safety and immunogenicity of the third booster dose with inactivated
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,2832,Omicron variant neutralization after mRNA-1273 booster vaccination
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,1582,SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,2137,COVID-19 vaccination followed by activation of 289 glomerular diseases: does association equal causation?
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine,6033,CoV-2-specific T cells cross-recognize the Omicron variant
4718,Strength and durability of antibody responses to,5336,Challenges in ensuring global access to 222
4718,Strength and durability of antibody responses to,3600,"COVID-19 vaccines: production, affordability, allocation, and deployment"
4718,Strength and durability of antibody responses to,1314,Neutralizing antibody levels are highly 225 predictive of immune protection from symptomatic SARS-CoV-2 infection
4718,Strength and durability of antibody responses to,46,Correlates of protection against symptomatic and 228 asymptomatic SARS-CoV-2 infection
4718,Strength and durability of antibody responses to,2841,Evidence for antibody as a protective 230 correlate for COVID-19 vaccines
4718,Strength and durability of antibody responses to,2805,Comparative immunogenicity of 232 mRNA and inactivated vaccines against COVID-19
4718,Strength and durability of antibody responses to,2365,BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,534,Spatiotemporal pattern of COVID-19 spread in Brazil
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,3922,Minist erio da Sa ude. COVID-19 painel coronavírus
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,2999,"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,697,Fiocruz detecta mutação associada a variantes de preocupação no país
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,2264,Genomic epidemiology of hCoV-19. 2021). www.gisaid.org (accessed
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,4158,Opendatasus. campanha nacional de vacinação contra COVID-19
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1750,Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1110,Effectiveness data of the COVID-19 vaccine collected in Israel until 13.2.2021
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1210,"Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1642,Effectiveness of coronavac in the setting of high SARS-CoV-2 P1 variant transmission in brazil: a testnegative case-control study
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,542,Performance of vaccination with coronavac in a cohort of healthcare workers (HCW) -preliminary report
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,144,SARS-CoV-2 incidence and vaccine escape
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,2778,Minist erio da Sa ude. SIM. sistema de informações de mortalidade
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,5122,"Evolution of the deaths registry system in Brazil: associations with changes in the mortality profile, under-registration of death counts, and illdefined causes of death"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,3956,a systematic subnational analysis for the global burden of disease study
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,2696,Emergency use ICD codes for COVID-19 disease outbreak
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,4979,Projeções da população
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1593,Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,3352,"Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,4330,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,2319,SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,5523,"Slow spread of SARS-CoV-2 in Southern Brazil over a six-month period: report on eight sequential statewide serological surveys including 35,611 participants"
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,5286,Desigualdades regionais na sa ude: mudanças observadas no Brasil de
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,1098,Minist erio da Sa ude. COVID-19 vacinação -distribuição de vacinas
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,4144,Projeto S: imunização em serrana faz casos de covid-19 despencarem 80% e mortes
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,3042,Effectiveness of the coronavac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality,5707,Vaccine inequality: how rich countries cut Covid deaths as poorer fall behind
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5747,Aversion to side effects in preventive medical treatment decisions
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,3429,COVID-19 vaccine hesitancy in a representative working-age population in France: A survey experiment based on vaccine characteristics
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1900,Vaccine Hesitancy Survey Questions Related to SAGE Vaccine Hesitancy Matrix
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,2423,Strategies for addressing vaccine hesitancy-A systematic review
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,2134,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,3271,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,657,Republic of Turkey Ministry of Health. Frequently Asked Questions. COVID-19 Vaccination Information Platform
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,2900,Turkey Begins Administering Sinovac Shot to Health Workers
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,3680,The Xs and Y of immune responses to viral vaccines
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,3192,Sex-based biology and the rational design of influenza vaccination strategies
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,2817,Republic of Turkey Ministry of Health. COVID-19 Vaccination Information Platform
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5333,Harvard Humanitarian Initiative
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1197,Oral Side Effects of COVID-19 Vaccine (OSECV). ClinicalTrials.gov. 2021
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5884,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,6059,Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1967,Republic of Turkey Ministry of Health. T.C. Saglık Bakanlıgı Bilimsel Araştırma Platformu
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,2071,General Data Protection Regulation (GDPR) Compliance Guidelines
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,4899,Draft Landscape and Tracker of COVID-19 Candidate Vaccines
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5606,"Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021"
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5876,Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,936,"Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine"
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5239,COVID-19 Vaccine AstraZeneca
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,4265,Global Health Observatory|By category|Sex distribution of health workers
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5746,Republic of Turkey Ministry of Health
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5340,Angular cheilitis of COVID-19 patients: A case-series and literature review
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,4916,The manifestation of oral mucositis in COVID-19 patients: A case-series
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1499,Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1780,Oral candidiasis in non-severe COVID-19 patients: Call for antibiotic stewardship. Oral Surg. 2020
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5123,Halitosis in COVID-19 patients. Spec. Care Dent
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,5838,Tongue ulcers associated with SARS-CoV-2 infection: A case series
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey,1663,Oral Candidiasis of COVID-19 Patients: Case Report and Review of Evidence
271,Low COVID-19 Vaccine Hesitancy in Brazil,488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
271,Low COVID-19 Vaccine Hesitancy in Brazil,211,Vaccine confidence and hesitancy in Brazil. Cadernos de Saúde Pública
271,Low COVID-19 Vaccine Hesitancy in Brazil,6108,Vaccine hesitancy: the next challenge in the fight against COVID-19
271,Low COVID-19 Vaccine Hesitancy in Brazil,4764,How can a global pandemic affect vaccine hesitancy?
271,Low COVID-19 Vaccine Hesitancy in Brazil,4487,Can a COVID-19 vaccine live up to Americans' expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions
271,Low COVID-19 Vaccine Hesitancy in Brazil,4759,Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom
271,Low COVID-19 Vaccine Hesitancy in Brazil,1439,Herd immunityestimating the level required to halt the COVID-19 epidemics in affected countries
271,Low COVID-19 Vaccine Hesitancy in Brazil,1751,Five reasons why COVID herd immunity is probably impossible
271,Low COVID-19 Vaccine Hesitancy in Brazil,5753,Covid-19 Casos e Óbitos
271,Low COVID-19 Vaccine Hesitancy in Brazil,4585,"Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 14 de agosto de"
271,Low COVID-19 Vaccine Hesitancy in Brazil,1209,COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment
271,Low COVID-19 Vaccine Hesitancy in Brazil,3905,Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong
271,Low COVID-19 Vaccine Hesitancy in Brazil,279,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health -Europe
271,Low COVID-19 Vaccine Hesitancy in Brazil,1592,Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China
271,Low COVID-19 Vaccine Hesitancy in Brazil,6064,"Hesitancy in the time of coronavirus: Temporal, spatial, and sociodemographic variations in COVID-19 vaccine hesitancy"
271,Low COVID-19 Vaccine Hesitancy in Brazil,5996,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines (Basel). 12 de janeiro de
271,Low COVID-19 Vaccine Hesitancy in Brazil,5617,Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya. Vaccines (Basel). 23 de agosto de 2021
271,Low COVID-19 Vaccine Hesitancy in Brazil,2129,Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms and Possible Responses
271,Low COVID-19 Vaccine Hesitancy in Brazil,2541,Male sex identified by global COVID-19 metaanalysis as a risk factor for death and ITU admission
271,Low COVID-19 Vaccine Hesitancy in Brazil,995,Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions
271,Low COVID-19 Vaccine Hesitancy in Brazil,265,Homens e masculinidades e o novo coronavírus: compartilhando questões de gênero na primeira fase da pandemia. Ciência & Saúde Coletiva
271,Low COVID-19 Vaccine Hesitancy in Brazil,3422,Vaccine Hesitancy and Building Confidence in COVID-19 Vaccination | GOARN
271,Low COVID-19 Vaccine Hesitancy in Brazil,3337,"Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn"
271,Low COVID-19 Vaccine Hesitancy in Brazil,709,The people's vaccine: How a covid-19 vaccine will be a test of global accountability and equity
271,Low COVID-19 Vaccine Hesitancy in Brazil,5895,"Covid-19: Social murder, they wrote-elected, unaccountable, and unrepentant"
271,Low COVID-19 Vaccine Hesitancy in Brazil,1666,"9%) 127,713 (90.1%) Family income (monthly) None ≤ $197.17 $197"
271,Low COVID-19 Vaccine Hesitancy in Brazil,5948,"8%) 2,828 (9.9%)"
271,Low COVID-19 Vaccine Hesitancy in Brazil,3109,How important is the vaccine for someone who has already had COVID-19? Not important Not very important I don´t know Important Very important
271,Low COVID-19 Vaccine Hesitancy in Brazil,3641,Has a family member died or been admitted to ICU for COVID-19? Yes No
271,Low COVID-19 Vaccine Hesitancy in Brazil,5050,Importance of efficacy in decision to vaccinate No Yes I don´t understand efficacy data Indifferent
271,Low COVID-19 Vaccine Hesitancy in Brazil,4423,Is the vaccine´s country of origin important in the decision to vaccinate? Yes No
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2130,"Immunologic aspects of characteristics, diagnosis, and treatment of coronavirusdisease 2019 (COVID-19)"
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3208,Structures and distributions of SARS-CoV-2spike proteins on intact virions
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,1336,Angiotensin-convertingenzyme2 is a functional receptor for the SARS coronavirus
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3086,"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,813,Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2890,Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5455,A New SARS CoV-2 Dual Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5171,COVID-19: Significance of Antibodies
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,297,Validation of a commercially available SARS-CoV-2 serological immunoassay
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5257,Evaluation of nine commercial SARS-CoV-2 immunoassays
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3078,An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5419,Antibody tests for identification ofcurrent and pastinfection with SARS-CoV-2. Cochrane Database Syst
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,4909,Diagnostic performance of COVID-19 serology assays
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,22,Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5787,Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3872,Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3452,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2788,SARS-CoV-2 neutralizing antibodies: A network meta-analysis across vaccines
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2396,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5964,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,3699,Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2967,Susceptibility of circulating SARS-CoV-2 variants to neutralization
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,1127,Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,559,Neutralizing activity of BNT162b2-elicited serum-Preliminary report
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,4016,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,4729,COVID-19-neutralizing antibodies predict disease severity and survival
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration,5409,Neutralizing antibody response and SARS severity
